PMID-sentid	Pub_year	Sent_text	comp_official_name	comp_offset	protein_name	organism	prot_offset
18589137-0	2008	Regulatory effect of FK506 on CD152 and PD-1 in the liver allorecipients.	Tacrolimus	21-26	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	30-35
18589137-7	2008	CONCLUSION: FK506 up-regulated the expression of CD152 and PD-1 on the T-cell surface inhibiting proliferation and activation of effector T cells, favoring the survival of allorecipients.	Tacrolimus	12-17	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	49-54
18154618-5	2008	Inhibition of regulatory cells, suppressor pathways or cytokines, is consistent with CS and can be attributed to IL-6, IL-2, PD-1 or PD-L-1 antibodies, blockade of CTLA-4 : CD80/86 pathway, inhibition of CD40-CD40L pathways, and TGF-beta, IL-10 antibodies.	Cesium	85-87	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	164-170
16977655-8	2007	The reaction successfully afforded the desired product, CTLA-4 (113-150) 13 containing mature and pure complex-type sialyloligosaccharides in excellent purity.	sialooligosaccharides	116-138	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	56-62
18095376-0	2008	CTLA-4 disrupts ZAP70 microcluster formation with reduced T cell/APC dwell times and calcium mobilization.	Calcium	85-92	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	0-6
18021968-9	2007	CsA therapy resulted in a reduction in the percentage of CD4(+)CD25(+)CTLA-4(+) and CD4(+)CD25(+)Foxp3(+) regulatory T cells after renal transplantation in both groups (RAR-S and RAR-CH) compared with patients treated with rapamycin or to healthy donors.	Cyclosporine	0-3	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	70-76
17334650-6	2007	These patients had a stronger association with CTLA4 (odds ratio [OR] = 1.49 for the G allele of the single nucleotide polymorphism rs3087243; 95% CI = 1.29-1.72) than did the TPOAbs-negative patients (p = 0.0004; OR = 1.16; 95% CI = 1.10-1.24) or type 1 diabetes patients overall (OR = 1.20; 95% CI = 1.13-1.27).	tpoabs	176-182	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	47-52
16902146-8	2007	The FK778-induced anergic cells showed suppressor activity in a cell-cell contact-dependent manner; were CD25(high), CD45RO+, CD27-, and CD62L-; and expressed cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4), glucocorticoid-induced tumor necrosis factor receptor (GITR), and FoxP3.	2-cyano-3-hydroxy-N-(4-(trifluoromethyl)phenyl)-2-hepten-6-ynamide	4-9	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	159-202
16902146-8	2007	The FK778-induced anergic cells showed suppressor activity in a cell-cell contact-dependent manner; were CD25(high), CD45RO+, CD27-, and CD62L-; and expressed cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4), glucocorticoid-induced tumor necrosis factor receptor (GITR), and FoxP3.	2-cyano-3-hydroxy-N-(4-(trifluoromethyl)phenyl)-2-hepten-6-ynamide	4-9	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	204-210
17912440-5	2007	In addition, the expression of surface CD69, both surface and intracellular GITR, FoxP3, CD152 (CTLA) of activated CD4+CD25+ T(reg) cells were inhibited by imatinib in a dose-dependent manner.	Imatinib Mesylate	156-164	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	89-94
18021981-0	2007	Possible association of CTLA-4 gene polymorphism with cyclosporine-induced gingival overgrowth in kidney transplant recipients.	Cyclosporine	54-66	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	24-30
18021981-2	2007	The gene encoding CTLA-4 (Cytotoxic T-lymphocyte antigen 4, a molecule influencing T-cell activation), is known to have a single nucleotide polymorphism (SNP) in promoter C>T -318; an exon 1 A>G 49, and a microsatellite dinucleotide repeat polymorphism (AT)(n) in exon 4.	Dinucleoside Phosphates	226-238	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	18-24
18021981-2	2007	The gene encoding CTLA-4 (Cytotoxic T-lymphocyte antigen 4, a molecule influencing T-cell activation), is known to have a single nucleotide polymorphism (SNP) in promoter C>T -318; an exon 1 A>G 49, and a microsatellite dinucleotide repeat polymorphism (AT)(n) in exon 4.	Dinucleoside Phosphates	226-238	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	26-58
18021981-11	2007	The results suggested that appearance of an adenosine allele(A) in position +49 of the CTLA-4 gene may be a permissive element for CsA-induced GO.	Adenosine	44-53	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	87-93
18021981-11	2007	The results suggested that appearance of an adenosine allele(A) in position +49 of the CTLA-4 gene may be a permissive element for CsA-induced GO.	Cyclosporine	131-134	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	87-93
18246813-10	2007	(3) The CD28+/CTLA-4+ ratio was positively related to the Th1+ /Th2+ ratio (P < 0.05).	th2+	64-68	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	14-20
17485260-8	2007	Moreover, there was an increase in CD4+CD25highFOXP3+ cells that were also IL-10+ in the IND group whereas, in the CARD group, there was an increase in the percentage of CD4+CD25high FOXP3+ cells that expressed CTLA-4.	indole	89-92	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	211-217
17164341-3	2007	In vitro, IDO+ AML cells increase the number of CD4+ CD25+ T cells expressing surface CTLA-4 and FOXP3 mRNA, and this effect is completely abrogated by the IDO inhibitor, 1-methyl tryptophan (1-MT).	1-methyltryptophan	171-190	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	86-92
17341301-6	2007	In cohort 1, the CTLA-4 +49A/G*A allele was found on 73% of chromosomes in patients with pSS, compared with 66% in controls (p = 0.036; odds ratio (OR) 1.41, 95% confidence interval (CI) 1.02 to 1.95).	pss	89-92	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	17-23
17341301-8	2007	In the replication cohort, the CTLA-4 +49A/G*A allele was found on 62% of chromosomes in patients with pSS, compared with 66% in controls (p = 0.30; OR 0.85, 95% CI 0.63 to 1.16).	pss	103-106	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	31-37
17138053-7	2006	In both, KdTxL and KdTxCad patients, responsiveness to steroid treatment during acute rejection was also in association with the CTLA-4 (+49A/G) SNP.	Steroids	55-62	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	129-135
17177975-0	2007	Resveratrol and curcumin suppress immune response through CD28/CTLA-4 and CD80 co-stimulatory pathway.	Resveratrol	0-11	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	63-69
17177975-0	2007	Resveratrol and curcumin suppress immune response through CD28/CTLA-4 and CD80 co-stimulatory pathway.	Curcumin	16-24	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	63-69
17177975-5	2007	Interestingly, curcumin imparted immunosuppression by mainly down-regulating the expression of CD28 and CD80 and up-regulating CTLA-4.	Curcumin	15-23	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	127-133
16896154-7	2006	CTLA-4 blockade decreased expression of the tryptophan-depleting enzyme IDO and the level of the suppressive cytokine transforming growth factor-beta (TGF-beta) in tissues.	Tryptophan	44-54	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	0-6
17138053-8	2006	The CTLA-4 +49G allele was found at a very low frequency among steroid-resistant compared with steroid-sensitive patients.	Steroids	63-70	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	4-10
17138053-8	2006	The CTLA-4 +49G allele was found at a very low frequency among steroid-resistant compared with steroid-sensitive patients.	Steroids	95-102	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	4-10
17009234-0	2006	CTLA-4IG suppresses reactive oxygen species by preventing synovial adherent cell-induced inactivation of Rap1, a Ras family GTPASE mediator of oxidative stress in rheumatoid arthritis T cells.	Reactive Oxygen Species	20-43	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	0-6
17009234-10	2006	CTLA4-Ig blockade of synovial adherent cell signaling to CD28 T cells reversed the inhibition of Rap1 activity and prevented induction of ROS.	Reactive Oxygen Species	138-141	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	0-5
16640877-7	2006	CONCLUSIONS: The results suggest that A/G polymorphism in exon-1 of CTLA-4 might confer the susceptibility to RSA in Chinese women.	rabbit sperm membrane autoantigen	110-113	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	68-74
16888088-1	2006	We have previously shown that cholera toxin (CT) and other cAMP-elevating agents induce up-regulation of the inhibitory molecule CTLA-4 on human resting T lymphocytes.	Cyclic AMP	59-63	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	129-135
16868438-8	2006	In Cox regression models adjusted for age and established contributory markers in CCR5 and HLA class I genes, CTLA4-318T was associated with rapid progression to AIDS in MACS (relative hazard 1.69; 95% confidence interval, 1.15-2.49; P < 0.01) as opposed to a non-significant slower disease progression in ACS and no appreciable association in DCG.	dcg	347-350	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	110-115
16564528-8	2006	The mean ratios of CTLA-4/CD28 were significantly higher in patients with RSA (P<0.01) and SA (P<0.05) than in controls.	rabbit sperm membrane autoantigen	74-77	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	19-25
16563575-3	2006	The BTT epitopes [VP1 (133-156)-3A (11-40)-VP4 (20-34)] were cloned into the plasmid pCMV, either alone or fused to ubiquitin, the lysosomal targeting signal from LIMPII, a soluble version of CTLA4 or a signal peptide from the human prion protein, to analyze the effect of processing through different antigenic presentation pathways on the immunogenicity of the FMDV epitopes.	btt	4-7	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	192-197
16454732-9	2006	In addition, CTLA-4-Ig can bind to B7 molecules expressed on dendritic cells and activate a pathway of tryptophan catabolism that can lead to indirect inhibition of lymphocyte activation and T cell death.	Tryptophan	103-113	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	13-19
17020648-5	2006	CTLA-4 exon 1 polymorphism (A49G) was defined by the PCR method and single-strand conformational polymorphism analysis and confirmed by using BbvI enzyme.	bbvi	142-146	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	0-6
16181751-12	2005	Although feline sB7.1-his and sB7.2-his proteins bound to the human homolog receptors, CTLA-4 and CD28, both soluble ligands possessed greater affinity for CTLA-4, compared to CD28.	sb7.1-his	16-25	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	87-93
16417239-5	2006	In the analysis of PBMCs in MF, we found that CTLA-4 is stimulated by phorbol myristate acetate/A23187 to a greater level when compared to normals.	Tetradecanoylphorbol Acetate	70-95	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	46-52
16417239-5	2006	In the analysis of PBMCs in MF, we found that CTLA-4 is stimulated by phorbol myristate acetate/A23187 to a greater level when compared to normals.	Calcimycin	96-102	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	46-52
16365402-6	2006	IPE Tregs through their expression of B7 are able to engage CTLA-4+ bystander T cells, and thus precisely, target delivery of membrane-bound TGFbeta.	ipe	0-3	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	60-66
16181751-12	2005	Although feline sB7.1-his and sB7.2-his proteins bound to the human homolog receptors, CTLA-4 and CD28, both soluble ligands possessed greater affinity for CTLA-4, compared to CD28.	sb7.2-his	30-39	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	87-93
15925532-1	2005	The synthetic immunomodulator cytotoxic T lymphocyte antigen 4-Ig (CTLA-4-Ig) initiates effects in human monocyte-derived dendritic cells (DC) that rely on immunosuppressive tryptophan catabolism.	Tryptophan	174-184	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	67-73
16380915-7	2005	The CTLA4 association is stronger in patients with RA from both cohorts who are seropositive for anti-citrulline antibodies (P=.0006).	Citrulline	102-112	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	4-9
16385301-8	2005	RESULTS: The prepared rhCTLA4Ig from the supernatant of Ad-CTLA4Ig-infected 293 cells was verified by sodium dodecyl sulfate polyacrylamide gel electrophoresis sodium dodecyl sulfate poly-acrylamide gel electrophoresis and Western blot.	Sodium Dodecyl Sulfate	102-124	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	24-29
16385301-8	2005	RESULTS: The prepared rhCTLA4Ig from the supernatant of Ad-CTLA4Ig-infected 293 cells was verified by sodium dodecyl sulfate polyacrylamide gel electrophoresis sodium dodecyl sulfate poly-acrylamide gel electrophoresis and Western blot.	polyacrylamide	125-139	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	24-29
16385301-8	2005	RESULTS: The prepared rhCTLA4Ig from the supernatant of Ad-CTLA4Ig-infected 293 cells was verified by sodium dodecyl sulfate polyacrylamide gel electrophoresis sodium dodecyl sulfate poly-acrylamide gel electrophoresis and Western blot.	Sodium Dodecyl Sulfate	160-182	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	24-29
16385301-8	2005	RESULTS: The prepared rhCTLA4Ig from the supernatant of Ad-CTLA4Ig-infected 293 cells was verified by sodium dodecyl sulfate polyacrylamide gel electrophoresis sodium dodecyl sulfate poly-acrylamide gel electrophoresis and Western blot.	polyacrylamide	183-198	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	24-29
16002699-6	2005	C122-independent dimerization of CTLA-4 involved N-glycosylation, because further mutation of the N78 and N110 glycosylation sites abrogated dimerization.	Nitrogen	49-50	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	33-39
16405845-12	2005	CONCLUSION: CTLA-4 gene exon 1 A49-->G substitution is associated with an increased IDC genetic susceptibility, which implicates that the CTLA-4 gene may have a significant role in IDC, possibly via a Thr-->Ala change in CTLA-4 signal peptide, with a result of functional change of sCTLA-4.	Threonine	204-207	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	12-18
16405845-12	2005	CONCLUSION: CTLA-4 gene exon 1 A49-->G substitution is associated with an increased IDC genetic susceptibility, which implicates that the CTLA-4 gene may have a significant role in IDC, possibly via a Thr-->Ala change in CTLA-4 signal peptide, with a result of functional change of sCTLA-4.	Threonine	204-207	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	141-147
16405845-12	2005	CONCLUSION: CTLA-4 gene exon 1 A49-->G substitution is associated with an increased IDC genetic susceptibility, which implicates that the CTLA-4 gene may have a significant role in IDC, possibly via a Thr-->Ala change in CTLA-4 signal peptide, with a result of functional change of sCTLA-4.	Threonine	204-207	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	141-147
16405845-12	2005	CONCLUSION: CTLA-4 gene exon 1 A49-->G substitution is associated with an increased IDC genetic susceptibility, which implicates that the CTLA-4 gene may have a significant role in IDC, possibly via a Thr-->Ala change in CTLA-4 signal peptide, with a result of functional change of sCTLA-4.	Alanine	213-216	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	12-18
16405845-12	2005	CONCLUSION: CTLA-4 gene exon 1 A49-->G substitution is associated with an increased IDC genetic susceptibility, which implicates that the CTLA-4 gene may have a significant role in IDC, possibly via a Thr-->Ala change in CTLA-4 signal peptide, with a result of functional change of sCTLA-4.	Alanine	213-216	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	141-147
16405845-12	2005	CONCLUSION: CTLA-4 gene exon 1 A49-->G substitution is associated with an increased IDC genetic susceptibility, which implicates that the CTLA-4 gene may have a significant role in IDC, possibly via a Thr-->Ala change in CTLA-4 signal peptide, with a result of functional change of sCTLA-4.	Alanine	213-216	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	141-147
15598660-2	2005	CD28 and CD152 share a conserved polyproline motif in the ligand-binding region.	polyproline	33-44	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	9-14
15814706-6	2005	CTLA-4 was identified in a perinuclear compartment overlapping with the cis-Golgi marker GM-130 but did not colocalize strongly with lysosomal markers such as CD63 and lysosome-associated membrane protein.	gm-130	89-95	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	0-6
15598660-4	2005	Interestingly, in the human CD80-CD152 complex, Pro(102) of CD152 restricts the preceding proline to PP(II) helix in the binding orientation in relation to the shallow binding pocket of CD80.	Proline	48-51	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	33-38
15598660-4	2005	Interestingly, in the human CD80-CD152 complex, Pro(102) of CD152 restricts the preceding proline to PP(II) helix in the binding orientation in relation to the shallow binding pocket of CD80.	Proline	48-51	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	60-65
15598660-4	2005	Interestingly, in the human CD80-CD152 complex, Pro(102) of CD152 restricts the preceding proline to PP(II) helix in the binding orientation in relation to the shallow binding pocket of CD80.	Proline	90-97	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	33-38
15598660-4	2005	Interestingly, in the human CD80-CD152 complex, Pro(102) of CD152 restricts the preceding proline to PP(II) helix in the binding orientation in relation to the shallow binding pocket of CD80.	Proline	90-97	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	60-65
15598660-4	2005	Interestingly, in the human CD80-CD152 complex, Pro(102) of CD152 restricts the preceding proline to PP(II) helix in the binding orientation in relation to the shallow binding pocket of CD80.	pp(ii)	101-107	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	33-38
15598660-4	2005	Interestingly, in the human CD80-CD152 complex, Pro(102) of CD152 restricts the preceding proline to PP(II) helix in the binding orientation in relation to the shallow binding pocket of CD80.	pp(ii)	101-107	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	60-65
15466932-10	2005	This is the first report of IDO and TTS regulation by the CTLA-4-B7 system in human CD4(+) and CD8(+) T cells, and raises the possibility that these 2 tryptophan-modulating enzymes provide an important mechanism for regulating immune responses.	Tryptophan	151-161	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	58-64
15871446-6	2005	The serum soluble CTLA-4 concentrations in the asthmatics statistically correlated with forced expiratory volume in one second (r = -0.410, p = 0.027), percentage of predicted peak expiratory flow (r = -0.449, p = 0.015), and PaCO2 (r = 0.555, p = 0.002), respectively.	paco2	226-231	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	18-24
15460536-0	2004	Lipoteichoic acid and muramic acid modulate the expression of CD80/CD86 on THP-1 cells and CD28/CD152 on Jurkat cells.	lipoteichoic acid	0-17	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	96-101
15218356-1	2004	The exon 1 polymorphism (49A/G) of ctla-4 gene corresponds to an amino acid exchange (threonine to alanine) in the leader peptide of the expressed protein.	Threonine	86-95	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	35-41
15218356-1	2004	The exon 1 polymorphism (49A/G) of ctla-4 gene corresponds to an amino acid exchange (threonine to alanine) in the leader peptide of the expressed protein.	Alanine	99-106	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	35-41
15514008-2	2005	We now report that the T-cell receptor (TCR) of the CD4(+) CTCL cells is triggered after interaction with DCs loaded with apoptotic CTCL cells, as shown by reduced membrane expression of CD3 and the TCR, up-regulation of cytotoxic T lymphocyte antigen-4 (CTLA-4), and calcium mobilization.	Calcium	268-275	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	255-261
15790344-3	2005	Case-control study to compare the frequency of G/A alleles, AA/AG/GG genotypes and A + (AA + AG) /G+ (GG + AG) phenotypes of CTLA-4 between RSA patients and controls were performed.	rabbit sperm membrane autoantigen	140-143	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	125-131
15790344-8	2005	CONCLUSIONS: Our findings suggest that A/G polymorphism in exon-1 of CTLA-4 is associated with the immunopathogenesis of RSA, and it confers susceptibility to RSA in Chinese population.	rabbit sperm membrane autoantigen	121-124	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	69-75
15790344-8	2005	CONCLUSIONS: Our findings suggest that A/G polymorphism in exon-1 of CTLA-4 is associated with the immunopathogenesis of RSA, and it confers susceptibility to RSA in Chinese population.	rabbit sperm membrane autoantigen	159-162	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	69-75
16220002-1	2005	The present study was performed to elucidate the relationship between CTLA-4/CD28 molecules and stimulating (TSAb) and blocking (TBAb) antibodies to the TSH-receptor (TSH-R) in Graves" disease.	tetrabutylammonium	129-133	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	70-76
16220002-9	2005	In patients with untreated GD there was a statistically significant positive correlation between the expression of CTLA-4 on the surface of peripheral blood T cells and the index of TSAb antibodies (R = 0.54, p < 0.001) as well as a negative correlation with TBAb antibody titer (R = -0.58, p < 0.001).	tetrabutylammonium	262-266	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	115-121
15316504-4	2004	METHODS: Seven single nucleotide polymorphisms (SNPs; MH30, -1147CT, +49AG, CT60, JO31, JO30, JO27_1) in CTLA-4 were analyzed for associations with total serum IgE, allergic sensitization (positive skin prick test to common allergens), bronchial hyperresponsiveness (BHR) to methacholine, asthma, and lung function (FEV1 % of predicted) in 364 asthmatic families from 3 European countries.	Methacholine Chloride	275-287	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	105-111
15208156-1	2004	AIMS: To determine whether the functional A49G polymorphism of cytotoxic T-lymphocyte antigen-4 (CTLA-4), a T-cell surface molecule that modulates T-lymphocyte activation and influences the risk of developing alcohol-induced autoantibodies, plays a role in susceptibility to alcoholic liver disease (ALD) and influences disease severity in Italian alcohol abusers.	Alcohols	209-216	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	63-95
15208156-1	2004	AIMS: To determine whether the functional A49G polymorphism of cytotoxic T-lymphocyte antigen-4 (CTLA-4), a T-cell surface molecule that modulates T-lymphocyte activation and influences the risk of developing alcohol-induced autoantibodies, plays a role in susceptibility to alcoholic liver disease (ALD) and influences disease severity in Italian alcohol abusers.	Alcohols	209-216	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	97-103
15208156-1	2004	AIMS: To determine whether the functional A49G polymorphism of cytotoxic T-lymphocyte antigen-4 (CTLA-4), a T-cell surface molecule that modulates T-lymphocyte activation and influences the risk of developing alcohol-induced autoantibodies, plays a role in susceptibility to alcoholic liver disease (ALD) and influences disease severity in Italian alcohol abusers.	Alcohols	275-282	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	63-95
15208156-1	2004	AIMS: To determine whether the functional A49G polymorphism of cytotoxic T-lymphocyte antigen-4 (CTLA-4), a T-cell surface molecule that modulates T-lymphocyte activation and influences the risk of developing alcohol-induced autoantibodies, plays a role in susceptibility to alcoholic liver disease (ALD) and influences disease severity in Italian alcohol abusers.	Alcohols	275-282	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	97-103
15460536-0	2004	Lipoteichoic acid and muramic acid modulate the expression of CD80/CD86 on THP-1 cells and CD28/CD152 on Jurkat cells.	Muramic Acids	22-34	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	96-101
15504312-2	2004	The present study was performed to elucidate the relationship between CTLA-4/CD28 molecules and stimulating (TSAb) or blocking (TBAb) antibodies to the TSH-receptor in Graves" disease.	tetrabutylammonium	128-132	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	70-76
12967785-6	2003	When a co-stimulation-deficient population of DCs was employed for the in vitro, steroid hormone-conditioned stimulations, two additional effects were observed: (a) a further skewing towards antigen-specific IL-10 production and (b) enhanced activation-induced up-regulation of the inhibitory receptor CTLA-4 (CD152).	Steroids	81-96	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	302-308
14634084-3	2003	Although CD25(+) Treg were anergic to nickel, a small percentage up-regulated membrane CTLA-4 upon nickel exposure.	Nickel	99-105	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	87-93
14515359-8	2003	Moreover, antibody neutralization of CTLA-4, GITR, IL-10, or IL-17 completely reversed Treg-induced suppression.	treg	87-91	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	37-43
12972512-4	2003	To test this hypothesis, we generated stably transfected T cell clones expressing doxycycline-inducible CTLA-4 with CD25:TCR-zeta (CD25-zeta) or CD25:CD3-epsilon (CD25-epsilon) fusion proteins.	Doxycycline	82-93	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	104-110
12952926-4	2003	In the presence of concentrations of CTLA-4Ig that inhibited the CD28-B7 interaction, beryllium-specific CD4+ T cells in lung were still able to proliferate and secrete IFN-gamma in response to beryllium in culture.	Beryllium	86-95	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	37-43
12952926-4	2003	In the presence of concentrations of CTLA-4Ig that inhibited the CD28-B7 interaction, beryllium-specific CD4+ T cells in lung were still able to proliferate and secrete IFN-gamma in response to beryllium in culture.	Beryllium	194-203	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	37-43
12956876-5	2003	The strict conservation of critical amino-acid residues like cystein and asparagine residues in Woodchuck CD28 and CTLA-4 suggests that both molecules may structurally resemble their human or mouse homologues.	Cysteine	61-68	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	115-121
12956876-5	2003	The strict conservation of critical amino-acid residues like cystein and asparagine residues in Woodchuck CD28 and CTLA-4 suggests that both molecules may structurally resemble their human or mouse homologues.	Asparagine	73-83	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	115-121
12930659-1	2003	OBJECTIVE: To construct and detect the targeted anti-caries fusion DNA vaccine pGJA-P encoding the A-P fragment of pac, glu fragment of gtfB and extracellular region of the human CTLA4 and the Fc region of human Iggamma(1) gene for the targeting antigen to APC.	Glutamic Acid	120-123	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	179-184
12967785-6	2003	When a co-stimulation-deficient population of DCs was employed for the in vitro, steroid hormone-conditioned stimulations, two additional effects were observed: (a) a further skewing towards antigen-specific IL-10 production and (b) enhanced activation-induced up-regulation of the inhibitory receptor CTLA-4 (CD152).	Steroids	81-96	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	310-315
12696006-0	2003	Association of CTLA4 polymorphisms with sustained response to interferon and ribavirin therapy for chronic hepatitis C virus infection.	Ribavirin	77-86	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	15-20
12540792-10	2003	In conclusion, antigenic stimulation by HER-modified CYP2E1 combined with an impaired control of T-cell proliferation by CTLA-4 mutation promotes the development of anti-CYP2E1 autoantibodies that might contribute to alcohol-induced liver injury.	Alcohols	217-224	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	121-127
12368911-0	2002	CTLA-4-Ig regulates tryptophan catabolism in vivo.	Tryptophan	20-30	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	0-6
12515820-3	2003	In the present study, we observed a direct interaction of CTLA-4 with the phosphorylated form of T cell receptor (TCR)zeta within the glycolipid-enriched microdomains associated with the T cell signaling complex.	Glycolipids	134-144	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	58-64
12515820-4	2003	In this setting, CTLA-4 regulated the accumulation/retention of TCRzeta in the signaling complex, as the lipid raft fractions from CTLA-4KO T cells contained significantly higher amounts of the TCR components when compared with wild-type littermates.	tcrzeta	64-71	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	17-23
12515820-4	2003	In this setting, CTLA-4 regulated the accumulation/retention of TCRzeta in the signaling complex, as the lipid raft fractions from CTLA-4KO T cells contained significantly higher amounts of the TCR components when compared with wild-type littermates.	tcrzeta	64-71	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	131-137
12515820-5	2003	In contrast, coligation of CTLA-4 with the TCR during T cell activation selectively decreased the amount of TCRzeta that accumulated in the rafts.	tcrzeta	108-115	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	27-33
12444128-0	2002	Cyclic adenosine 5"-monophosphate and calcium induce CD152 (CTLA-4) up-regulation in resting CD4+ T lymphocytes.	cyclic adenosine 5"-monophosphate	0-33	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	53-58
12444128-0	2002	Cyclic adenosine 5"-monophosphate and calcium induce CD152 (CTLA-4) up-regulation in resting CD4+ T lymphocytes.	cyclic adenosine 5"-monophosphate	0-33	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	60-66
12444128-0	2002	Cyclic adenosine 5"-monophosphate and calcium induce CD152 (CTLA-4) up-regulation in resting CD4+ T lymphocytes.	Calcium	38-45	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	53-58
12444128-0	2002	Cyclic adenosine 5"-monophosphate and calcium induce CD152 (CTLA-4) up-regulation in resting CD4+ T lymphocytes.	Calcium	38-45	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	60-66
12444128-2	2002	We show in this study that cAMP induces up-regulation of CD152 in human CD4(+) T lymphocytes.	Cyclic AMP	27-31	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	57-62
12444128-4	2002	In addition, we found that the Ca(2+) ionophore ionomycin also up-regulates CD152, and that the combination of a cAMP analog or cAMP inducers with ionomycin further enhances the expression of CD152 in resting CD4(+) T lymphocytes.	Ionomycin	48-57	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	76-81
12444128-4	2002	In addition, we found that the Ca(2+) ionophore ionomycin also up-regulates CD152, and that the combination of a cAMP analog or cAMP inducers with ionomycin further enhances the expression of CD152 in resting CD4(+) T lymphocytes.	Ionomycin	48-57	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	192-197
12444128-4	2002	In addition, we found that the Ca(2+) ionophore ionomycin also up-regulates CD152, and that the combination of a cAMP analog or cAMP inducers with ionomycin further enhances the expression of CD152 in resting CD4(+) T lymphocytes.	Cyclic AMP	113-117	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	192-197
12444128-4	2002	In addition, we found that the Ca(2+) ionophore ionomycin also up-regulates CD152, and that the combination of a cAMP analog or cAMP inducers with ionomycin further enhances the expression of CD152 in resting CD4(+) T lymphocytes.	Cyclic AMP	128-132	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	192-197
12444128-4	2002	In addition, we found that the Ca(2+) ionophore ionomycin also up-regulates CD152, and that the combination of a cAMP analog or cAMP inducers with ionomycin further enhances the expression of CD152 in resting CD4(+) T lymphocytes.	Ionomycin	147-156	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	192-197
12444128-6	2002	The effects of cAMP and ionomycin involve increase of both CD152 mRNA transcripts, coding for the membrane and the soluble forms of CD152.	Cyclic AMP	15-19	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	59-64
12444128-6	2002	The effects of cAMP and ionomycin involve increase of both CD152 mRNA transcripts, coding for the membrane and the soluble forms of CD152.	Cyclic AMP	15-19	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	132-137
12444128-6	2002	The effects of cAMP and ionomycin involve increase of both CD152 mRNA transcripts, coding for the membrane and the soluble forms of CD152.	Ionomycin	24-33	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	59-64
12444128-6	2002	The effects of cAMP and ionomycin involve increase of both CD152 mRNA transcripts, coding for the membrane and the soluble forms of CD152.	Ionomycin	24-33	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	132-137
12368911-3	2002	We show here that long-term survival of pancreatic islet allografts induced by the soluble fusion protein CTLA-4-immunoglobulin (CTLA-4-Ig) is contingent upon effective tryptophan catabolism in the host.	Tryptophan	169-179	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	106-112
12368911-3	2002	We show here that long-term survival of pancreatic islet allografts induced by the soluble fusion protein CTLA-4-immunoglobulin (CTLA-4-Ig) is contingent upon effective tryptophan catabolism in the host.	Tryptophan	169-179	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	129-135
12368911-4	2002	In vitro, we show that CTLA-4-Ig regulates cytokine-dependent tryptophan catabolism in B7-expressing dendritic cells.	Tryptophan	62-72	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	23-29
12368911-5	2002	These data suggest that modulation of tryptophan catabolism is a means by which CTLA-4 functions in vivo and that CTLA-4 acts as a ligand for B7 receptor molecules that transduce intracellular signals.	Tryptophan	38-48	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	80-86
12101428-3	2002	We have constructed a recombinant adenovirus, Ad-hUGT1A1-CTLA4Ig that coexpresses human bilirubin-uridinediphosphoglucuronate glucuronosyltransferase (hUGT1A1) and soluble murine CTLA4Ig, both driven by CMV immediate-early promoters.	Bilirubin	88-97	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	57-62
12135671-11	2002	Moreover, cyclosporin A, which is known to modulate NFAT activation, reduced CTLA-4 protein expression in adult and UCB T cells.	Cyclosporine	10-23	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	77-83
12021313-4	2002	Here, we show that after T cell stimulation, CTLA-4 coclusters with the TCR and the lipid raft ganglioside GM1 within the IS.	Gangliosides	95-106	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	45-51
12071705-8	2002	Purified B7-2 binds tightly to bacterially expressed monomeric and disulfide-linked homodimeric human CTLA-4 as shown by gel-filtration chromatography and native PAGE.	Disulfides	67-76	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	102-108
12047362-2	2002	Several studies have demonstrated an association of cytotoxic T lymphocyte-associated molecule 4 (CTLA-4) (IDDM 12) alanine 17 with type 1 diabetes, but we wished to study the parental effect of CTLA-4 49 A/G dimorphism in diabetic families.	Alanine	116-123	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	52-96
12047362-2	2002	Several studies have demonstrated an association of cytotoxic T lymphocyte-associated molecule 4 (CTLA-4) (IDDM 12) alanine 17 with type 1 diabetes, but we wished to study the parental effect of CTLA-4 49 A/G dimorphism in diabetic families.	Alanine	116-123	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	98-104
12047362-2	2002	Several studies have demonstrated an association of cytotoxic T lymphocyte-associated molecule 4 (CTLA-4) (IDDM 12) alanine 17 with type 1 diabetes, but we wished to study the parental effect of CTLA-4 49 A/G dimorphism in diabetic families.	Alanine	116-123	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	107-114
12021313-4	2002	Here, we show that after T cell stimulation, CTLA-4 coclusters with the TCR and the lipid raft ganglioside GM1 within the IS.	G(M1) Ganglioside	107-110	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	45-51
11994459-5	2002	The association between PP2AA and CTLA-4 involves a conserved three-lysine motif in the juxtamembrane portion of the cytoplasmic tail of CTLA-4.	Lysine	68-74	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	34-40
12021313-6	2002	Such compartmentalization is dependent on the cytoplasmic tail of CTLA-4 and can be forced with a glycosylphosphatidylinositol-anchor in CTLA-4.	Glycosylphosphatidylinositols	98-126	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	66-72
12021313-6	2002	Such compartmentalization is dependent on the cytoplasmic tail of CTLA-4 and can be forced with a glycosylphosphatidylinositol-anchor in CTLA-4.	Glycosylphosphatidylinositols	98-126	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	137-143
11994459-5	2002	The association between PP2AA and CTLA-4 involves a conserved three-lysine motif in the juxtamembrane portion of the cytoplasmic tail of CTLA-4.	Lysine	68-74	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	137-143
11994459-6	2002	Mutations of these lysine residues prevent the binding of PP2AA and enhance the inhibition of IL-2 gene transcription by CTLA-4, indicating that PP2A represses CTLA-4 function.	Lysine	19-25	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	121-127
11981427-8	2002	In addition, a short course of cyclosporine therapy synergized with either anti-CD28 monoclonal antibody or CTLA4 immunoglobulin, suggesting that it may be clinically relevant to combine low-dose calcineurin inhibitors with CTLA4 immunoglobulin or anti-B7 antibodies.	Cyclosporine	31-43	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	108-113
11994459-6	2002	Mutations of these lysine residues prevent the binding of PP2AA and enhance the inhibition of IL-2 gene transcription by CTLA-4, indicating that PP2A represses CTLA-4 function.	Lysine	19-25	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	160-166
11994459-7	2002	Our data imply that the lysine-rich motif in CTLA-4 may be used to identify small molecules that block its binding to PP2A and act as agonists for CTLA-4 function.	Lysine	24-30	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	45-51
11994459-7	2002	Our data imply that the lysine-rich motif in CTLA-4 may be used to identify small molecules that block its binding to PP2A and act as agonists for CTLA-4 function.	Lysine	24-30	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	147-153
11970985-0	2002	CTLA-4 suppresses proximal TCR signaling in resting human CD4(+) T cells by inhibiting ZAP-70 Tyr(319) phosphorylation: a potential role for tyrosine phosphatases.	Tyrosine	94-97	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	0-6
11970985-5	2002	CTLA-4 coligation with the TCR resulted in reduced downstream protein tyrosine phosphorylation of signaling effectors and a striking inhibition of extracellular signal-regulated kinase 1/2 activation.	Tyrosine	70-78	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	0-6
11981427-8	2002	In addition, a short course of cyclosporine therapy synergized with either anti-CD28 monoclonal antibody or CTLA4 immunoglobulin, suggesting that it may be clinically relevant to combine low-dose calcineurin inhibitors with CTLA4 immunoglobulin or anti-B7 antibodies.	Cyclosporine	31-43	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	224-229
11880164-2	2002	The CTLA-4 polymorphisms genotyped were a 3" untranslated (AT)(n) microsatellite and an alanine/threonine RFLP of exon 1.	Alanine	88-95	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	4-10
11726229-3	2001	In order to confirm this association in a Tunisian population, three polymorphisms of the CTLA-4 gene were analyzed: the first is at the -318 position from the ATG start codon consisting of a C/T change; the second is in position 49 of exon 1, which lies in the A/G transition; and the third is in the 3" untranslated region with variant lengths of the dinucleotide (AT)n repeat.	Dinucleoside Phosphates	353-365	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	90-96
11838849-2	2002	The disease is associated with expanded dinucleotide repeats in the cytotoxic T lymphocyte antigen 4 (CTLA-4) gene, suggesting that genetic variation(s) in T cell related gene(s) could contribute to the T cell hyperactivity in WG.	Dinucleoside Phosphates	40-52	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	68-100
11838849-2	2002	The disease is associated with expanded dinucleotide repeats in the cytotoxic T lymphocyte antigen 4 (CTLA-4) gene, suggesting that genetic variation(s) in T cell related gene(s) could contribute to the T cell hyperactivity in WG.	Dinucleoside Phosphates	40-52	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	102-108
11900275-5	2002	Moreover, we assessed the CTLA-4 49 (Thr/Ala) polymorphism in diabetic patients and first-degree relatives as compared to control subjects.	Threonine	37-40	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	26-32
11900275-5	2002	Moreover, we assessed the CTLA-4 49 (Thr/Ala) polymorphism in diabetic patients and first-degree relatives as compared to control subjects.	Alanine	41-44	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	26-32
11900275-11	2002	CONCLUSION: The CTLA-4 49 Ala allele confers an increased risk of type 1 diabetes, independent of age and HLA-DQ genetic markers.	Alanine	26-29	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	16-22
11841692-8	2002	The CTLA-4 expression was upregulated upon treatment with phorbol 12-myristate 13-acetate (PMA) and IFN-gamma.	Tetradecanoylphorbol Acetate	58-89	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	4-10
11841692-8	2002	The CTLA-4 expression was upregulated upon treatment with phorbol 12-myristate 13-acetate (PMA) and IFN-gamma.	Tetradecanoylphorbol Acetate	91-94	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	4-10
11788096-3	2001	A polymorphism at position 49 in the CTLA-4 gene, causing a substitution of Thr --> Ala, has been associated with various autoimmune diseases, including diabetes.	Alanine	87-90	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	37-43
11756004-5	2001	The transmission/disequilibrium test revealed increased transmission of the (AT)8 (dinucleotide repeat) and A (exon 1) alleles of CTLA-4 gene from heterozygous parents to affected offspring (87.5% and 83.5%) with type 1 AIH, compared with unaffected offspring (50.0% for both, p = 0.009 and 0.02, respectively).	Dinucleoside Phosphates	83-95	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	130-136
11698435-2	2001	Anti-CTLA-4 mAb treatment during primary Ag exposure increases cell cycle progression and enhances recall Ag responsiveness; however, simultaneous treatment with rapamycin, an inhibitor of the mammalian target of rapamycin and potent antiproliferative agent, prevents both effects.	Sirolimus	162-171	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	5-11
11571462-2	2001	We retrospectively examined the association between acute rejection and two polymorphisms in the CTLA4 gene, the dinucleotide (AT)n repeat polymorphism in exon 3 and the single nucleotide polymorphism A/G at position 49 in exon 1, in a cohort of liver and kidney transplant recipients.	Dinucleoside Phosphates	113-125	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	97-102
11788096-3	2001	A polymorphism at position 49 in the CTLA-4 gene, causing a substitution of Thr --> Ala, has been associated with various autoimmune diseases, including diabetes.	Threonine	76-79	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	37-43
11375523-2	2001	The disulfide-linked homodimer of the extracellular segment of human CTLA-4 and the receptor-binding domain of human B7-2 were purified and cocrystallized.	Disulfides	4-13	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	69-75
11437348-4	2001	Using immunological approaches, the present studies were designed to elucidate the relative contributions of RLIP76, MRP1, and P-glycoprotein (Pgp), in the ATP-dependent transport of GS-E and DOX in human erythrocytes.	Adenosine Triphosphate	156-159	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	183-195
11449357-3	2001	In contrast, in this study, we demonstrate that, although not essential, the YVKM motif contributes to optimal CTLA-4 blockage of TCRzeta or combined TCRzeta/CD28 signaling.	tcrzeta	130-137	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	111-117
11449357-3	2001	In contrast, in this study, we demonstrate that, although not essential, the YVKM motif contributes to optimal CTLA-4 blockage of TCRzeta or combined TCRzeta/CD28 signaling.	tcrzeta	150-157	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	111-117
11096449-6	2000	Dex also inhibited the expression of CD28 and CTLA-4 on phytohemagglutinin (PHA)-stimulated CD3+ T lymphocytes, which was attenuated by the addition of interleukin-12 (IL-12).	Dexamethasone	0-3	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	46-52
11426323-5	2001	Specifically, individuals carrying thymine at position -318 of the CTLA4 promoter (T(-318)) and homozygous for adenine at position 49 in exon 1 showed significantly increased expression both of cell-surface CTLA-4 after cellular stimulation and of CTLA-4 mRNA in non-stimulated cells.	Thymine	35-42	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	67-72
11426323-5	2001	Specifically, individuals carrying thymine at position -318 of the CTLA4 promoter (T(-318)) and homozygous for adenine at position 49 in exon 1 showed significantly increased expression both of cell-surface CTLA-4 after cellular stimulation and of CTLA-4 mRNA in non-stimulated cells.	Thymine	35-42	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	207-213
11426323-5	2001	Specifically, individuals carrying thymine at position -318 of the CTLA4 promoter (T(-318)) and homozygous for adenine at position 49 in exon 1 showed significantly increased expression both of cell-surface CTLA-4 after cellular stimulation and of CTLA-4 mRNA in non-stimulated cells.	Thymine	35-42	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	248-254
11426323-5	2001	Specifically, individuals carrying thymine at position -318 of the CTLA4 promoter (T(-318)) and homozygous for adenine at position 49 in exon 1 showed significantly increased expression both of cell-surface CTLA-4 after cellular stimulation and of CTLA-4 mRNA in non-stimulated cells.	Adenine	111-118	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	207-213
11426323-5	2001	Specifically, individuals carrying thymine at position -318 of the CTLA4 promoter (T(-318)) and homozygous for adenine at position 49 in exon 1 showed significantly increased expression both of cell-surface CTLA-4 after cellular stimulation and of CTLA-4 mRNA in non-stimulated cells.	Adenine	111-118	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	248-254
11158025-1	2001	Several studies have demonstrated an association of CTLA4 (IDDM12) alanine-17 with type 1 diabetes, but CTLA4 variants have not yet been investigated in type 2 diabetes.	Alanine	67-74	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	52-57
11158025-1	2001	Several studies have demonstrated an association of CTLA4 (IDDM12) alanine-17 with type 1 diabetes, but CTLA4 variants have not yet been investigated in type 2 diabetes.	Alanine	67-74	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	59-65
11288988-4	2001	We evaluated the allele distribution of the following loci: CTLA-4 exon 1 A49G dimorphism, which resulted in an amino acidic exchange (Thr/Ala) in the leader peptide, CTLA-4 3" microsatellite, HLA DRB1 and DQB1 in 126 patients with HT and in 301 control subjects from an Italian population (Lazio region).	Threonine	135-138	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	60-66
11288988-4	2001	We evaluated the allele distribution of the following loci: CTLA-4 exon 1 A49G dimorphism, which resulted in an amino acidic exchange (Thr/Ala) in the leader peptide, CTLA-4 3" microsatellite, HLA DRB1 and DQB1 in 126 patients with HT and in 301 control subjects from an Italian population (Lazio region).	Alanine	139-142	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	60-66
11279501-6	2001	Here we report the 3.2-A resolution structure of the complex between the disulphide-linked homodimer of human CTLA-4 and the receptor-binding domain of human B7-2.	disulphide	73-83	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	110-116
11135579-6	2001	In addition, treatment with cyclosporin A blocks anti-CD45RB-induced CTLA-4 expression and promotes acute rejection.	Cyclosporine	28-41	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	69-75
10843688-5	2000	A histidine-tagged form of porcine sB7-1 (sB7-1-His) interacted with both CD28 and CTLA-4, and effectively blocked IL-2 production from human responder cells stimulated with PHA and either porcine or human stimulator cells.	Histidine	2-11	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	83-89
11012750-9	2000	This correlates well with the observation that ligation of cytolytic T lymphocyte-associated antigen-4 (CTLA-4) (expression of which has been reported to be dependent on a sustained calcium signal), inhibits RANTES secretion induced by CD3/CD28, but has no effect on PMA-stimulated RANTES secretion.	Calcium	182-189	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	59-102
11012750-9	2000	This correlates well with the observation that ligation of cytolytic T lymphocyte-associated antigen-4 (CTLA-4) (expression of which has been reported to be dependent on a sustained calcium signal), inhibits RANTES secretion induced by CD3/CD28, but has no effect on PMA-stimulated RANTES secretion.	Calcium	182-189	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	104-110
10882627-6	2000	The level of CTLA-4 expression at the time of hospital admission was correlated positively with other markers of disease severity-the peak of the parasitemia and the peak of serum neopterin levels.	Neopterin	180-189	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	13-19
10843688-5	2000	A histidine-tagged form of porcine sB7-1 (sB7-1-His) interacted with both CD28 and CTLA-4, and effectively blocked IL-2 production from human responder cells stimulated with PHA and either porcine or human stimulator cells.	sb7-1-his	42-51	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	83-89
10604984-0	2000	Cutting edge: tyrosine-independent transmission of inhibitory signals by CTLA-4.	Tyrosine	14-22	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	73-79
10842319-0	2000	Janus kinase 2 is associated with a box 1-like motif and phosphorylates a critical tyrosine residue in the cytoplasmic region of cytotoxic T lymphocyte associated molecule-4.	Tyrosine	83-91	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	129-173
10842319-2	2000	It has been reported that phosphorylation and dephosphorylation of tyrosine residue Y-165 in the cytoplasmic region of CTLA-4 play an important role in its negative signaling and cell surface expression.	Tyrosine	67-75	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	119-125
10842319-4	2000	On the other hand, the adapter complex proteins, AP-2 and AP-50 interact with the same tyrosine residue when unphosphorylated, resulting in clathrin-mediated endocytosis of CTLA-4 molecules.	Tyrosine	87-95	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	173-179
10842319-5	2000	The objective of this study is to identify a tyrosine kinase that can directly bind and phosphorylate the critical tyrosine residue, Y-165 in the cytoplasmic domain of CTLA-4.	Tyrosine	45-53	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	168-174
10782900-5	2000	METHODS: The CTLA-4 exon 1 polymorphism (A/G encoding for threonine or alanine, respectively) was genotyped via polymerase chain reaction in 200 Caucasoid PBC patients and 200 non-related geographically matched Caucasoid controls.	Threonine	58-67	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	13-19
10782900-5	2000	METHODS: The CTLA-4 exon 1 polymorphism (A/G encoding for threonine or alanine, respectively) was genotyped via polymerase chain reaction in 200 Caucasoid PBC patients and 200 non-related geographically matched Caucasoid controls.	Alanine	71-78	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	13-19
10604984-3	2000	We find that signals for the inhibition of IL-2 secretion are delivered efficiently by a CTLA-4 mutant in which both cytoplasmic tyrosines have been replaced by phenylalanines.	Phenylalanine	161-175	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	89-95
10713366-0	2000	Dinucleotide repeat expansion in the CTLA-4 gene leads to T cell hyper-reactivity via the CD28 pathway in myasthenia gravis.	Dinucleoside Phosphates	0-12	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	37-43
10713366-5	2000	Blockade of CTLA-4 increased the telomerase activity in PBMC stimulated by acetylcholine receptor in vitro.	Acetylcholine	75-88	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	12-18
10613727-3	2000	To determine the frequency and significance of the exon 1 adenine (A)-guanine (G) base-exchange polymorphism for CTLA-4 in patients with type 1 autoimmune hepatitis, 155 northern European Caucasoid patients and 102 ethnically-matched control subjects were tested by polymerase chain reaction.	exon 1 adenine	51-65	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	113-119
10613727-3	2000	To determine the frequency and significance of the exon 1 adenine (A)-guanine (G) base-exchange polymorphism for CTLA-4 in patients with type 1 autoimmune hepatitis, 155 northern European Caucasoid patients and 102 ethnically-matched control subjects were tested by polymerase chain reaction.	Guanine	70-77	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	113-119
10604984-3	2000	We find that signals for the inhibition of IL-2 secretion are delivered efficiently by a CTLA-4 mutant in which both cytoplasmic tyrosines have been replaced by phenylalanines.	Tyrosine	129-138	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	89-95
10724097-5	1999	CTLA4 exon 1 position 49 (A/G: codon 17: Thr/Ala) polymorphism was defined, employing PCR-RFLP.	Threonine	41-44	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	0-5
10556814-6	1999	Activation of T cells with phorbol 12-myristate 13-acetate plus ionomycin or anti-CD3 plus anti-CD28 monoclonal antibodies induces a suppression of CTLA-4delTM mRNA expression associated with a preferential expression of the membrane CTLA-4 mRNA, showing that CTLA-4delTM mRNA expression is restricted to nonactivated T cells.	Tetradecanoylphorbol Acetate	27-58	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	148-154
10556814-6	1999	Activation of T cells with phorbol 12-myristate 13-acetate plus ionomycin or anti-CD3 plus anti-CD28 monoclonal antibodies induces a suppression of CTLA-4delTM mRNA expression associated with a preferential expression of the membrane CTLA-4 mRNA, showing that CTLA-4delTM mRNA expression is restricted to nonactivated T cells.	Ionomycin	64-73	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	148-154
10604992-4	2000	Here, we show that sole TCR ligation induces zeta-associated protein (ZAP)-70-dependent tyrosine phosphorylation of CTLA-4 that is important for cell surface retention of this molecule.	Tyrosine	88-96	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	116-122
10604992-6	2000	Specifically, inhibition of extracellular signal-regulated kinase (ERK) activation and of IL-2 production by CTLA-4-mediated signaling occurs in T cells expressing mutant CTLA-4 molecules lacking the cytoplasmic tyrosine residues, and in lck-deficient or ZAP-70-deficient T cells.	Tyrosine	212-220	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	109-115
10604992-6	2000	Specifically, inhibition of extracellular signal-regulated kinase (ERK) activation and of IL-2 production by CTLA-4-mediated signaling occurs in T cells expressing mutant CTLA-4 molecules lacking the cytoplasmic tyrosine residues, and in lck-deficient or ZAP-70-deficient T cells.	Tyrosine	212-220	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	171-177
10604992-7	2000	Therefore, CTLA-4 function involves interplay between two different levels of regulation: phosphotyrosine-dependent cell surface retention and phosphotyrosine-independent association with signaling molecules.	Phosphotyrosine	90-105	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	11-17
10604992-7	2000	Therefore, CTLA-4 function involves interplay between two different levels of regulation: phosphotyrosine-dependent cell surface retention and phosphotyrosine-independent association with signaling molecules.	Phosphotyrosine	143-158	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	11-17
10600000-6	1999	CD152 expression was lower on neonatal T cells than adult T cells stimulated with PMA and ionomycin and undetectable on neonatal T cells stimulated with CD3.	Ionomycin	90-99	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	0-5
10724097-5	1999	CTLA4 exon 1 position 49 (A/G: codon 17: Thr/Ala) polymorphism was defined, employing PCR-RFLP.	Alanine	45-48	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	0-5
10334846-4	1999	We combine several approaches to characterize the molecular weights of the extracellular domains of the glycoproteins CTLA-4 and CD80 using carbohydrate analysis, electrospray mass spectrometry, size exclusion chromatography, and analytical ultracentrifugation.	Carbohydrates	140-152	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	118-124
10505973-7	1999	In addition, there was a higher cytotoxicity mediated by sera from thymoma patients with extended dinucleotide repeats, (AT)n repeats, in the CTLA-4 gene.	Dinucleoside Phosphates	98-110	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	142-148
10398368-7	1999	Bacteriophage displaying CTLA-4 with somatostatin in CDR3 (CTLA-4R-Som3) specifically bound somatostatin receptors on transfected CHO-K1 cells pre-incubated with 1 microg/ml tunicamycin to remove receptor glycosylation.	Tunicamycin	174-185	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	25-31
10464177-0	1999	Augmentation of CTLA-4 expression by wortmannin: involvement of lysosomal sorting properties of CTLA-4.	Wortmannin	37-47	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	16-22
10464177-3	1999	Treatment with micromolar concentrations of wortmannin (WN) for >4 h enhanced both cell-surface and intracellular CTLA-4 without affecting its transcriptional activities in a murine mastocytoma cell line transfected with the human CTLA-4 gene and normal activated CD4(+) T cells.	Wortmannin	44-54	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	234-240
10334846-5	1999	In addition, we have applied a method described previously, using sedimentation equilibrium analysis to calculate the contribution of carbohydrates to the molecular masses of CTLA-4 and CD80.	Carbohydrates	134-147	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	175-181
9857283-5	1998	The kinetics of CTLA-4 expression on T cells stimulated in vitro with PMA plus ionomycin were similar in normal controls and patients with SLE.	Ionomycin	79-88	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	16-22
9973379-4	1999	In this report, we show that CTLA-4 can associate with the Src kinases Fyn and Lck and that transfection of Fyn or Lck, but not the unrelated kinase ZAP70, can induce tyrosine phosphorylation of CTLA-4 on residues Y201 and Y218.	Tyrosine	167-175	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	195-201
9973379-5	1999	A similar pattern of tyrosine phosphorylation was found in pervanadate-treated Jurkat T cells stably expressing CTLA-4.	Tyrosine	21-29	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	112-118
9973379-5	1999	A similar pattern of tyrosine phosphorylation was found in pervanadate-treated Jurkat T cells stably expressing CTLA-4.	pervanadate	59-70	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	112-118
9856951-2	1998	The association of TCRzeta with CTLA-4, reconstituted in 293 transfectants, was enhanced by p56(lck)-induced tyrosine phosphorylation.	tcrzeta	19-26	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	32-38
9856951-2	1998	The association of TCRzeta with CTLA-4, reconstituted in 293 transfectants, was enhanced by p56(lck)-induced tyrosine phosphorylation.	Tyrosine	109-117	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	32-38
9856951-3	1998	Coexpression of the CTLA-4-associated tyrosine phosphatase, SHP-2, resulted in dephosphorylation of TCRzeta bound to CTLA-4 and abolished the p56(lck)-inducible TCRzeta-CTLA-4 interaction.	tcrzeta	100-107	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	20-26
9856951-3	1998	Coexpression of the CTLA-4-associated tyrosine phosphatase, SHP-2, resulted in dephosphorylation of TCRzeta bound to CTLA-4 and abolished the p56(lck)-inducible TCRzeta-CTLA-4 interaction.	tcrzeta	100-107	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	117-123
9856951-3	1998	Coexpression of the CTLA-4-associated tyrosine phosphatase, SHP-2, resulted in dephosphorylation of TCRzeta bound to CTLA-4 and abolished the p56(lck)-inducible TCRzeta-CTLA-4 interaction.	tcrzeta	100-107	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	117-123
9856951-4	1998	Thus, CTLA-4 inhibits TCR signal transduction by binding to TCRzeta and inhibiting tyrosine phosphorylation after T cell activation.	tcrzeta	60-67	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	6-12
9856951-4	1998	Thus, CTLA-4 inhibits TCR signal transduction by binding to TCRzeta and inhibiting tyrosine phosphorylation after T cell activation.	Tyrosine	83-91	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	6-12
9973379-2	1999	Studies with phosphorylated peptides based on the CTLA-4 intracellular domain have suggested that tyrosine phosphorylation of CTLA-4 may regulate its interactions with cytoplasmic proteins that could determine its intracellular trafficking and/or signal transduction.	Tyrosine	98-106	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	50-56
9973379-2	1999	Studies with phosphorylated peptides based on the CTLA-4 intracellular domain have suggested that tyrosine phosphorylation of CTLA-4 may regulate its interactions with cytoplasmic proteins that could determine its intracellular trafficking and/or signal transduction.	Tyrosine	98-106	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	126-132
9973379-4	1999	In this report, we show that CTLA-4 can associate with the Src kinases Fyn and Lck and that transfection of Fyn or Lck, but not the unrelated kinase ZAP70, can induce tyrosine phosphorylation of CTLA-4 on residues Y201 and Y218.	Tyrosine	167-175	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	29-35
10077990-2	1999	In the process of T cell activation, immune tyrosine-based activation motifs (ITAMs) and immune tyrosine-based inhibitory motifs(ITIMs) within the cytoplasmic region of CD3 and CD152 molecules play a key role in the activation of PTKs and PTPases.	Tyrosine	44-52	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	177-182
10077990-2	1999	In the process of T cell activation, immune tyrosine-based activation motifs (ITAMs) and immune tyrosine-based inhibitory motifs(ITIMs) within the cytoplasmic region of CD3 and CD152 molecules play a key role in the activation of PTKs and PTPases.	Tyrosine	96-104	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	177-182
10215771-2	1999	Recent studies have demonstrated an association of a microsatellite polymorphism [variant lengths of a dinucleotide (AT)n repeat] lying in exon 3 of the CTLA-4 gene, specifically a 106-bp allele, with autoimmune disorders, such as Graves" disease, autoimmune Addison"s disease and autoimmune hypothyroidism.	Dinucleoside Phosphates	103-115	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	153-159
9712716-2	1998	Phosphorylation and dephosphorylation of tyrosine residue (Y)-165 in the cytoplasmic region of CTLA-4 play an important role in the signal transduction and in the cell surface.	Tyrosine	41-49	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	95-101
9712716-3	1998	While signaling molecules such as SHP-2 and the p85 subunit of PI3 kinase associate with this tyrosine residue through SH2 domains upon phosphorylation, the adapter complex AP-2 interacts with the same tyrosine when dephosphorylated, leading to clathrin-mediated endocytosis of CTLA-4.	Tyrosine	94-102	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	278-284
9638368-2	1998	Endocytosis and signaling of CTLA-4 are regulated by tyrosine phosphorylation.	Tyrosine	53-61	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	29-35
9653046-5	1998	In contrast, binding of the natural CD28 ligand B7 or antibodies to the CD28 homologue CTLA-4 can upregulate CCR5 expression, sug- gesting a reciprocal interaction between CD28 and CTLA-4 and the regulation of beta-chemokine receptor expression.	N(2)-succinyl-L-arginine	126-129	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	87-93
9654121-5	1998	Significantly, the non-glycosylated cell surface-associated B7-1 on tunicamycin-treated cells retained the capacity to bind CTLA-4 x Ig, a soluble derivative of the CTLA-4(CD152) counter-receptor.	Tunicamycin	68-79	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	124-130
9654121-5	1998	Significantly, the non-glycosylated cell surface-associated B7-1 on tunicamycin-treated cells retained the capacity to bind CTLA-4 x Ig, a soluble derivative of the CTLA-4(CD152) counter-receptor.	Tunicamycin	68-79	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	165-171
9654121-5	1998	Significantly, the non-glycosylated cell surface-associated B7-1 on tunicamycin-treated cells retained the capacity to bind CTLA-4 x Ig, a soluble derivative of the CTLA-4(CD152) counter-receptor.	Tunicamycin	68-79	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	172-177
9653046-5	1998	In contrast, binding of the natural CD28 ligand B7 or antibodies to the CD28 homologue CTLA-4 can upregulate CCR5 expression, sug- gesting a reciprocal interaction between CD28 and CTLA-4 and the regulation of beta-chemokine receptor expression.	N(2)-succinyl-L-arginine	126-129	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	181-187
9672157-3	1998	Since the CTLA-4-guanine at position 49 of exon 1 is associated with susceptibility to GD as well as to HT and IDDM, we investigated a recently detected cytosine/thymine substitution at position -318 within the CTLA-4 promoter region in patients with GD and HT.	Cytosine	153-161	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	10-16
9672157-3	1998	Since the CTLA-4-guanine at position 49 of exon 1 is associated with susceptibility to GD as well as to HT and IDDM, we investigated a recently detected cytosine/thymine substitution at position -318 within the CTLA-4 promoter region in patients with GD and HT.	Cytosine	153-161	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	211-217
9374463-3	1997	Glycosylceramide-mediated proliferative responses of Valpha14 NKT cells were abrogated by treatment with chloroquine-concanamycin A or by monoclonal antibodies against CD1d/Vbeta8, CD40/CD40L, or B7/CTLA-4/CD28, but not by interference with the function of a transporter-associated protein.	Soyacerebroside I	0-16	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	199-205
9459504-6	1998	In contrast, analyses of the CTLA4 exon 1 polymorphism with respect to HLA-DRB1*04 revealed significantly more patients with Ala in the homozygous (19% versus 15% controls) or heterozygous state (54% versus 39% controls) and less homozygous for Thr (27% versus 46% controls), with a particular increase of Ala/Ala genotypes among rheumatoid arthritis patients carrying the HLA-DRB1*0401 subtype.	Alanine	125-128	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	29-34
9459504-6	1998	In contrast, analyses of the CTLA4 exon 1 polymorphism with respect to HLA-DRB1*04 revealed significantly more patients with Ala in the homozygous (19% versus 15% controls) or heterozygous state (54% versus 39% controls) and less homozygous for Thr (27% versus 46% controls), with a particular increase of Ala/Ala genotypes among rheumatoid arthritis patients carrying the HLA-DRB1*0401 subtype.	Threonine	245-248	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	29-34
9459504-6	1998	In contrast, analyses of the CTLA4 exon 1 polymorphism with respect to HLA-DRB1*04 revealed significantly more patients with Ala in the homozygous (19% versus 15% controls) or heterozygous state (54% versus 39% controls) and less homozygous for Thr (27% versus 46% controls), with a particular increase of Ala/Ala genotypes among rheumatoid arthritis patients carrying the HLA-DRB1*0401 subtype.	Alanine	306-309	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	29-34
9459504-6	1998	In contrast, analyses of the CTLA4 exon 1 polymorphism with respect to HLA-DRB1*04 revealed significantly more patients with Ala in the homozygous (19% versus 15% controls) or heterozygous state (54% versus 39% controls) and less homozygous for Thr (27% versus 46% controls), with a particular increase of Ala/Ala genotypes among rheumatoid arthritis patients carrying the HLA-DRB1*0401 subtype.	Alanine	306-309	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	29-34
9398726-2	1997	Because the cytotoxic T lymphocyte antigen 4 (CTLA4) alanine-17 encoded by the CTLA4 gene on chromosome 2q33 confers susceptibility to Graves" disease, as well as to type 1 (insulin-dependent) diabetes mellitus, we investigated this dimorphism in the other endocrine autoimmune disorders: Hashimoto"s thyroiditis and Addison"s disease.	Alanine	53-60	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	12-44
9398726-2	1997	Because the cytotoxic T lymphocyte antigen 4 (CTLA4) alanine-17 encoded by the CTLA4 gene on chromosome 2q33 confers susceptibility to Graves" disease, as well as to type 1 (insulin-dependent) diabetes mellitus, we investigated this dimorphism in the other endocrine autoimmune disorders: Hashimoto"s thyroiditis and Addison"s disease.	Alanine	53-60	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	46-51
9398726-2	1997	Because the cytotoxic T lymphocyte antigen 4 (CTLA4) alanine-17 encoded by the CTLA4 gene on chromosome 2q33 confers susceptibility to Graves" disease, as well as to type 1 (insulin-dependent) diabetes mellitus, we investigated this dimorphism in the other endocrine autoimmune disorders: Hashimoto"s thyroiditis and Addison"s disease.	Alanine	53-60	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	79-84
9398726-9	1997	In conclusion, an alanine at codon 17 of CTLA4 confers genetic susceptibility to Hashimoto"s thyroiditis, whereas this applies only to the subgroup of DQA1*0501+ patients with Addison"s disease.	Alanine	18-25	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	41-46
9398332-0	1997	Interaction of the cytoplasmic tail of CTLA-4 (CD152) with a clathrin-associated protein is negatively regulated by tyrosine phosphorylation.	Tyrosine	116-124	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	39-45
9398332-0	1997	Interaction of the cytoplasmic tail of CTLA-4 (CD152) with a clathrin-associated protein is negatively regulated by tyrosine phosphorylation.	Tyrosine	116-124	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	47-52
9398332-9	1997	In co-transfection experiments, both tyrosine residues in the cytoplasmic tail of CTLA-4 (165Y and 182Y) were phosphorylated by the T lymphocyte-associated tyrosine kinase, p56lck.	Tyrosine	37-45	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	82-88
9175836-0	1997	Tyrosine phosphorylation controls internalization of CTLA-4 by regulating its interaction with clathrin-associated adaptor complex AP-2.	Tyrosine	0-8	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	53-59
9326417-5	1997	The addition of either sirolimus or cyclosporine to CTLA4-Ig increased graft survival over that achieved with CTLA4-Ig alone.	Cyclosporine	36-48	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	52-57
9326417-5	1997	The addition of either sirolimus or cyclosporine to CTLA4-Ig increased graft survival over that achieved with CTLA4-Ig alone.	Cyclosporine	36-48	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	110-115
9326417-8	1997	CONCLUSION: These data suggest that CTLA4-Ig may be effective clinically in combination with cyclosporine or sirolimus but offers no additional effectiveness in combination with antilymphocyte serum with or without donor-specific bone marrow.	Cyclosporine	93-105	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	36-41
9326417-8	1997	CONCLUSION: These data suggest that CTLA4-Ig may be effective clinically in combination with cyclosporine or sirolimus but offers no additional effectiveness in combination with antilymphocyte serum with or without donor-specific bone marrow.	Sirolimus	109-118	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	36-41
9175836-2	1997	CTLA-4 delivers an inhibitory signal through association of a phosphotyrosine-containing motif in the cytoplasmic domain with Syp tyrosine phosphatase.	Phosphotyrosine	62-77	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	0-6
9175836-3	1997	We now demonstrate that CTLA-4 interacts with the mu2 subunit of the plasma membrane-associated adaptor complex, AP-2, through the same motif involved in the interaction with Syp, except that the interaction with mu2 requires unphosphorylated tyrosine.	Tyrosine	243-251	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	24-30
9175836-5	1997	Our results suggest that the phosphorylation state of a single tyrosine residue determines whether CTLA-4 delivers a negative signal or is internalized.	Tyrosine	63-71	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	99-105
9176106-7	1997	CTLA4-Ig-mediated suppression was not due to blockade of the Con A "receptor(s)" or of the primary activation signal (as measured by the intracellular calcium response).	Calcium	151-158	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	0-5
9133464-8	1997	These data indicate that the mechanism of action of CTLA4Ig in attenuating chronic rejection is cyclosporine sensitive, and that strategies implying combination of CTLA4Ig and cyclosporine may not be clinically desirable.	Cyclosporine	96-108	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	52-57
9127268-2	1997	The EIA method employed a technique in which a monoclonal anti-CTLA4 antibody was adsorbed onto 96-well polystyrene microtiter plates and used to capture the CTLA4Ig in mouse serum samples.	Polystyrenes	104-115	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	63-68
9385561-8	1997	The location of N-linked glycosylation sites in CD28/CD152 restricts the surface area available for binding.	Nitrogen	16-17	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	53-58
8989248-0	1997	CTLA4 alanine-17 confers genetic susceptibility to Graves" disease and to type 1 diabetes mellitus.	Alanine	6-13	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	0-5
8989248-8	1997	In conclusion, an alanine at codon 17 of CTLA4 is associated with genetic susceptibility to Graves" disease as well as to IDDM.	Alanine	18-25	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	41-46
8901600-7	1996	Competitive reverse transcriptase-PCR and immunohistological analysis of allografts at 8, 16, and 24 weeks showed attenuation of lymphocyte and macrophage infiltration and activation in the CTLA4Ig-treated animals, as compared with cyclosporine-alone treated controls.	Cyclosporine	232-244	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	190-195
7559643-7	1995	Mutation of the tyrosine residue (Tyr165) in this motif to phenylalanine resulted in increased surface expression of CTLA-4.	Tyrosine	16-24	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	117-123
8673700-5	1996	Cell surface expression of CTLA-4 was rapidly increased by raising intracellular calcium levels.	Calcium	81-88	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	27-33
8900156-5	1996	Native disulfide-linked homodimers of CD28 and CTLA-4 bound with two kinetically distinct binding sites, one of high avidity and slow dissociation and one of low avidity and more rapid dissociation.	Disulfides	7-16	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	47-53
8981012-7	1996	This study also confirms that the allele HLA DQA1* 0501 confers susceptibility to Graves" disease, furthermore, that the CTLA4-alanine 17 allele is an additional predisposing factor.	Alanine	127-134	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	121-126
7559643-7	1995	Mutation of the tyrosine residue (Tyr165) in this motif to phenylalanine resulted in increased surface expression of CTLA-4.	Phenylalanine	59-72	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	117-123
7559643-8	1995	Thus, the subcellular localization of CTLA-4 is controlled by a tyrosine-containing motif within its cytoplasmic domain.	Tyrosine	64-72	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	38-44
7541042-4	1995	We demonstrate CTLA-4 is a homodimer interconnected by one disulfide bond in the extracellular domain at cysteine residue 120.	Disulfides	59-68	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	15-21
7541042-4	1995	We demonstrate CTLA-4 is a homodimer interconnected by one disulfide bond in the extracellular domain at cysteine residue 120.	Cysteine	105-113	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	15-21
7507511-1	1994	Interaction of CD28/CTLA-4 on T cells with B7 on antigen-presenting cells constitutes an important costimulatory signal for T cells and is responsible for cyclosporin A-resistant interleukin 2 (IL-2) gene expression and potentially also for prevention of anergy induction after T cell receptor triggering.	Cyclosporine	155-168	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	20-26
7964482-3	1994	Soluble forms of CD28 and CTLA-4 in which the V-like extracellular domains were fused to Ig constant domains (CD28Ig and CTLA4Ig), have been used to study their interactions with B7-1 and B7-2, with CTLA4Ig binding B7-1 more strongly than CD28Ig (approximately 20-fold higher avidity).	cd28ig	110-116	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	26-32
7964482-7	1994	Chimeric molecules HS4, HS4-A, and HS4-B were constructed in which CDR3-like regions of CTLA-4, COOH-terminally extended to include nonconserved residues, were grafted onto CD28Ig.	cd28ig	173-179	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	88-94
8016872-3	1994	In this report we show that treatment of the C3H/He recipient of a BALB/c vascularized cardiac allograft with a 12-day course of CTLA4-Ig produced indefinite graft survival (> 100 days) in the majority of recipients.	Helium	49-51	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	129-134
8397258-5	1993	CTLA-4 mRNA expression can be induced on quiescent T cells via phorbol ester-mediated activation of protein kinase C but not with calcium ionophore treatment alone.	Phorbol Esters	63-76	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	0-6
8397258-5	1993	CTLA-4 mRNA expression can be induced on quiescent T cells via phorbol ester-mediated activation of protein kinase C but not with calcium ionophore treatment alone.	Calcium	130-137	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	0-6
8397258-6	1993	Phorbol ester-induced expression of CTLA-4 mRNA could be enhanced with calcium ionophore treatment, and treatment of cells in this manner resulted in a reciprocal decrease in expression of CD28 mRNA.	Phorbol Esters	0-13	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	36-42
8397258-6	1993	Phorbol ester-induced expression of CTLA-4 mRNA could be enhanced with calcium ionophore treatment, and treatment of cells in this manner resulted in a reciprocal decrease in expression of CD28 mRNA.	Calcium	71-78	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	36-42
1862004-0	1991	Dinucleotide repeat polymorphism at the human CTLA4 gene.	Dinucleoside Phosphates	0-12	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	46-51
33802979-0	2021	Impaired Butyrate Induced Regulation of T Cell Surface Expression of CTLA-4 in Patients with Ulcerative Colitis.	Butyrates	9-17	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	69-75
33819967-3	2021	Several publications have explored the relationship between cytotoxic T lymphocyte antigen-4 (CTLA-4) +49 adenine (A)/guanine (G) polymorphism and susceptibility of lung cancer, but the results remain controversial.	Adenine	106-113	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	60-92
33802979-5	2021	However, surface expression of the inhibitory molecule CTLA-4 on stimulated blood and intestinal T cells was impaired in UC patients and was not restored following butyrate treatment.	Butyrates	164-172	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	55-61
33802979-7	2021	Although seemingly normal inhibitory effects on T cell activation and proliferation, butyrate has an impaired ability to reduce cytokine secretion and induce surface expression of CTLA-4 in T cells from UC patients with active disease.	Butyrates	85-93	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	180-186
33802979-8	2021	Overall, these observations indicate a dysfunction in butyrate induced immune regulation linked to CTLA-4 signaling in T cells from UC patients during a flare.	Butyrates	54-62	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	99-105
25589619-8	2015	Combinations of trametinib with immunomodulators targeting PD-1, PD-L1, or CTLA-4 in a CT26 model were more efficacious than any single agent.	trametinib	16-26	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	75-81
34615724-0	2022	18F-FMISO PET Imaging Identifies Hypoxia and Immunosuppressive Tumor Microenvironments and Guides Targeted Evofosfamide Therapy in Tumors Refractory to PD-1 and CTLA-4 Inhibition.	fluoromisonidazole	0-9	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	161-167
25589619-0	2015	The BRAF and MEK Inhibitors Dabrafenib and Trametinib: Effects on Immune Function and in Combination with Immunomodulatory Antibodies Targeting PD-1, PD-L1, and CTLA-4.	dabrafenib	28-38	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	161-167
25589619-0	2015	The BRAF and MEK Inhibitors Dabrafenib and Trametinib: Effects on Immune Function and in Combination with Immunomodulatory Antibodies Targeting PD-1, PD-L1, and CTLA-4.	trametinib	43-53	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	161-167
34615724-0	2022	18F-FMISO PET Imaging Identifies Hypoxia and Immunosuppressive Tumor Microenvironments and Guides Targeted Evofosfamide Therapy in Tumors Refractory to PD-1 and CTLA-4 Inhibition.	TH 302	107-119	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	161-167
34615724-3	2022	EXPERIMENTAL DESIGN: In this study, we probed the tumor and its surrounding microenvironment with 18F-FMISO PET imaging to non-invasively quantify tumor hypoxia in vivo prior to and during PD-1 and CTLA-4 checkpoint blockade in preclinical models of breast and colon cancer.	fluoromisonidazole	98-107	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	198-204
34965018-9	2022	Compared to the negative control, DBM-CTLA4 (+) promoted the proliferation of hBMMSCs, and enhanced calcium deposition, ALP activity, and protein levels of COL1A1, RUNX2, BMP2, and OPN.	Calcium	100-107	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	38-43
34958422-2	2022	METHODS: 18F-FDG PET/CT images of 58 MM patients treated with anti-PD-1 or anti-CTLA-4 ICI were retrospectively analyzed for indication of irAE.	Fluorodeoxyglucose F18	9-16	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	80-86
34962580-7	2022	Median time to onset of heme-irAEs varies between patients but occurs earlier with CTLA-4 inhibitors than with anti-PD-L1/PD-1 agents.	Heme	24-28	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	83-89
34897839-6	2022	Aldehyde-modified cytotoxic T-lymphocyte-associated protein-4 (CTLA-4) is used as a chimeric antigen receptor (CAR) targeting group to modify the surface of macrophages by aldehyde/hydroxylamine condensation to precisely target central M1-type microglia (CAR-M-UZPM).	Aldehydes	0-8	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	18-61
34993154-5	2021	Gene chip technology research showed that TSHR, BACH2, FOXE1, RNASET2, CTLA4, PTPN22, IL2RA and other HT-related genes were all expressed in PTC, in which TSHR was significantly over-expressed in PTC patients sensitive to radioactive iodine therapy, while BACH2 was significantly under-expressed in these patients.	radioactive iodine	222-240	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	71-76
34897839-6	2022	Aldehyde-modified cytotoxic T-lymphocyte-associated protein-4 (CTLA-4) is used as a chimeric antigen receptor (CAR) targeting group to modify the surface of macrophages by aldehyde/hydroxylamine condensation to precisely target central M1-type microglia (CAR-M-UZPM).	Aldehydes	0-8	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	63-69
34834202-9	2021	In addition, several studies have reported that the use of immunogenic/immunomodulatory metal-based nanoparticles increases the antitumor efficacy of immune-checkpoint inhibitor-based immunotherapy mediated by anti-PD-(L)1 or CTLA-4 antibodies.	Metals	88-93	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	226-232
34897839-6	2022	Aldehyde-modified cytotoxic T-lymphocyte-associated protein-4 (CTLA-4) is used as a chimeric antigen receptor (CAR) targeting group to modify the surface of macrophages by aldehyde/hydroxylamine condensation to precisely target central M1-type microglia (CAR-M-UZPM).	Aldehydes	172-180	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	18-61
34897839-6	2022	Aldehyde-modified cytotoxic T-lymphocyte-associated protein-4 (CTLA-4) is used as a chimeric antigen receptor (CAR) targeting group to modify the surface of macrophages by aldehyde/hydroxylamine condensation to precisely target central M1-type microglia (CAR-M-UZPM).	Aldehydes	172-180	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	63-69
34897839-6	2022	Aldehyde-modified cytotoxic T-lymphocyte-associated protein-4 (CTLA-4) is used as a chimeric antigen receptor (CAR) targeting group to modify the surface of macrophages by aldehyde/hydroxylamine condensation to precisely target central M1-type microglia (CAR-M-UZPM).	Hydroxylamine	181-194	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	18-61
34897839-6	2022	Aldehyde-modified cytotoxic T-lymphocyte-associated protein-4 (CTLA-4) is used as a chimeric antigen receptor (CAR) targeting group to modify the surface of macrophages by aldehyde/hydroxylamine condensation to precisely target central M1-type microglia (CAR-M-UZPM).	Hydroxylamine	181-194	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	63-69
34255356-3	2021	This study aimed to evaluate CTLA-4 expression in GC and its impact on survival, including patients treated with standard platinum-based chemotherapy (CMT), and association with PD-L1 expression.	Platinum	122-130	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	29-35
34899684-8	2021	Moreover, TMCs 4-8 were correlated with tumor mutation burden and expression of PD-1/PD-L1/CTLA4 in 33 cancers.	trimethylsilyl chloride	10-14	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	91-96
34841735-6	2021	Meanwhile, percentages of regulatory T cells (Tregs) and expression of CTLA-4 were both up to two-fold higher in the RAPA group, suggesting the inconsistent reactivation potential of the FK506 and RAPA groups when an anti-tumour or anti-infection immune response is concerned.	Sirolimus	117-121	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	71-77
34841735-6	2021	Meanwhile, percentages of regulatory T cells (Tregs) and expression of CTLA-4 were both up to two-fold higher in the RAPA group, suggesting the inconsistent reactivation potential of the FK506 and RAPA groups when an anti-tumour or anti-infection immune response is concerned.	Tacrolimus	187-192	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	71-77
34841735-6	2021	Meanwhile, percentages of regulatory T cells (Tregs) and expression of CTLA-4 were both up to two-fold higher in the RAPA group, suggesting the inconsistent reactivation potential of the FK506 and RAPA groups when an anti-tumour or anti-infection immune response is concerned.	Sirolimus	197-201	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	71-77
34518299-3	2021	Previously cytotoxic T-lymphocyte antigen 4 (CTLA4)-targeted NIR-PIT has been shown to strongly inhibit tumor progression and prolonged survival was seen in several different tumor models due to enhanced T cell mediated antitumor immunity.	nir-pit	61-68	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	45-50
34859391-11	2022	CTLA-4 (rs231775 SNP) was significantly (p < 0.005) associated with TRAb titers above the median three months after radioiodine.	Iodine-131	116-127	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	0-6
34859391-12	2022	CONCLUSIONS: The increase in TRAb titers after treatment with radioiodine is associated with GO and a genetic variation in CTLA-4 is associated with higher titers of TRAb.	Iodine-131	62-73	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	123-129
34937742-9	2021	In addition, resiquimod decreased the number of adherent inhibitory antigen-presenting cells (APCs) and suppressed the inhibitory function of APCs by decreasing PD-L1 and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) expression in these cells during in vitro Vdelta2 T-cell expansion.	resiquimod	13-23	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	171-214
34937742-9	2021	In addition, resiquimod decreased the number of adherent inhibitory antigen-presenting cells (APCs) and suppressed the inhibitory function of APCs by decreasing PD-L1 and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) expression in these cells during in vitro Vdelta2 T-cell expansion.	resiquimod	13-23	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	216-222
34771459-5	2021	For the first time, clinical trials testing ICIs, anti-CTLA-4 and anti-PD1/PDL1 reported a survival benefit in patients with sorafenib resistance.	Sorafenib	125-134	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	55-61
34744733-11	2021	In conclusion, our findings suggest that during SD in the internal environment, exosome CTLA-4 regulates the PTEN/CD44 signal pathway to promote the proliferation, self-renewal, and metastasis of liver cancer.	SD 0006	48-50	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	88-94
34403371-7	2021	In contrast, the more immunogenic and highly mutated GL261 model responded best to anti-PD-1 and anti-CTLA-4 therapy and more modestly to BAL101553 and anti-CD40 combination.	gl261	53-58	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	102-108
34691057-7	2021	Moreover, pathogens seem also to enhance Treg functions as shown in human immunodeficiency virus infection, where Tregs express higher levels of effector molecules such as cytotoxic T-lymphocyte-associated protein 4, CD39 and cAMP and show increased suppressive capacity.	treg	41-45	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	172-215
34691057-7	2021	Moreover, pathogens seem also to enhance Treg functions as shown in human immunodeficiency virus infection, where Tregs express higher levels of effector molecules such as cytotoxic T-lymphocyte-associated protein 4, CD39 and cAMP and show increased suppressive capacity.	tregs	114-119	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	172-215
34592958-8	2021	RESULTS: The frequency of Tregs was higher in chronic patients than in healthy controls (P = 0.026) and acute patients (P = 0.042); The frequency of CTLA-4+ Tregs in chronic patients was significantly higher than that in healthy controls (P = 0.011).	tregs	26-31	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	149-155
34592958-13	2021	CTLA-4 and TGF-beta1 may contribute to Tregs-mediated immunosuppression in the chronic infection stage of a Brucella infection.	tregs	39-44	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	0-6
34384744-7	2021	Both immune checkpoint deficiencies are biologically characterized by low levels of CTLA-4 protein on the cell surface of Tregs, accounting for the autoimmune manifestations observed in CTLA4-insufficient and LRBA-deficient patients.	tregs	122-127	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	84-90
34475226-10	2022	Human Tregs entered the lung parenchyma during EVLP where they expressed key immunoregulatory molecules (CTLA4+, 4-1BB+, CD39+, and CD15s+).Pre-transplant Treg administration can inhibit alloimmunity within the lung allograft at early time points post- transplant.	treg	155-159	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	105-110
34384744-7	2021	Both immune checkpoint deficiencies are biologically characterized by low levels of CTLA-4 protein on the cell surface of Tregs, accounting for the autoimmune manifestations observed in CTLA4-insufficient and LRBA-deficient patients.	tregs	122-127	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	186-191
34442365-0	2021	Regulation of CTLA-4 and PD-L1 Expression in Relapsing-Remitting Multiple Sclerosis Patients after Treatment with Fingolimod, IFNbeta-1alpha, Glatiramer Acetate, and Dimethyl Fumarate Drugs.	Fingolimod Hydrochloride	114-124	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	14-20
34442365-0	2021	Regulation of CTLA-4 and PD-L1 Expression in Relapsing-Remitting Multiple Sclerosis Patients after Treatment with Fingolimod, IFNbeta-1alpha, Glatiramer Acetate, and Dimethyl Fumarate Drugs.	ifnbeta-1alpha	126-140	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	14-20
34442365-0	2021	Regulation of CTLA-4 and PD-L1 Expression in Relapsing-Remitting Multiple Sclerosis Patients after Treatment with Fingolimod, IFNbeta-1alpha, Glatiramer Acetate, and Dimethyl Fumarate Drugs.	Glatiramer Acetate	142-160	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	14-20
34442365-0	2021	Regulation of CTLA-4 and PD-L1 Expression in Relapsing-Remitting Multiple Sclerosis Patients after Treatment with Fingolimod, IFNbeta-1alpha, Glatiramer Acetate, and Dimethyl Fumarate Drugs.	Dimethyl Fumarate	166-183	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	14-20
34239352-11	2021	CTLA-4+T cells are also significantly decreased in tumors treated with Lef, Gem or in combination (Gem+Lef) compared to controls (P<0.05).	Leflunomide	71-74	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	0-6
34336706-11	2021	Moreover, miR-20b-5p was identified as a potential miRNA target of CTLA4 in KIRC.	mir-20b-5p	10-20	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	67-72
34213416-7	2021	Conversely, compared to APs, TBKs showed higher levels of sIgG4 (p<0.001) and IL-10 (p<0.001) as well as an enhanced CTLA-4+ Treg population (p=0.001), expanded Helios- Treg (p<0.003), and reduced T-helper 1 (p=0.008), T-helper 2 (p=0.004) and T-helper 17 (p=0.007) subsets.	Adenosine Phosphosulfate	24-27	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	117-123
34213416-7	2021	Conversely, compared to APs, TBKs showed higher levels of sIgG4 (p<0.001) and IL-10 (p<0.001) as well as an enhanced CTLA-4+ Treg population (p=0.001), expanded Helios- Treg (p<0.003), and reduced T-helper 1 (p=0.008), T-helper 2 (p=0.004) and T-helper 17 (p=0.007) subsets.	tbks	29-33	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	117-123
34140795-0	2021	High Inflammatory Tendency Induced by Malignant Stimulation Through Imbalance of CD28 and CTLA-4/PD-1 Contributes to Dopamine Neuron Injury.	Dopamine	117-125	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	90-96
34239352-11	2021	CTLA-4+T cells are also significantly decreased in tumors treated with Lef, Gem or in combination (Gem+Lef) compared to controls (P<0.05).	gemcitabine	76-79	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	0-6
34239352-11	2021	CTLA-4+T cells are also significantly decreased in tumors treated with Lef, Gem or in combination (Gem+Lef) compared to controls (P<0.05).	gemcitabine	99-102	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	0-6
34239352-11	2021	CTLA-4+T cells are also significantly decreased in tumors treated with Lef, Gem or in combination (Gem+Lef) compared to controls (P<0.05).	Leflunomide	103-106	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	0-6
35365357-4	2022	Single-nucleotide polymorphisms (SNPs) in CTLA-4 are known to be associated with acute rejection; however, their association with dnDSA formation is not established.	dndsa	130-135	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	42-48
34073458-3	2021	We show that, while CD4 CTL are resistant to suppression by Tregs in vitro, the conditioned medium of CD4 CTL accentuates the suppressive phenotype of Tregs by upregulating IL-10, Granzyme B, CTLA-4, and PD-1.	tregs	60-65	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	192-198
34073458-3	2021	We show that, while CD4 CTL are resistant to suppression by Tregs in vitro, the conditioned medium of CD4 CTL accentuates the suppressive phenotype of Tregs by upregulating IL-10, Granzyme B, CTLA-4, and PD-1.	tregs	151-156	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	192-198
34067631-8	2021	In addition, capecitabine can remarkably downregulate the expression of CTLA-4 in SW480 cells.	Capecitabine	13-25	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	72-78
34067631-9	2021	Collectively, capecitabine can inhibit the expression of CTLA-4 in CRC cells and might bridge the immunotherapy approaches with chemotherapy.	Capecitabine	14-26	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	57-63
35417536-1	2022	Preliminary data from a phase I trial of MEDI5752, a bispecific antibody targeting both PD-1 and CTLA4, indicate the drug is well tolerated and active, with durable responses seen across diverse tumor types.	medi5752	41-49	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	97-102
35365357-6	2022	Patients with the GG genotype of CTLA-4 SNPs rs231775 and rs3087243 had higher rates of dnDSA formation than patients with the AA genotype or heterozygous genotypes.	dndsa	88-93	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	33-39
35365357-7	2022	In conclusion, our findings indicate that CTLA-4 SNPs are predisposing factors for dnDSA formation after KT.	dndsa	83-88	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	42-48
35091676-5	2022	Comparing both CTLA-4 antibodies revealed a clone dependent unspecific staining pattern in adrenal cortical adenoma (63%) for MSVA-152R and in pheochromocytoma (67%) as well as hepatocellular carcinoma (36%) for CAL49.	msva-152r	126-135	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	15-21
35626016-7	2022	We conclude that GNP-LLO91-99 nanovaccines can work as monotherapies or combinatory immunotherapies with anti-CTLA-4 or anti-PD-1 antibodies for solid tumors with high T cell infiltration, such as bladder cancer or melanoma.	gnp-llo91-99	17-29	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	110-116
35626016-7	2022	We conclude that GNP-LLO91-99 nanovaccines can work as monotherapies or combinatory immunotherapies with anti-CTLA-4 or anti-PD-1 antibodies for solid tumors with high T cell infiltration, such as bladder cancer or melanoma.	nanovaccines	30-42	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	110-116
35524454-3	2022	Conjugation of anti-CTLA-4 antibodies onto the polymer nanoparticles through 1 O2 -cleavable linker affords SPNAb with relatively low CTLA-4 binding affinity.	Polymers	47-54	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	20-26
35524454-3	2022	Conjugation of anti-CTLA-4 antibodies onto the polymer nanoparticles through 1 O2 -cleavable linker affords SPNAb with relatively low CTLA-4 binding affinity.	Polymers	47-54	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	134-140
35524454-4	2022	Upon sono-irradiation, SPNAb generates 1 O2 not only to elicit sonodynamic effect to induce the immunogenic cell death, but also to release anti-CTLA-4 antibodies and trigger in situ checkpoint blockade.	Oxygen	41-43	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	145-151
35494533-2	2022	We report a 45-year-old man with non-small-cell lung cancer who developed hypophysitis 11 months after initiation of treatment with an anti-PD-L1/CTLA-4 bispecific antibody (KN046) that blocks both programmed death ligand-1 (PD-L1) and cytotoxic T-lymphocyte antigen-4 (CTLA-4), followed by regular oral replacement doses of prednisone and levothyroxine tablets.	Thyroxine	340-353	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	146-152
35523809-7	2022	B7x-mediated regulation of Tregs reduces the efficacy of anti-CTLA-4 treatment, a therapeutic that partially relies on Treg-depletion.	tregs	27-32	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	62-68
35523809-7	2022	B7x-mediated regulation of Tregs reduces the efficacy of anti-CTLA-4 treatment, a therapeutic that partially relies on Treg-depletion.	treg	119-123	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	62-68
35516457-9	2022	Furthermore, the high-risk group with higher TMB levels and expression of immune checkpoints was more likely to benefit from immune checkpoint therapy such as PD-1 and CTLA-4 inhibitors.	1,2,4,5-tetramethoxybenzene	45-48	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	168-174
35494533-2	2022	We report a 45-year-old man with non-small-cell lung cancer who developed hypophysitis 11 months after initiation of treatment with an anti-PD-L1/CTLA-4 bispecific antibody (KN046) that blocks both programmed death ligand-1 (PD-L1) and cytotoxic T-lymphocyte antigen-4 (CTLA-4), followed by regular oral replacement doses of prednisone and levothyroxine tablets.	Prednisone	325-335	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	146-152
35486317-6	2022	We observed a decrease in CD4+CD25+Foxp3+ and CD4+CTLA-4+ cells in presence of selenium.	Selenium	79-87	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	50-56
35379324-15	2022	Furthermore, physical activity inhibited Treg cell infiltration and immune checkpoint expression (including CTLA4, TIGIT and TIM3) induced by long-term combined lenvatinib plus anti-PD-1 therapy, improving efficacy.	lenvatinib	161-171	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	108-113
35453810-3	2022	A nonsignificant difference was seen in the CTLA-4 expression on CD3+ T cells compared to the healthy control at basal level and after stimulation with PMA/ionomycin.	Tetradecanoylphorbol Acetate	152-155	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	44-50
35453810-3	2022	A nonsignificant difference was seen in the CTLA-4 expression on CD3+ T cells compared to the healthy control at basal level and after stimulation with PMA/ionomycin.	Ionomycin	156-165	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	44-50
35326731-5	2022	Although activating T-cells is regarded as the primary anti-tumor mechanism of anti-CTLA-4 therapies, mounting evidence in the literature suggests targeting intra-tumoral Tregs as the primary mechanism of action of these agents.	tregs	171-176	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	84-90
35294071-0	2022	Nanoliposome C6-Ceramide in combination with anti-CTLA4 antibody improves anti-tumor immunity in hepatocellular cancer.	N-caproylsphingosine	13-24	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	50-55
35294071-3	2022	We generated orthotopic HCC-bearing mice, which have typical features in common with human patients, and then treated them with LipC6 in combination with the antibodies (Abs) for programmed cell death protein 1 (PD-1) or cytotoxic T-lymphocyte antigen 4 (CTLA4).	lipc6	128-133	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	255-260
35194944-8	2022	In a syngeneic CRC model, DCZ0415 treatment induced an immune response by decreasing PD1 and CTLA4 levels and increasing granzyme B, perforin and interferon gamma.	DCZ0415	26-33	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	93-98
35326731-7	2022	Anti-CTLA-4 therapy can enhance the priming of T-cells by blockading CD80/86-CTLA-4 interactions or depleting Tregs through antibody-dependent cellular cytotoxicity and phagocytosis.	tregs	110-115	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	5-11
35304456-2	2022	We describe herein a thermosensitive co-polymer hydrogel system formed from biocompatible polymers gelatin and Pluronic  F127 that are widely used in humans to enable the sustained release of a nitric oxide donor and antibody blocking immune checkpoint cytotoxic T-lymphocyte-associated protein-4 for efficient and durable anti-tumor immunotherapy.	co-polymer	37-47	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	253-296
35304456-2	2022	We describe herein a thermosensitive co-polymer hydrogel system formed from biocompatible polymers gelatin and Pluronic  F127 that are widely used in humans to enable the sustained release of a nitric oxide donor and antibody blocking immune checkpoint cytotoxic T-lymphocyte-associated protein-4 for efficient and durable anti-tumor immunotherapy.	Polymers	90-98	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	253-296
35304456-2	2022	We describe herein a thermosensitive co-polymer hydrogel system formed from biocompatible polymers gelatin and Pluronic  F127 that are widely used in humans to enable the sustained release of a nitric oxide donor and antibody blocking immune checkpoint cytotoxic T-lymphocyte-associated protein-4 for efficient and durable anti-tumor immunotherapy.	Nitric Oxide	194-206	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	253-296
35092506-8	2022	An effort to meet such unmet need has culminated in inventing new immune checkpoint inhibitors namely PD-1 inhibitor, AGEN2034 (Balstilimab) and CTLA-4 inhibitor, AGEN1884 (Zalifrelimab).They have shown meaningful and durable activity as single-agent therapy in previously treated patients with persistent R/M CC in a large phase II trial (NCT03104699) in PD-L1 + and PD-L1- tumour.	agen1884	163-171	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	145-151
35241494-12	2022	Patients with EBVaGC with a high cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) level were less responsive to anti-programmed death-1/ligand 1 (PD-1/L1) monotherapy, and the combination of anti-CTLA-4 plus anti-PD-1/L1 checkpoint blockade benefited patients with EBVaGC more than anti-PD-1/L1 monotherapy with a trend close to significance (p=0.074).	ebvagc	14-20	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	33-76
35241494-12	2022	Patients with EBVaGC with a high cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) level were less responsive to anti-programmed death-1/ligand 1 (PD-1/L1) monotherapy, and the combination of anti-CTLA-4 plus anti-PD-1/L1 checkpoint blockade benefited patients with EBVaGC more than anti-PD-1/L1 monotherapy with a trend close to significance (p=0.074).	ebvagc	14-20	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	78-84
35241494-12	2022	Patients with EBVaGC with a high cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) level were less responsive to anti-programmed death-1/ligand 1 (PD-1/L1) monotherapy, and the combination of anti-CTLA-4 plus anti-PD-1/L1 checkpoint blockade benefited patients with EBVaGC more than anti-PD-1/L1 monotherapy with a trend close to significance (p=0.074).	ebvagc	14-20	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	200-206
35241494-12	2022	Patients with EBVaGC with a high cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) level were less responsive to anti-programmed death-1/ligand 1 (PD-1/L1) monotherapy, and the combination of anti-CTLA-4 plus anti-PD-1/L1 checkpoint blockade benefited patients with EBVaGC more than anti-PD-1/L1 monotherapy with a trend close to significance (p=0.074).	ebvagc	269-275	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	33-76
35241494-12	2022	Patients with EBVaGC with a high cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) level were less responsive to anti-programmed death-1/ligand 1 (PD-1/L1) monotherapy, and the combination of anti-CTLA-4 plus anti-PD-1/L1 checkpoint blockade benefited patients with EBVaGC more than anti-PD-1/L1 monotherapy with a trend close to significance (p=0.074).	ebvagc	269-275	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	78-84
35017664-10	2022	Lastly, we observe that the co-administration of propranolol significantly enhances the efficacy of anti-CTLA4 therapy.	Propranolol	49-60	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	105-110
35236323-10	2022	The correlation analysis between this signature and immunosuppressive molecules, Immunophenoscore (IPS) and chemotherapeutic efficacy demonstrated that low-risk group had a higher  IC50 of cisplatin, mitomycin and doxorubicin and negatively related with CTLA4, HAVCR2, LAG3, PDCD1, TIGIT and ICIs treatment represented by CTLA4-/PD-1-, CTLA4 + /PD-1-, CTLA4-/PD-1 + .	Cisplatin	189-198	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	254-259
35236323-10	2022	The correlation analysis between this signature and immunosuppressive molecules, Immunophenoscore (IPS) and chemotherapeutic efficacy demonstrated that low-risk group had a higher  IC50 of cisplatin, mitomycin and doxorubicin and negatively related with CTLA4, HAVCR2, LAG3, PDCD1, TIGIT and ICIs treatment represented by CTLA4-/PD-1-, CTLA4 + /PD-1-, CTLA4-/PD-1 + .	Cisplatin	189-198	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	322-327
35236323-10	2022	The correlation analysis between this signature and immunosuppressive molecules, Immunophenoscore (IPS) and chemotherapeutic efficacy demonstrated that low-risk group had a higher  IC50 of cisplatin, mitomycin and doxorubicin and negatively related with CTLA4, HAVCR2, LAG3, PDCD1, TIGIT and ICIs treatment represented by CTLA4-/PD-1-, CTLA4 + /PD-1-, CTLA4-/PD-1 + .	Cisplatin	189-198	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	336-341
35236323-10	2022	The correlation analysis between this signature and immunosuppressive molecules, Immunophenoscore (IPS) and chemotherapeutic efficacy demonstrated that low-risk group had a higher  IC50 of cisplatin, mitomycin and doxorubicin and negatively related with CTLA4, HAVCR2, LAG3, PDCD1, TIGIT and ICIs treatment represented by CTLA4-/PD-1-, CTLA4 + /PD-1-, CTLA4-/PD-1 + .	Cisplatin	189-198	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	352-357
35236323-10	2022	The correlation analysis between this signature and immunosuppressive molecules, Immunophenoscore (IPS) and chemotherapeutic efficacy demonstrated that low-risk group had a higher  IC50 of cisplatin, mitomycin and doxorubicin and negatively related with CTLA4, HAVCR2, LAG3, PDCD1, TIGIT and ICIs treatment represented by CTLA4-/PD-1-, CTLA4 + /PD-1-, CTLA4-/PD-1 + .	Doxorubicin	214-225	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	254-259
35236323-10	2022	The correlation analysis between this signature and immunosuppressive molecules, Immunophenoscore (IPS) and chemotherapeutic efficacy demonstrated that low-risk group had a higher  IC50 of cisplatin, mitomycin and doxorubicin and negatively related with CTLA4, HAVCR2, LAG3, PDCD1, TIGIT and ICIs treatment represented by CTLA4-/PD-1-, CTLA4 + /PD-1-, CTLA4-/PD-1 + .	Doxorubicin	214-225	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	322-327
35236323-10	2022	The correlation analysis between this signature and immunosuppressive molecules, Immunophenoscore (IPS) and chemotherapeutic efficacy demonstrated that low-risk group had a higher  IC50 of cisplatin, mitomycin and doxorubicin and negatively related with CTLA4, HAVCR2, LAG3, PDCD1, TIGIT and ICIs treatment represented by CTLA4-/PD-1-, CTLA4 + /PD-1-, CTLA4-/PD-1 + .	Doxorubicin	214-225	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	336-341
35236323-10	2022	The correlation analysis between this signature and immunosuppressive molecules, Immunophenoscore (IPS) and chemotherapeutic efficacy demonstrated that low-risk group had a higher  IC50 of cisplatin, mitomycin and doxorubicin and negatively related with CTLA4, HAVCR2, LAG3, PDCD1, TIGIT and ICIs treatment represented by CTLA4-/PD-1-, CTLA4 + /PD-1-, CTLA4-/PD-1 + .	Doxorubicin	214-225	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	352-357
35015785-4	2022	In the present paper we develop a mathematical model to assess the efficacy of any combination of ADT with cancer vaccine, PD-1 inhibitor, and CTLA-4 inhibitor.	adt	98-101	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	143-149
35058324-7	2022	METHODS: A novel human IgG1 CTLA-4 antibody (4-E03) was identified using function-first screening for monoclonal antibodies (mAbs) and targets associated with superior Treg-depleting activity.	treg	168-172	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	28-34
33986285-7	2021	Ex vivo expansion of Tregs from patients with PD restored and enhanced their suppressive functions while expanded Tregs displayed increased expression of foxp3, il2ra (CD25), nt5e (CD73), il10, il13, ctla4, pdcd1 (PD1), and gzmb.	tregs	114-119	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	200-205
33930312-0	2021	Evaluation of TMB as a predictive biomarker in patients with solid cancers treated with anti-PD-1/CTLA-4 combination immunotherapy.	1,2,4,5-tetramethoxybenzene	14-17	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	98-104
33637482-0	2021	Anti-CTLA4 Perturbs Treg-Based Immunosuppression in Glycolysis-Low Tumors.	perturbs	11-19	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	5-10
33592328-3	2021	The immunomodulatory capacity of BPs has been focused on the mechanisms involved in the acute-phase response associated with the administration of nitrogen containing BPs (N-BPs), with the stimulus of pro-inflammatory cytokines, through the mevalonate pathway, activation of T-cells and the decrease in the cytotoxic T-lymphocyte antigen-4 (CTLA-4).	Diphosphonates	33-36	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	307-339
33592328-3	2021	The immunomodulatory capacity of BPs has been focused on the mechanisms involved in the acute-phase response associated with the administration of nitrogen containing BPs (N-BPs), with the stimulus of pro-inflammatory cytokines, through the mevalonate pathway, activation of T-cells and the decrease in the cytotoxic T-lymphocyte antigen-4 (CTLA-4).	Diphosphonates	33-36	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	341-347
33592328-3	2021	The immunomodulatory capacity of BPs has been focused on the mechanisms involved in the acute-phase response associated with the administration of nitrogen containing BPs (N-BPs), with the stimulus of pro-inflammatory cytokines, through the mevalonate pathway, activation of T-cells and the decrease in the cytotoxic T-lymphocyte antigen-4 (CTLA-4).	Nitrogen	147-155	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	307-339
33637482-0	2021	Anti-CTLA4 Perturbs Treg-Based Immunosuppression in Glycolysis-Low Tumors.	treg	20-24	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	5-10
33592328-3	2021	The immunomodulatory capacity of BPs has been focused on the mechanisms involved in the acute-phase response associated with the administration of nitrogen containing BPs (N-BPs), with the stimulus of pro-inflammatory cytokines, through the mevalonate pathway, activation of T-cells and the decrease in the cytotoxic T-lymphocyte antigen-4 (CTLA-4).	Nitrogen	147-155	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	341-347
33929751-6	2021	Treg induction was measured by flow cytometric detection of FOXP3 and other Treg markers, such as CD25 and CTLA-4.	treg	0-4	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	107-113
33592328-3	2021	The immunomodulatory capacity of BPs has been focused on the mechanisms involved in the acute-phase response associated with the administration of nitrogen containing BPs (N-BPs), with the stimulus of pro-inflammatory cytokines, through the mevalonate pathway, activation of T-cells and the decrease in the cytotoxic T-lymphocyte antigen-4 (CTLA-4).	Diphosphonates	167-170	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	307-339
33592328-3	2021	The immunomodulatory capacity of BPs has been focused on the mechanisms involved in the acute-phase response associated with the administration of nitrogen containing BPs (N-BPs), with the stimulus of pro-inflammatory cytokines, through the mevalonate pathway, activation of T-cells and the decrease in the cytotoxic T-lymphocyte antigen-4 (CTLA-4).	Diphosphonates	167-170	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	341-347
33592328-3	2021	The immunomodulatory capacity of BPs has been focused on the mechanisms involved in the acute-phase response associated with the administration of nitrogen containing BPs (N-BPs), with the stimulus of pro-inflammatory cytokines, through the mevalonate pathway, activation of T-cells and the decrease in the cytotoxic T-lymphocyte antigen-4 (CTLA-4).	n-bps	172-177	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	307-339
33592328-3	2021	The immunomodulatory capacity of BPs has been focused on the mechanisms involved in the acute-phase response associated with the administration of nitrogen containing BPs (N-BPs), with the stimulus of pro-inflammatory cytokines, through the mevalonate pathway, activation of T-cells and the decrease in the cytotoxic T-lymphocyte antigen-4 (CTLA-4).	n-bps	172-177	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	341-347
33592328-3	2021	The immunomodulatory capacity of BPs has been focused on the mechanisms involved in the acute-phase response associated with the administration of nitrogen containing BPs (N-BPs), with the stimulus of pro-inflammatory cytokines, through the mevalonate pathway, activation of T-cells and the decrease in the cytotoxic T-lymphocyte antigen-4 (CTLA-4).	Mevalonic Acid	241-251	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	307-339
33592328-3	2021	The immunomodulatory capacity of BPs has been focused on the mechanisms involved in the acute-phase response associated with the administration of nitrogen containing BPs (N-BPs), with the stimulus of pro-inflammatory cytokines, through the mevalonate pathway, activation of T-cells and the decrease in the cytotoxic T-lymphocyte antigen-4 (CTLA-4).	Mevalonic Acid	241-251	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	341-347
33568343-14	2021	CONCLUSIONS: We demonstrate the feasibility and safety of adding LDFRT and HFRT to PD-L1/CTLA-4 blockade.	ldfrt	65-70	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	89-95
33568343-14	2021	CONCLUSIONS: We demonstrate the feasibility and safety of adding LDFRT and HFRT to PD-L1/CTLA-4 blockade.	hfrt	75-79	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	89-95
33929751-9	2021	Hp-TGM efficiently induced FOXP3 expression (> 60%), in addition to CD25 and CTLA-4, and caused epigenetic modification of the FOXP3 locus to a greater extent than TGF-beta.	hp-tgm	0-6	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	77-83
33923750-6	2021	Moreover, the frequency of lymphoid and myeloid cells and the CTLA-4 expression by T helper (Th)17 cells were increased in TC-1/dCD80-1- compared with that in the TC-1-induced tumors.	TC 1	123-127	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	62-68
33550204-1	2021	BACKGROUND: We have previously shown an association with substantially improved survival in breast cancer and melanoma for desloratadine and loratadine users, and set out to find whether an improved survival can be seen in tumors with and without a known response to immune checkpoint therapy, such as anti-CTLA-4 or anti-PD-1.	desloratadine	123-136	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	307-313
33859108-9	2021	P2 demonstrated a striking increase in the frequency of gag-specific central and effector memory CD8+ T cells producing IFN-gamma, TNF-alpha, and CD107a following anti-PD1 and anti-CTLA-4.	P-2	0-2	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	181-187
33859108-9	2021	P2 demonstrated a striking increase in the frequency of gag-specific central and effector memory CD8+ T cells producing IFN-gamma, TNF-alpha, and CD107a following anti-PD1 and anti-CTLA-4.	Glycosaminoglycans	56-59	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	181-187
33593794-4	2021	We hypothesized that EomeshiCD8+ T cells were necessary for anti-OX40/anti-CTLA-4 immunotherapy efficacy and that further enhancement of this population would improve tumor-free survival.	eomeshicd8	21-31	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	75-81
33593794-8	2021	We investigated the impact of modulating ITK signaling with ibrutinib, an FDA-approved tyrosine kinase inhibitor, and found that anti-OX40/anti-CTLA-4/ibrutinib therapy further enhanced CD8+ T cell-specific Eomes expression, leading to enhanced tumor regression and improved survival, both of which were associated with increased T-cell effector function across multiple tumor models.	ibrutinib	60-69	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	144-150
33841630-1	2021	First-generation immunological checkpoint inhibitors, such as CTLA-4, PD-L1 and PD-1 exhibit significant advantages over conventional cytotoxic drugs, such as oxaliplatin and 5-FU, for the treatment of colorectal cancer.	Oxaliplatin	159-170	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	62-68
33744355-10	2021	CONCLUSIONS: Patients actively receiving CPIs are more susceptible to dermatologic infections, with anti-CTLA-4 monotherapy carrying the highest risk, suggesting that the index of suspicion for infections should be increased in these patients to minimize morbidity and optimize care.	cpis	41-45	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	105-111
33855282-4	2021	MSCl cells promote the differentiation of CTLA-4 expressing DCs via the production of all-trans retinoic acid (ATRA) functioning as a ligand of RARalpha, a key nuclear receptor in DC development.	Tretinoin	86-109	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	42-48
33855282-4	2021	MSCl cells promote the differentiation of CTLA-4 expressing DCs via the production of all-trans retinoic acid (ATRA) functioning as a ligand of RARalpha, a key nuclear receptor in DC development.	Tretinoin	111-115	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	42-48
33841630-1	2021	First-generation immunological checkpoint inhibitors, such as CTLA-4, PD-L1 and PD-1 exhibit significant advantages over conventional cytotoxic drugs, such as oxaliplatin and 5-FU, for the treatment of colorectal cancer.	Fluorouracil	175-179	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	62-68
33386150-2	2021	In the cytoplasmic tails of CD28 and CTLA-4, phosphoinositide 3-kinase (PI3K) binds to the consensus sequence including phosphotyrosine via SH2 domains, N- and C-terminal SH2 domains (nSH2 and cSH2), of its regulatory subunit, p85.	Phosphotyrosine	120-135	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	37-43
33276076-0	2021	Safety and Efficacy of Quavonlimab, a Novel Anti-CTLA-4 Antibody (MK-1308), in Combination with Pembrolizumab in First-Line Advanced Non-Small Cell Lung Cancer.	mk-1308	66-73	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	49-55
33276076-1	2021	BACKGROUND: Quavonlimab (MK-1308), a novel anti-CTLA-4 antibody, in combination with pembrolizumab was investigated in a phase I study.	mk-1308	25-32	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	48-54
33386150-3	2021	In this study, we determined the crystal structure of a CTLA-4-derived phosphopeptide in complex with a Cys-substituted mutant of cSH2, C656S/C659V/C670L, at a 1.1 A resolution.	Cysteine	104-107	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	56-62
33386150-5	2021	Upon the Cys mutation, the cSH2 thermal stability increased while the CTLA-4 binding affinity slightly changed.	Cysteine	9-12	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	70-76
33386150-7	2021	Similar to CD28 binding, the CTLA-4 binding affinity of nSH2 was lower than that of cSH2.	nsh2	56-60	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	29-35
33584637-0	2020	Lysophosphatidic Acid Is an Inflammatory Lipid Exploited by Cancers for Immune Evasion via Mechanisms Similar and Distinct From CTLA-4 and PD-1.	lysophosphatidic acid	0-21	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	128-134
33553684-7	2021	The results showed that (30 and 40 mg/kg bwt) PTX dose suppressed the CTLA4 development significantly.	Pentoxifylline	46-49	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	70-75
33585439-17	2020	Additionally, the Tumor Immune Dysfunction and Exclusion (TIDE) algorithm and GDSC analysis suggested the IPM-low as a promising responder to anti-CTLA-4 therapy and the common FDA-targeted drugs, while the IPM-high was non-responsive to these treatments.	ipm	106-109	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	147-153
33112279-4	2021	Case: We report a patient with ACTH-secreting pituitary carcinoma, progressive after multiple lines of therapy including chemotherapy with TMZ, who demonstrated disease stabilization by a combination of ipilimumab (anti-CTLA-4) and nivolumab (anti-PD-1) ICI therapy.	Temozolomide	139-142	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	220-226
33273967-8	2021	Progesterone, the traditional maternal-care drug, also had a certain immunomodulatory role through restoring the levels of several co-inhibitory molecules (including T-cell immunoglobulin mucin family member-3, programmed cell death-1 and cytotoxic T-lymphocyte associated protein-4) in the treatment of RSA.	Progesterone	0-12	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	239-282
33476510-3	2022	Recent studies have demonstrated that mutations in other Treg-associated genes, such as CD25 and CTLA4, show an IPEX-like phenotype.	treg	57-61	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	97-102
33506034-12	2021	Moreover, GSEA showed that several pathways were enriched in CPEB3, such as PD1 signaling, CTLA4 pathway, CTCF pathway, CHEMOKIN signaling, VEGF signaling, and JAK-STAT pathway.	gsea	10-14	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	91-96
33112279-8	2021	Conclusion: ICI therapy could be a promising treatment option for pituitary carcinoma, considering the mechanisms of TMZ-induced hypermutation with increased immunogenicity, pituitary expression of CTLA-4 and PD-L1, and the frequent occurrence of hypophysitis as a side effect of ICI therapy.	Temozolomide	117-120	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	198-204
33490159-15	2020	Furthermore, tumor necrosis factor (TNF), through interaction with TNFR2, enhanced the suppressive capacity of Tregs by up-regulating CTLA-4 and PD-L1 expression.	tregs	111-116	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	134-140
33377134-3	2020	In vitro, MGD019 mediates the combinatorial blockade of PD-1 and CTLA-4, confirming dual inhibition via a single molecule.	mgd019	10-16	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	65-71
33377134-4	2020	MGD019 is well tolerated in non-human primates, with evidence of both PD-1 and CTLA-4 blockade, including increases in Ki67+CD8 and ICOS+CD4 T cells, respectively.	mgd019	0-6	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	79-85
33327303-9	2020	In the subgroup analysis based on ethnicity, the results showed that the relationship between the CTLA-4 -1722T/C polymorphism and GC susceptibility was strongest in the Chinese population rather than in the Iranian population (TC vs CC: OR = 1.405, 95% CI: 1.100-1.796, P = .007; TC+TT vs CC: OR = 1.329, 95% CI: 1.052-1.680, P = .017).	Technetium	228-230	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	98-104
33327303-9	2020	In the subgroup analysis based on ethnicity, the results showed that the relationship between the CTLA-4 -1722T/C polymorphism and GC susceptibility was strongest in the Chinese population rather than in the Iranian population (TC vs CC: OR = 1.405, 95% CI: 1.100-1.796, P = .007; TC+TT vs CC: OR = 1.329, 95% CI: 1.052-1.680, P = .017).	Technetium	281-283	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	98-104
33363541-7	2020	Taken together, our data suggest that CD86 is the dominant costimulatory ligand for Treg homeostasis, despite its lower affinity for CD28, because CD80-CD28 interactions are selectively impaired by the high levels of CTLA-4.	treg	84-88	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	217-223
33335689-7	2020	As predicted, O-glycan-free CTLA4 Fc-fusion proteins were more homogenous for sialylation, and interestingly less prone to protein aggregation.	o-glycan	14-22	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	28-33
33427690-8	2020	PLS-DA resulted in a CCR of 100% and 93% in the anti-CTLA-4 and anti-PD1 melanoma discovery cohorts, respectively.	pls-da	0-6	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	53-59
33510997-7	2021	Taken together, by utilizing rigorous computational analysis, functional characterization in vitro and in vivo, and neoadjuvent clinical trial, a novel molecular mechanism is revealed regarding the regulation of PD-L1 via p62, thus providing a novel therapeutic strategy by the combination treatment of CTLA-4 with Sunitinib.	Sunitinib	315-324	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	303-309
32889778-10	2020	Icaritin treatment-induced dynamics of serum cytokines IL-6, IL-8, IL-10 and TNF-alpha, and soluble immune checkpoint proteins TIM3, LAG3, CD28, CD80, and CTLA-4 were assessed.	icaritin	0-8	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	155-161
33090639-7	2020	Higher prednisolone dosage and PDAI-score were positively correlated with CTLA4 and FCGR3A expressions after three months, respectively (P-value=0.019 and 0.048, respectively).	Prednisolone	7-19	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	74-79
33046869-3	2020	Here we report on the first pilot combination neoadjuvant trial ( NCT02812420 ) with anti-PD-L1 (durvalumab) plus anti-CTLA-4 (tremelimumab) in cisplatin-ineligible patients, with all tumors identified as having high-risk features (n = 28).	Cisplatin	144-153	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	119-125
33046869-7	2020	In summary, we provide initial safety, efficacy and biomarker data with neoadjuvant combination anti-PD-L1 plus anti-CTLA-4, which warrants further development for patients with localized urothelial carcinoma, especially cisplatin-ineligible patients with high-risk features who do not currently have an established standard-of-care neoadjuvant treatment.	Cisplatin	221-230	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	117-123
33256165-3	2020	By understanding tumor immunology in UC, immune checkpoint inhibitors, targeting on programmed death 1 (PD-1) and cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) pathways, had been proven as first-line treatment for cisplatin-ineligible metastatic UC and as second-line treatment for patients with platinum-refractory metastatic UC by the U.S Food and Drug Administration (FDA).	Cisplatin	221-230	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	114-157
33256165-3	2020	By understanding tumor immunology in UC, immune checkpoint inhibitors, targeting on programmed death 1 (PD-1) and cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) pathways, had been proven as first-line treatment for cisplatin-ineligible metastatic UC and as second-line treatment for patients with platinum-refractory metastatic UC by the U.S Food and Drug Administration (FDA).	Cisplatin	221-230	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	159-165
33256165-3	2020	By understanding tumor immunology in UC, immune checkpoint inhibitors, targeting on programmed death 1 (PD-1) and cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) pathways, had been proven as first-line treatment for cisplatin-ineligible metastatic UC and as second-line treatment for patients with platinum-refractory metastatic UC by the U.S Food and Drug Administration (FDA).	Platinum	303-311	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	114-157
33256165-3	2020	By understanding tumor immunology in UC, immune checkpoint inhibitors, targeting on programmed death 1 (PD-1) and cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) pathways, had been proven as first-line treatment for cisplatin-ineligible metastatic UC and as second-line treatment for patients with platinum-refractory metastatic UC by the U.S Food and Drug Administration (FDA).	Platinum	303-311	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	159-165
32810393-9	2020	Therefore, TERT mutations were closely related to a higher TMB value and unique tumor microenvironment, which may be the reason that TERT mutations may be a potential biomarker for anti-CTLA4 treatment.	1,2,4,5-tetramethoxybenzene	59-62	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	186-191
32496569-0	2020	Advanced malignant melanoma successfully treated with dacarbazine following anti-PD-1/CTLA-4 treatment.	Dacarbazine	54-65	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	86-92
33011403-5	2020	Our computational results provide a better understanding of the binding mechanisms and new insights about the CTLA-4: ipilimumab interaction, identifying essential amino acid residues to support the complex.	Amino Acids, Essential	154-174	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	110-116
33011403-6	2020	Additionally, we report new interactions such as aromatic-aromatic, aromatic-sulfur, and cation-pi interactions to stabilize the CTLA-4:ipilimumab complex.	Sulfur	77-83	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	129-135
33011403-7	2020	Finally, quantum biochemistry analyses reveal the most important amino acid residues involved in the CTLA-4:ipilimumab interface, which were used to design synthetic peptides to inhibit CTLA-4.	Peptides	166-174	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	101-107
33011403-7	2020	Finally, quantum biochemistry analyses reveal the most important amino acid residues involved in the CTLA-4:ipilimumab interface, which were used to design synthetic peptides to inhibit CTLA-4.	Peptides	166-174	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	186-192
32810393-0	2020	TERT mutations correlate with higher TMB value and unique tumor microenvironment and may be a potential biomarker for anti-CTLA4 treatment.	1,2,4,5-tetramethoxybenzene	37-40	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	123-128
32766612-6	2020	More significantly, combined with cytotoxic T lymphocyte-associated protein 4 (CTLA-4) checkpoint blockade, FePt/BP-PEI-FA NC-induced PTT can control both primary and untreated distant tumors" growth.	bp-pei-fa	113-122	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	34-77
32621335-0	2020	CTLA-4 and HLA-DQ are key molecules in the regulation of mDC-mediated cellular immunity by Tregs in severe aplastic anemia.	tregs	91-96	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	0-6
32988398-11	2020	Pre-clinically, SB-3CT treatment enhanced the therapeutic efficacy of PD-1 or CTLA-4 blockade in the treatment of both primary and metastatic tumors.	SB 3CT compound	16-22	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	78-84
32652470-2	2020	Responding to this need for novel therapies for high-risk patients, we have developed a "nanoimmunotherapy," which combines photothermal therapy (PTT) using CpG oligodeoxynucleotide-coated Prussian blue nanoparticles (CpG-PBNPs) combined with anti-CTLA-4 (aCTLA-4) immunotherapy.	Oligodeoxyribonucleotides	161-181	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	248-254
32603908-0	2020	Zoledronate decreases CTLA-4 in vivo and in vitro independently of its action on bone resorption.	Zoledronic Acid	0-11	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	22-28
32944086-7	2020	In addition, by introducing bacteria involved in vitamin B and polyamine transport to the GI tracts of patients treated with anti-CTLA-4 drugs led to increased resistance to colitis while maintaining therapeutic efficacy.	Niacinamide	49-58	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	130-136
32586938-7	2020	Meta-regression analysis revealed that TMB was significantly associated with ORR for anti-PD(L)1, anti-CTLA-4, and combination (p<0.0001 for all), but not associated with toxicity in all treatment groups.	1,2,4,5-tetramethoxybenzene	39-42	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	103-109
32586938-10	2020	CONCLUSION: There is a positive association between TMB and clinical response with anti-PD(L)1, anti-CTLA-4, and combination ICIs, but no association between TMB and toxicity.	1,2,4,5-tetramethoxybenzene	52-55	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	101-107
32840510-5	2020	Further results revealed that the synergistic immune stimulatory effects of CTLA-4 and PD-1 blockades in the form of hSNPs were at least partly through regulating the immune suppressive function of both Tregs and TIM3+ exhausted-like CD8 T cells and allowing effector T cells to expand.	tregs	203-208	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	76-82
32603908-4	2020	The objectives of the present study were firstly, to characterize the ZOL-induced APR in patients with inflammatory rheumatic diseases (IRDs) and its relationship with changes in circulating sCTLA-4 and secondly, to investigate the effects of ZOL on CTLA-4 production and expression by peripheral blood mononuclear cells (PBMCs).	Zoledronic Acid	70-73	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	192-198
32333082-4	2020	Injection of hydrogel-encapsulated anti-CTLA-4 at a peri-tumor location (MC-38 tumor model) produced dose-dependent antitumor responses and survival that exceeded those by anti-CTLA-4 alone (p < 0.05).	mc-38	73-78	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	40-46
32603908-7	2020	Consistent with the results of the in vivo study, ZOL (1 muM) decreased the production of sCTLA-4 by 87% and 57% after 3 and 5 days in cultures of peripheral blood mononuclear cells (PBMCs) in vitro, respectively, and inhibited the expression of both cytoplasmic and membrane-bound CTLA-4.	Zoledronic Acid	50-53	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	91-97
32333082-4	2020	Injection of hydrogel-encapsulated anti-CTLA-4 at a peri-tumor location (MC-38 tumor model) produced dose-dependent antitumor responses and survival that exceeded those by anti-CTLA-4 alone (p < 0.05).	mc-38	73-78	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	177-183
32246174-0	2020	The glucocorticoids prednisone and dexamethasone differentially modulate T cell function in response to anti-PD-1 and anti-CTLA-4 immune checkpoint blockade.	Prednisone	20-30	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	123-129
32859050-7	2020	Furthermore, OCT LAR treatment induces a functional impairment of the remaining circulating Tregs, significantly decreasing the expression of PD1, CTLA4 and ENTPD1.	oct lar	13-20	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	147-152
32894535-1	2020	OBJECTIVE: To assess associations between parameters derived from F-18 fluorodeoxyglucose (FDG) positron emission tomography (PET) and mRNA expression levels of immune checkpoint biomarkers such as programmed death receptor 1 (PD-1), programmed death-ligand 1 (PD-L1), cytotoxic T-lymphocyte antigen 4 (CTLA-4) as well as tumor mutation burden (TMB) in non-small cell lung cancer (NSCLC) patients.	Fluorodeoxyglucose F18	91-94	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	303-309
32246174-0	2020	The glucocorticoids prednisone and dexamethasone differentially modulate T cell function in response to anti-PD-1 and anti-CTLA-4 immune checkpoint blockade.	Dexamethasone	35-48	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	123-129
32562209-0	2020	Everolimus-Induced Remission of Classic Kaposi"s Sarcoma Secondary to Cryptic Splicing Mediated CTLA4 Haploinsufficiency.	Everolimus	0-10	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	96-101
32304268-5	2020	High frequency eTreg infiltration into HNSCC tissues was observed and high expressions of CD25, FOXP3, stimulatory-ICMs (4-1BB, ICOS, OX40 and GITR), and inhibitory-ICMs (PD-1 and CTLA-4) were found on invasive eTregs.	etreg	15-20	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	180-186
32724457-11	2020	Moreover, CQ enhanced CTLA-4 expression in activated human T cells and reduced the secretion of IFN-gamma in human mixed lymphocyte reaction.	Chloroquine	10-12	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	22-28
31993940-9	2020	The patient was diagnosed with an immune dysregulation syndrome associated with de novo germline CTLA4 mutation, complicated by steroid-refractory rheumatoid arthritis.	Steroids	128-135	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	97-102
32368175-6	2020	Combination use of PD-1 and ctla-4 inhibitors has been approved by the U.S. Food and Drug Administration for chemorefractory dmmr or msi-h colorectal cancer.	dmmr	125-129	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	28-34
32351508-5	2020	Administration of CTLA-4 monoclonal antibodies (mAbs) strongly enhanced IL36-stimulated antitumor activities through depletion of Tregs.	tregs	130-135	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	18-24
32240844-9	2020	Conversely, serum cytotoxic T lymphocyte-associated antigen-4 (CTLA-4), which is a cytokine related to activated NK cells, was higher in Yusho patients than in healthy subjects and was positively correlated with PCDF blood levels.	Dibenzofurans, Polychlorinated	212-216	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	18-61
32240844-9	2020	Conversely, serum cytotoxic T lymphocyte-associated antigen-4 (CTLA-4), which is a cytokine related to activated NK cells, was higher in Yusho patients than in healthy subjects and was positively correlated with PCDF blood levels.	Dibenzofurans, Polychlorinated	212-216	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	63-69
32358520-0	2020	Systemic short chain fatty acids limit antitumor effect of CTLA-4 blockade in hosts with cancer.	Fatty Acids, Volatile	9-32	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	59-65
32358520-5	2020	High blood butyrate and propionate levels are associated with resistance to CTLA-4 blockade and higher proportion of Treg cells.	Butyrates	11-19	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	76-82
32358520-5	2020	High blood butyrate and propionate levels are associated with resistance to CTLA-4 blockade and higher proportion of Treg cells.	Propionates	24-34	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	76-82
31089272-0	2020	CTLA4Ig-based T-cell costimulation blockade is associated with reduction of adenovirus viremia following post-transplantation cyclophosphamide-based haploidentical transplantation.	Cyclophosphamide	126-142	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	0-5
32358520-8	2020	Altogether, these results suggest that SCFA limits anti-CTLA-4 activity.	Fatty Acids, Volatile	39-43	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	56-62
32033266-2	2020	Accordingly, our phase II NIBIT-MESO-1 study demonstrated an improved clinical efficacy in mesothelioma patients treated with the anti-PD-L1 durvalumab combined with the anti-cytotoxic T-lymphocyte antigen (CTLA)-4 tremelimumab, as compared to tremelimumab alone.	nibit-meso	26-36	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	170-214
32158597-7	2020	ICI-related gastrointestinal toxicity, dermatologic toxicity, and hypophysitis are more common with anti- CTLA-4 agents.	ici	0-3	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	106-112
32000815-3	2020	The goal of this targeted literature review is to identify data available for TMB status and/or PD-L1 expression that predict response to checkpoint inhibitors and/or anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) antibodies.	1,2,4,5-tetramethoxybenzene	78-81	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	172-215
32420897-4	2020	Using mathematical modeling, it was shown that peptides interacted with the 99MYPPPY104 loop of the CTLA-4 protein and could potentially block the interaction of the CTLA-4 receptor with its natural ligand B7-1.	99mypppy104	76-87	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	100-106
31787598-0	2020	The Soluble Isoform of CTLA-4 Correlates with Interferon-alpha Activity in Systemic Lupus Erythematosus.	Interferons	46-56	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	23-29
31731231-0	2020	Vitamin D3-mediated resistance to a multiple sclerosis model disease depends on myeloid cell 1,25-dihydroxyvitamin D3 synthesis and correlates with increased CD4+ T cell CTLA-4 expression.	Cholecalciferol	0-10	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	170-176
31731231-6	2020	These new data provide solid support for the view that vitamin D3 reduces MS risk in part through a mechanism involving myeloid cell 1,25-(OH)2D3 production and CTLA-4 upregulation in CNS-infiltrating CD4+ T cells.	Cholecalciferol	55-65	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	161-167
31731231-7	2020	We suggest that CTLA-4 serves as a vitamin D3-regulated immunological checkpoint in multiple sclerosis prevention.	Cholecalciferol	35-45	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	16-22
32238143-7	2020	The immunmodulatory effects of the active metabolite of vitamin D (alpha-25 (OH)2D3) on the production of NO, IL-6, IL-10, TGF-beta and s-CTLA-4 was assessed by Griess method and ELISA, in peripheral blood mononuclear cells (PBMCs) of Algerian MetS patients and HC.	Vitamin D	56-65	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	138-144
32238143-12	2020	We observed in the same way, the implication of s-CTLA-4 in MetS, which was markedly up regulated with alpha-25 (OH)2D3.	oh)2d3	113-119	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	50-56
32110280-4	2020	ICB therapy was defined as treatment with any CTLA-4, PD-1, and/or PD-L1 monoclonal antibody.	indole-2-carboxylic acid	0-3	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	46-52
31734564-5	2020	A statistically significant correlation was found between children with AR and A and ambient Polycyclic Aromatic Hydrocarbons exposure, live in an industrialized city with elevated traffic, dampness and moulds exposure, electric cooking, male gender, single nucleotide polymorphisms in PTNP22 gene and CTLA-4 gene, fast food and margarine products consumption, use of paracetamol in last year, history of tuberculosis, parental atopy, high total serum IgE, antibiotics in uterus and infections in uterus exposure, history of formula feeding and caesarian section.	Hydrocarbons, Aromatic	104-125	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	302-308
32185708-1	2020	Immune checkpoint blockades (ICBs), as a major breakthrough in cancer immunotherapy, target CTLA-4 and the PD-1/PD-L1 axis and reinvigorate anti-tumor activities by disrupting co-inhibitory T-cell signaling.	icbs	29-33	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	92-98
31907140-1	2019	Bladder urothelial carcinoma(BUC)is a common malignant tumor in the urinary system.Pt-based chemotherapy has long been a standard therapeutic method for resectable or metastatic BUC,but with poor outcomes.Immune checkpoint inhibitors specific to programmed death 1(PD-1)/programmed death-ligand 1(PD-L1)and cytotoxic T lymphocyte-associated protein 4(CTLA-4)pathways have shown significant antitumor activities,safety,and enduring reactivity in clinical trials,thus creating a new epoch for the treatment of advanced-stage BUC.This article reviews the relationships of BUC with PD-1/PD-L1 and CTLA-4 pathways,as demonstrated in clinical trials.In particular,the authors elucidate the clinical studies on the application of immune checkpoint inhibitors in different BUC stages and their optimal combining strategies,with an attempt to improve the clinical use of immune inhibitors for BUC treatment.	Platinum	83-85	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	307-350
32345776-6	2020	CD28 is the main positive costimulatory receptor on nai ve T cells; upon activation, CTLA4 is induced but reduces T cell activation.	nai	52-55	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	85-90
32054416-5	2020	Alanine scanning of CTLA-4 using mammalian cell expression cassette identified the unique epitopes of this novel antibody.	Alanine	0-7	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	20-26
31502147-2	2020	In studies of unselected patient populations, it was shown that melanoma, non small cell lung cancer (NSCLC), renal cell carcinoma and urothelial carcinoma patients treated with CTLA-4, PD-1 or PD-L1 inhibitors had an improved objective response and overall survival relative to chemotherapy or historical trends, and several ICIs have been approved for the treatment of these and other indications.More recently, several groups found that response to ICI therapy strongly correlates with a high burden of single nucleotide variant (SNV) mutations in the tumor genome, termed tumor mutational burden (TMB), usually expressed as the number of nonsynonymous single nucleotide variants per megabase of sequenced genome.	1,2,4,5-tetramethoxybenzene	601-604	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	178-184
31907140-1	2019	Bladder urothelial carcinoma(BUC)is a common malignant tumor in the urinary system.Pt-based chemotherapy has long been a standard therapeutic method for resectable or metastatic BUC,but with poor outcomes.Immune checkpoint inhibitors specific to programmed death 1(PD-1)/programmed death-ligand 1(PD-L1)and cytotoxic T lymphocyte-associated protein 4(CTLA-4)pathways have shown significant antitumor activities,safety,and enduring reactivity in clinical trials,thus creating a new epoch for the treatment of advanced-stage BUC.This article reviews the relationships of BUC with PD-1/PD-L1 and CTLA-4 pathways,as demonstrated in clinical trials.In particular,the authors elucidate the clinical studies on the application of immune checkpoint inhibitors in different BUC stages and their optimal combining strategies,with an attempt to improve the clinical use of immune inhibitors for BUC treatment.	Platinum	83-85	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	351-357
31907140-1	2019	Bladder urothelial carcinoma(BUC)is a common malignant tumor in the urinary system.Pt-based chemotherapy has long been a standard therapeutic method for resectable or metastatic BUC,but with poor outcomes.Immune checkpoint inhibitors specific to programmed death 1(PD-1)/programmed death-ligand 1(PD-L1)and cytotoxic T lymphocyte-associated protein 4(CTLA-4)pathways have shown significant antitumor activities,safety,and enduring reactivity in clinical trials,thus creating a new epoch for the treatment of advanced-stage BUC.This article reviews the relationships of BUC with PD-1/PD-L1 and CTLA-4 pathways,as demonstrated in clinical trials.In particular,the authors elucidate the clinical studies on the application of immune checkpoint inhibitors in different BUC stages and their optimal combining strategies,with an attempt to improve the clinical use of immune inhibitors for BUC treatment.	Platinum	83-85	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	593-599
31870373-5	2019	CASES PRESENTATION: We report an acute onset T1DM with severe inaugural diabetic ketoacidosis (DKA) and remarkably elevated Glutamic Acid Decarboxylase antibody (GADA) titres following a single administration of combined ICI therapy with nivolumab (anti-PD-1) and ipilimumab (anti-CTLA-4) in two adult patients with advanced metastatic melanoma.	oxytocin, Glu(4)-	124-137	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	281-287
32335548-2	2020	In addition to radiotherapy and surgery, CTLA4-blocking antibodies and alkylating agents such as temozolomide can also lead to hypogonadism, through different mechanisms.	Temozolomide	97-109	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	41-46
31684013-9	2019	Haplotype analysis showed that CTLA4 Crs733618Crs16840252 might increase the risk of GO (OR = 2.375, 95%CI: 1.636-3.448, p = 0.043).	Chromium	37-57	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	31-36
31697809-6	2019	We further found that HRS cells, and a subset of TAMs, are positive for the CTLA-4 ligand CD86 and that the fractions of T cells and TAMs that are CTLA-4-positive and CD86-positive, respectively, are greater within a 75 mum HRS cell niche relative to areas outside this region (CTLA-4, 38% vs 18% [P = .0001]; CD86, 38% vs 24% [P = .0007]).	tams	49-53	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	76-82
31697809-6	2019	We further found that HRS cells, and a subset of TAMs, are positive for the CTLA-4 ligand CD86 and that the fractions of T cells and TAMs that are CTLA-4-positive and CD86-positive, respectively, are greater within a 75 mum HRS cell niche relative to areas outside this region (CTLA-4, 38% vs 18% [P = .0001]; CD86, 38% vs 24% [P = .0007]).	tams	133-137	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	147-153
31697809-6	2019	We further found that HRS cells, and a subset of TAMs, are positive for the CTLA-4 ligand CD86 and that the fractions of T cells and TAMs that are CTLA-4-positive and CD86-positive, respectively, are greater within a 75 mum HRS cell niche relative to areas outside this region (CTLA-4, 38% vs 18% [P = .0001]; CD86, 38% vs 24% [P = .0007]).	tams	133-137	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	147-153
31679184-10	2019	Although the rates of these events were low, the risk was increased following ICI-based treatment, particularly for CTLA-4 inhibitors, which were associated with a higher incidence of pituitary-adrenal dysfunction than PD-1/PD-L1 inhibitors.	2-I-ICI-H	78-81	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	116-122
31694698-18	2019	CONCLUSION: Our pharmacovigilance analysis shows a high reporting frequency of endocrine AEs provoked by ICI monotherapy (especially anti-CTLA-4 therapy) and further reinforced by combination therapy.	2-I-ICI-H	105-108	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	138-144
32002288-8	2020	More remarkably, hIL-2/TCB2c showed synergy with checkpoint inhibitors such as anti-CTLA-4 or PD1 antibodies, and resulted in almost complete regression of implanted tumors and resistance to secondary tumor challenge.	2,3,4-trimethoxy-4'-carbomethoxy-1,1'-biphenyl	23-28	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	84-90
31791080-3	2019	Inhibitory signaling pathways are interrupted by binding to CTLA-4 and PD-1 or PD-L1, which increases the activity of cytotoxic T lymphocytes and reduces the immunological tolerance to tumor cells.Diarrhea - a symptom of enterocolitis - is the most common side effect of ICPI therapy after dermatological phenomena.	icpi	271-275	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	60-66
31627712-0	2019	Bispecific anti-OX40/CTLA-4 antibodies for advanced solid tumors: a patent evaluation of WO2018202649.	wo2018202649	89-101	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	21-27
31627712-2	2019	Authors of WO2018202649 patent propose a method to eradicate cancer using a bispecific antibodies against OX40/CTLA-4.Areas covered: WO2018202649 patent describes several bispecific antibodies capable of specifically binding to OX40 and CTLA-4 that target regulatory T cells in the tumor microenvironment.Expert opinion: WO2018202649 patent demonstrates that bispecific antibodies against OX40/CTLA-4 have anti-tumor activity against colon, pancreatic and bladder cancer, and that there is a synergistic action with anti-PD-1 antibodies for the treatment of colon cancer.	wo2018202649	11-23	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	111-117
31627712-2	2019	Authors of WO2018202649 patent propose a method to eradicate cancer using a bispecific antibodies against OX40/CTLA-4.Areas covered: WO2018202649 patent describes several bispecific antibodies capable of specifically binding to OX40 and CTLA-4 that target regulatory T cells in the tumor microenvironment.Expert opinion: WO2018202649 patent demonstrates that bispecific antibodies against OX40/CTLA-4 have anti-tumor activity against colon, pancreatic and bladder cancer, and that there is a synergistic action with anti-PD-1 antibodies for the treatment of colon cancer.	wo2018202649	11-23	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	237-243
31627712-2	2019	Authors of WO2018202649 patent propose a method to eradicate cancer using a bispecific antibodies against OX40/CTLA-4.Areas covered: WO2018202649 patent describes several bispecific antibodies capable of specifically binding to OX40 and CTLA-4 that target regulatory T cells in the tumor microenvironment.Expert opinion: WO2018202649 patent demonstrates that bispecific antibodies against OX40/CTLA-4 have anti-tumor activity against colon, pancreatic and bladder cancer, and that there is a synergistic action with anti-PD-1 antibodies for the treatment of colon cancer.	wo2018202649	11-23	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	237-243
31609157-2	2019	We used commercial polyclonal and monoclonal antibodies and characterized three chromogenic cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) assays with suitable specificity and sensitivity for use in formalin-fixed, paraffin-embedded (FFPE) tissues.	Formaldehyde	205-213	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	137-143
31609157-2	2019	We used commercial polyclonal and monoclonal antibodies and characterized three chromogenic cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) assays with suitable specificity and sensitivity for use in formalin-fixed, paraffin-embedded (FFPE) tissues.	Paraffin	221-229	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	137-143
31599915-6	2019	Moreover, the metastatic tumors were eliminated effectively with the help of oligodeoxynucleotides containing cytosine-guanine (CpG ODNs) combined with systemic checkpoint blockade therapy using an anti-CTLA4 antibody.	Oligodeoxyribonucleotides	77-98	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	203-208
31599915-6	2019	Moreover, the metastatic tumors were eliminated effectively with the help of oligodeoxynucleotides containing cytosine-guanine (CpG ODNs) combined with systemic checkpoint blockade therapy using an anti-CTLA4 antibody.	cytosine-guanine	110-126	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	203-208
31599915-6	2019	Moreover, the metastatic tumors were eliminated effectively with the help of oligodeoxynucleotides containing cytosine-guanine (CpG ODNs) combined with systemic checkpoint blockade therapy using an anti-CTLA4 antibody.	CPG-oligonucleotide	128-136	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	203-208
31684013-10	2019	In conclusion, CTLA4 Crs733618Crs16840252 was found to be a potential marker for GO, and these haplotypes would be ethnicity-specific.	Chromium	21-41	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	15-20
31684013-11	2019	Clinical application of CTLA4 Crs733618Crs16840252 in predicting GO in GD patients may be beneficial.	Chromium	30-50	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	24-29
31267017-4	2019	Conversely, increasing the pH sensitivity of TremeIgG1 by introducing designed tyrosine-to-histidine mutations prevents antibody-triggered lysosomal CTLA-4 downregulation and dramatically attenuates irAE.	Tyrosine	79-87	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	149-155
31824622-0	2019	Vitamin D Increases CTLA-4 Gene Expression in Patients with Mild to Moderate Ulcerative Colitis.	Vitamin D	0-9	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	20-26
31824622-3	2019	The aim of this study was to investigate the effect of vitamin D on CTLA-4 gene expression in whole blood samples of patients with UC.	Vitamin D	55-64	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	68-74
31824622-7	2019	CTLA-4 fold changes were significantly higher in the vitamin D group compared with the placebo group (median +- IQR: 1.21 +- 2.3 vs. 1.00 +- 1.5, respectively; p = 0.007).	Vitamin D	53-62	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	0-6
31824622-8	2019	CONCLUSION The results of this study revealed that vitamin D administration in patients with UC enhances the CTLA-4 gene expression.	Vitamin D	51-60	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	109-115
31663034-0	2019	Re-engineering anti-CTLA-4 antibodies for enhancing cancer immunotherapy efficacy and safety.	Rhenium	0-2	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	20-26
30801917-2	2019	Recently, anti-CD28 domain antibodies (dAb) that selectively target CD28 while leaving CTLA-4 intact were shown to more effectively inhibit alloimmune responses and prolong graft survival.	3,3'-Diaminobenzidine	39-42	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	87-93
31177287-5	2019	The objective of this study was to determine the role of CTLA-4 in the pathogenesis of PGN and NPGN by evaluating the frequencies of T and B lymphocytes expressing CTLA-4 and the serum concentration of the sCTLA-4 isoform in patients with PGN and NPGN in relation to clinical parameters.	pgn	87-90	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	57-63
31177287-5	2019	The objective of this study was to determine the role of CTLA-4 in the pathogenesis of PGN and NPGN by evaluating the frequencies of T and B lymphocytes expressing CTLA-4 and the serum concentration of the sCTLA-4 isoform in patients with PGN and NPGN in relation to clinical parameters.	pgn	96-99	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	57-63
31177287-9	2019	The frequencies and absolute counts of CD4+/CTLA-4+ T lymphocytes, CD8+/CTLA-4+ T lymphocytes and CD19+/CTLA-4+ B lymphocytes and the serum sCTLA-4 concentration were lower in PGN and NPGN patients that in the control group.	pgn	176-179	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	44-50
31177287-9	2019	The frequencies and absolute counts of CD4+/CTLA-4+ T lymphocytes, CD8+/CTLA-4+ T lymphocytes and CD19+/CTLA-4+ B lymphocytes and the serum sCTLA-4 concentration were lower in PGN and NPGN patients that in the control group.	pgn	176-179	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	72-78
31177287-9	2019	The frequencies and absolute counts of CD4+/CTLA-4+ T lymphocytes, CD8+/CTLA-4+ T lymphocytes and CD19+/CTLA-4+ B lymphocytes and the serum sCTLA-4 concentration were lower in PGN and NPGN patients that in the control group.	pgn	176-179	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	72-78
31177287-11	2019	Our results indicate that deregulation of CTLA-4 expression may result in continuous activation of T cells and contribute to the pathogenesis of PGN and NPGN.	pgn	145-148	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	42-48
31340988-5	2019	AtoG polymorphism at position +49 of CTLA4 gene is the only polymorphism which changes amino acid sequence from alanine to threonine in the leader sequence, which may affect the function of CTLA-4.	Alanine	112-119	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	37-42
31340988-5	2019	AtoG polymorphism at position +49 of CTLA4 gene is the only polymorphism which changes amino acid sequence from alanine to threonine in the leader sequence, which may affect the function of CTLA-4.	Alanine	112-119	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	190-196
31340988-5	2019	AtoG polymorphism at position +49 of CTLA4 gene is the only polymorphism which changes amino acid sequence from alanine to threonine in the leader sequence, which may affect the function of CTLA-4.	Threonine	123-132	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	37-42
31340988-5	2019	AtoG polymorphism at position +49 of CTLA4 gene is the only polymorphism which changes amino acid sequence from alanine to threonine in the leader sequence, which may affect the function of CTLA-4.	Threonine	123-132	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	190-196
31442575-6	2019	Our results showed that these three antidiabetic agents, particularly Sitagliptin, downregulate HLA Class I and II expression and upregulate the immune-regulatory molecules PD-L1 and CTLA4.	Sitagliptin Phosphate	70-81	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	183-188
31552016-4	2019	Here we reported that inhibition of Cdk8/Cdk19 activity by small molecule inhibitors CCT251921 or Senexin A greatly promoted the differentiation of Treg cells and the expression of Treg signature genes, such as Foxp3, CTLA4, PD-1, and GITR.	tert-butyl beta-carboline-3-carboxylate	85-94	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	218-223
31267017-4	2019	Conversely, increasing the pH sensitivity of TremeIgG1 by introducing designed tyrosine-to-histidine mutations prevents antibody-triggered lysosomal CTLA-4 downregulation and dramatically attenuates irAE.	Histidine	91-100	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	149-155
31308374-4	2019	Mechanistically, we identify the small GTPase RAB11 as an interactor of the guanine nucleotide exchange factor DEF6, and find disrupted binding of mutant DEF6 to RAB11 as well as reduced RAB11+CTLA-4+ vesicles in DEF6-mutated cells.	Guanine Nucleotides	76-94	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	193-199
31170216-6	2019	While 2DG treatment at the onset of activation significantly reduced the proliferation and expression of suppressive molecules such as ICOS and CTLA-4 in tTregs, its effect on FOXP3 expression was small.	Deoxyglucose	6-9	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	144-150
31132270-4	2019	We further demonstrate that the combination of FeNP-based MHT with local injection of nanoadjuvant and systemic injection of anticytotoxic T-lymphocyte antigen-4 (anti-CTLA4) checkpoint blockade would result in systemic therapeutic responses to inhibit tumor metastasis.	fenp-based mht	47-61	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	168-173
32042863-2	2019	Thus far, FDA-approved ICBs primarily target immune checkpoints CTLA-4, PD-1, and PD-L1.	icbs	23-27	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	64-70
31289479-0	2019	Highly sensitive detection of CTLA-4-positive T-cell subgroups based on nanobody and fluorescent carbon quantum dots.	Carbon	97-103	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	30-36
31289479-2	2019	In the present study, a rapid, succinct and efficient method was designed for the detection of CTLA-4+ human T cells using a CTLA-4-specific nanobody-fluorescent carbon quantum dots complex (QDs-Nb36).	Carbon	162-168	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	95-101
31289479-2	2019	In the present study, a rapid, succinct and efficient method was designed for the detection of CTLA-4+ human T cells using a CTLA-4-specific nanobody-fluorescent carbon quantum dots complex (QDs-Nb36).	Carbon	162-168	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	125-131
31335675-6	2019	Haplotype analysis showed that CTLA4 Crs16840252Ars231775Ars3087243Trs733618, Crs16840252Grs231775Ars3087243Trs733618, and other haplotypes might increase the risk of HCC risk (P = .018, &lt;.001, and .017, respectively).	crs16840252ars231775ars3087243trs733618	37-76	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	31-36
31335675-7	2019	However, we found that CTLA4 Trs16840252A rs231775Grs3087243Trs733618 decreased the risk of HCC (P = .020).Our results suggest that the CTLA-4 rs3087243 G&gt;A polymorphism increases susceptibility to HCC in an eastern Chinese Han population.	trs16840252a	29-41	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	23-28
31335675-7	2019	However, we found that CTLA4 Trs16840252A rs231775Grs3087243Trs733618 decreased the risk of HCC (P = .020).Our results suggest that the CTLA-4 rs3087243 G&gt;A polymorphism increases susceptibility to HCC in an eastern Chinese Han population.	trs16840252a	29-41	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	136-142
30633591-7	2019	The expressions of co-inhibitory receptors (CTLA-4, PD-1, Tim-3, LAG-3 and TIGIT) on Tregs in FK506 + MMF group were significant higher than those in the FK506 group and control group.	Tacrolimus	94-99	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	44-50
31146119-4	2019	CTLA-4 and Kallikrein-7 were found to have similar binding sites, we therefore used 1, 3, 6-trisubstituted 1, 4-diazepane-7-ones (TDSO) which is an inhibitor of Kallikrein-7 as our lead compound.	tdso	130-134	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	0-6
31146119-8	2019	The per-residue decomposition highlighted Tyr24, Ala25, Gly28, Ala30, Tyr53 and Asn72 as having significantly high electrostatic energy contributions and the main contributing residues to the binding of TDSO, ZINC04515726 and ZINC08985213 to Cytotoxic T lymphocytes CTLA-4.	zinc08985213	226-238	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	266-272
30633591-7	2019	The expressions of co-inhibitory receptors (CTLA-4, PD-1, Tim-3, LAG-3 and TIGIT) on Tregs in FK506 + MMF group were significant higher than those in the FK506 group and control group.	Mycophenolic Acid	102-105	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	44-50
31137694-6	2019	PD-1 expression and CTLA-4 expression were significantly associated with a worse OS and CSS in log rank survival analysis and univariate Cox regression analysis.	thiocysteine	88-91	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	20-26
31137694-7	2019	CTLA-4 expression is a prognostic marker that is independently associated with a worse outcome in multivariate Cox regression analysis in the whole cohort (OS: p = 0.013; CSS: p = 0.048) as well as in a non-metastatic subgroup analysis (OS: p = 0.028; CSS: p = 0.022).	thiocysteine	171-174	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	0-6
31137694-7	2019	CTLA-4 expression is a prognostic marker that is independently associated with a worse outcome in multivariate Cox regression analysis in the whole cohort (OS: p = 0.013; CSS: p = 0.048) as well as in a non-metastatic subgroup analysis (OS: p = 0.028; CSS: p = 0.022).	thiocysteine	252-255	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	0-6
31137694-8	2019	Patients with combined CTLA-4 expression and PD-1-expression are at highest risk in OS and CSS.	thiocysteine	91-94	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	23-29
31137694-9	2019	In RCC patients, PD-1 expression in TIMC and CTLA-4 expression in TIMC are associated with a worse OS and CSS.	Osmium	99-101	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	45-51
31137694-9	2019	In RCC patients, PD-1 expression in TIMC and CTLA-4 expression in TIMC are associated with a worse OS and CSS.	thiocysteine	106-109	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	45-51
30673828-8	2019	A Grade 2 or higher effect of NAC was associated with high pre-NAC cytotoxic T lymphocyte-associated protein 4 (CTLA-4) levels (p = 0.0281) and elevated post-NAC NK (p = 0.0005) cells and transforming growth factor-beta (TGF-beta; p = 0.0350) levels.	nac	30-33	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	112-118
30689261-7	2019	In addition, among the atopic and early-onset asthma (EOA), the frequency of CD4+ CTLA-4+ T cells was lower in the SAR group than the CSA group.	Cyclosporine	134-137	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	82-88
31068935-7	2019	Interestingly, CAFs promoted the expression of TIM-3, PD-1, CTLA-4 and LAG-3 in proliferating T-cells.	cafs	15-19	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	60-66
30975201-0	2019	The CTLA-4 x OX40 bispecific antibody ATOR-1015 induces anti-tumor effects through tumor-directed immune activation.	ator-1015	38-47	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	4-10
30975201-4	2019	METHODS: ATOR-1015 is a human CTLA-4 x OX40 targeting IgG1 bispecific antibody generated by linking an optimized version of the Ig-like V-type domain of human CD86, a natural CTLA-4 ligand, to an agonistic OX40 antibody.	ator-1015	9-18	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	30-36
30673828-9	2019	The disappearance of Ax+ was associated with high pre-NAC CTLA-4 levels (p = 0.0278) and elevated CD4 levels after NAC (p = 0.0250).	Amoxicillin	21-24	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	58-64
30658697-4	2019	Both conventional CD4+CD25+CD127-Foxp3hi Tregs and their Tbethi counterparts exhibited an activated phenotype, co-expressed high levels of CTLA4 and Helios and exhibited a maximally demethylated Foxp3 gene locus TSDR, indicating their full capacity to impede a type 1 effector T cell response.	tbethi	57-63	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	139-144
30642290-8	2019	We hypothesize that dual targeting of PD-L1 and CTLA-4 pathways combined with SBRT will lead to &lt; 35% grade 3-5 acute toxicities related to TTC.	6-thiotheophylline	143-146	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	48-54
29992636-3	2019	The aim of this study was to associate CD28 and CTLA4 haplotypes with susceptibility to pSS in patients from western Mexico.	pss	88-91	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	48-53
30195074-2	2019	CTLA-4 inhibitors and PD-1 inhibitors are 2 main types of CPIs, which work through activation of the immune system.	cpis	58-62	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	0-6
29992636-12	2019	CONCLUSION: Our findings suggest that CD28 GC, CTLA4 CAG, and CGA haplotypes are associated with susceptibility to pSS in patients from western Mexico.	pss	115-118	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	47-52
31727250-5	2019	In this chapter, we describe the methods for efficient production of extracellular domain of human immune checkpoint receptors and Fv fragments of ICI therapeutic antibodies in milligram quantities sufficient for structural studies, taking examples of the PD-1/pembrolizumab Fv and CTLA-4-ipilimumab Fv complexes.	2-I-ICI-H	147-150	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	282-288
30713804-9	2019	In comparison, we found that CTLA-4, TIM-3, TIGIT and PD-L1 in PBC, and CTLA-4 in CRC patients were significantly upregulated in peripheral blood, compared with tumor tissues of the same patients.	potassium bicarbonate	63-66	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	29-35
30213644-4	2018	These results indicate that combining anti-CTLA-4 and anti-OX-40 with antibodies and other protein-based therapeutics may enhance ADA formation in humans.	N-(2-acetamido)iminodiacetic acid	130-133	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	43-49
30287678-8	2018	Anti-human CTLA-4 DMAbs produced in vivo bound to human CTLA-4 protein expressed on stimulated human peripheral blood mononuclear cells and induced T-cell activation in a functional assay ex vivo In summary, direct in vivo expression of DMAb encoding checkpoint inhibitors serves as a novel tool for immunotherapy that could significantly improve availability and provide broader access to such therapies.Significance: DNA-encoded monoclonal antibodies represent a novel technology for delivery and expression of immune checkpoint blockade antibodies, thus expanding patient access to, and possible clinical applications of, these therapies.	dmabs	18-23	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	11-17
30287678-8	2018	Anti-human CTLA-4 DMAbs produced in vivo bound to human CTLA-4 protein expressed on stimulated human peripheral blood mononuclear cells and induced T-cell activation in a functional assay ex vivo In summary, direct in vivo expression of DMAb encoding checkpoint inhibitors serves as a novel tool for immunotherapy that could significantly improve availability and provide broader access to such therapies.Significance: DNA-encoded monoclonal antibodies represent a novel technology for delivery and expression of immune checkpoint blockade antibodies, thus expanding patient access to, and possible clinical applications of, these therapies.	dmabs	18-23	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	56-62
29997292-8	2018	Our data strongly support the assumption that mCTLA4 predicts response to both anti-PD-1 and anti-CTLA-4 targeted ICB in melanoma and provides paramount information for the selection of patients likely to respond to ICB.	indole-2-carboxylic acid	114-117	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	98-104
29878901-0	2018	DZ-2384 has a superior preclinical profile to taxanes for the treatment of triple-negative breast cancer and is synergistic with anti-CTLA-4 immunotherapy.	DZ-2384	0-7	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	134-140
29965858-7	2018	Here we report a case of severe, steroid refractory, lymphocytic myocarditis that occurred after the first cycle of combination immunotherapy with the programmed cell death protein-1 inhibitor, nivolumab, and the cytotoxic T-lymphocyte-associated protein 4 blocker, ipilimumab, for metastatic melanoma.	Steroids	33-40	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	213-256
29905573-6	2018	Collectively, our data demonstrated that modulating EZH2 expression in T cells can improve antitumor responses elicited by anti-CTLA-4 therapy, which provides a strong rationale for a combination trial of CPI-1205 plus ipilimumab.	(R)-N-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1H-indole-3-carboxamide	205-213	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	128-134
29938495-2	2018	We have previously shown that modulating the immune system by impairing programmed cell death protein (PD-1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) signaling, both receptors involved in immune tolerance, was capable of producing an animal model of amodiaquine (AQ) IDILI with characteristics very similar to IDILI in humans.	Amodiaquine	266-277	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	113-156
29938495-2	2018	We have previously shown that modulating the immune system by impairing programmed cell death protein (PD-1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) signaling, both receptors involved in immune tolerance, was capable of producing an animal model of amodiaquine (AQ) IDILI with characteristics very similar to IDILI in humans.	Amodiaquine	266-277	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	158-164
29938495-2	2018	We have previously shown that modulating the immune system by impairing programmed cell death protein (PD-1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) signaling, both receptors involved in immune tolerance, was capable of producing an animal model of amodiaquine (AQ) IDILI with characteristics very similar to IDILI in humans.	Amodiaquine	279-281	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	113-156
29938495-2	2018	We have previously shown that modulating the immune system by impairing programmed cell death protein (PD-1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) signaling, both receptors involved in immune tolerance, was capable of producing an animal model of amodiaquine (AQ) IDILI with characteristics very similar to IDILI in humans.	Amodiaquine	279-281	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	158-164
30118680-8	2018	Our findings identify a new regulatory mechanism of PD-L1 expression through the ERAD pathway and suggest that the metformin-CTLA4 blockade combination has the potential to increase the efficacy of immunotherapy.	Metformin	115-124	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	125-130
28776731-0	2018	Correlations of CTLA-4 exon-1 49 A/G and promoter region 318C/T polymorphisms with the therapeutic efficacy of 131 I radionuclide in graves" disease in Chinese Han population.	Radioisotopes	117-129	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	16-22
29491310-2	2018	Three weeks after switching to anti-cytotoxic T-lymphocyte associated antigen 4 (CTLA-4) antibody (ipilimumab), her plasma glucose level was elevated to 639 mg/dL, her HbA1c was 7.7%, and her fastening serum C-peptide immunoreactivity was undetectable.	Glucose	123-130	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	31-79
29491310-2	2018	Three weeks after switching to anti-cytotoxic T-lymphocyte associated antigen 4 (CTLA-4) antibody (ipilimumab), her plasma glucose level was elevated to 639 mg/dL, her HbA1c was 7.7%, and her fastening serum C-peptide immunoreactivity was undetectable.	Glucose	123-130	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	81-87
30415745-11	2018	Indeed, Tregs generated in the presence of hAECs expressed higher levels of CTLA-4 compared to Tregs generated in their absence and restrained the proliferation of autologus PBMCs in MLR system.	tregs	8-13	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	76-82
30334961-8	2018	CTLA4 protein had significantly higher serum level in RSA patients than in healthy controls (P = .028).	rabbit sperm membrane autoantigen	54-57	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	0-5
30334961-9	2018	In RSA patients, AA genotype carriers had higher CTLA4 serum level than that GG genotype carriers (17.83 +- 6.35 ng/mL vs 10.41 +- 7.28 ng/mL, P = .039).Minor alleles of CTLA4 polymorphisms might inhibit the RSA susceptibility via upregulated the protein expression level.	rabbit sperm membrane autoantigen	3-6	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	49-54
30135316-8	2018	Evofosfamide showed efficacy as monotherapy and with radiotherapy in PDX models, augmented CTLA-4 blockade in syngeneic tumors, and reduced hypoxia in nodes disseminated from an orthotopic model.	TH 302	0-12	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	91-97
30122952-8	2018	Haplotype comparison analysis showed that CTLA-4 Grs3087243Crs16840252Crs733618 Ars231775, Grs3087243Crs16840252Trs733618Ars231775, and other haplotypes increased the risk of CRC (P&lt;0.001, &lt;0.001, and 0.002, respectively).	grs3087243crs16840252crs733618	49-79	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	42-48
30083478-6	2018	Results: Steroid-sensitive MCD patients in remission had lower urinary CD80 levels and higher CTLA-4 levels than patients in relapse (156.65 +- 24.62 vs 1066.40 +- 176.76 ng/g creatinine; p &lt; 0.0001), (728.73 +- 89.93 vs 151.70 +- 27.01 ng/g creatinine; p &lt; 0.0001).	Steroids	9-16	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	94-100
30083478-9	2018	The absent or minimal expression of CTLA-4 in glomeruli could distinguish steroid-sensitive MCD from steroid-resistant MCD.	Steroids	74-81	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	36-42
30083478-9	2018	The absent or minimal expression of CTLA-4 in glomeruli could distinguish steroid-sensitive MCD from steroid-resistant MCD.	Steroids	101-108	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	36-42
29425052-8	2018	Tregs isolated from patients with XDR-TB suppressed T-cell proliferation (up to 90%) and subverted containment of H37Rv-infected monocyte-derived macrophages (by 30%; P = 0.03) by impairing effector T-cell function through a mechanism independent of direct cell-to-cell contact, IL-10, TGF (transforming growth factor)-beta, and CTLA-4 (cytotoxic T-lymphocyte-associated protein 4).	xdr-tb	34-40	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	329-335
29425052-8	2018	Tregs isolated from patients with XDR-TB suppressed T-cell proliferation (up to 90%) and subverted containment of H37Rv-infected monocyte-derived macrophages (by 30%; P = 0.03) by impairing effector T-cell function through a mechanism independent of direct cell-to-cell contact, IL-10, TGF (transforming growth factor)-beta, and CTLA-4 (cytotoxic T-lymphocyte-associated protein 4).	xdr-tb	34-40	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	337-380
29614336-6	2018	ROC curve analysis suggested that CIITA (AUC = 0.902) and CTLA-4 (AUC = 0.785) may serve as valuable biomarkers of the stage of dn DSA production and clinical cAMR, respectively.	dsa	131-134	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	58-64
29891009-8	2018	RESULTS: Dexamethasone upregulated CTLA-4 mRNA and protein in CD4 and CD8 T cells and blocked CD28-mediated cell cycle entry and differentiation.	Dexamethasone	9-22	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	35-41
29891009-10	2018	Resistance to dexamethasone was conferred by blocking CTLA-4 or providing strong CD28 co-stimulation prior to dexamethasone exposure.	Dexamethasone	14-27	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	54-60
29891009-11	2018	CTLA-4 blockade increased IFNgamma expression, but not IL-2, in stimulated human peripheral blood T cells exposed to dexamethasone.	Dexamethasone	117-130	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	0-6
29891009-15	2018	However, CTLA-4, but not PD-1 blockade can partially prevent some of the inhibitory effects of dexamethasone on the immune response.	Dexamethasone	95-108	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	9-15
29635527-6	2018	Results: The addition of raltegravir to PI/r monotherapy resulted in a transient increase in 2-LTR (long-terminal repeat) circles in a significant proportion of participants, along with decreases in CD8+ T cell activation levels and a temporary increase in the expression of the exhaustion marker CTLA-4 in peripheral T lymphocytes.	Raltegravir Potassium	25-36	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	297-303
29635527-6	2018	Results: The addition of raltegravir to PI/r monotherapy resulted in a transient increase in 2-LTR (long-terminal repeat) circles in a significant proportion of participants, along with decreases in CD8+ T cell activation levels and a temporary increase in the expression of the exhaustion marker CTLA-4 in peripheral T lymphocytes.	r	25-26	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	297-303
29942666-6	2018	This study is designed to evaluate whether the addition of PD-L1 and CTLA-4 inhibition to oxaliplatin, fluorouracil and leucovorin (FOLFOX) increases treatment efficacy.	Folfox protocol	132-138	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	69-75
29476189-5	2018	As a consequence, rs231775 and rs3087243 of CTLA4, as well as rs2232365 and rs2232368 of Foxp3, all appeared to modify the risk of RSA.	rabbit sperm membrane autoantigen	131-134	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	44-49
29490989-0	2018	A Genetic Polymorphism in CTLA-4 Is Associated with Overall Survival in Sunitinib-Treated Patients with Clear Cell Metastatic Renal Cell Carcinoma.	Sunitinib	72-81	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	26-32
29490989-8	2018	No significant associations with PFS were found.Conclusions: The G-allele of rs231775 in the CTLA-4 gene is associated with an improved OS in sunitinib-treated cc-mRCC patients and could potentially be used as a prognostic biomarker.	Sunitinib	142-151	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	93-99
29657128-2	2018	Using whole-exome sequencing to examine non-small-cell lung cancer (NSCLC) treated with PD-1 plus CTLA-4 blockade, we found that high tumor mutation burden (TMB) predicted improved objective response, durable benefit, and progression-free survival.	1,2,4,5-tetramethoxybenzene	157-160	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	98-104
29657128-6	2018	TMB should be incorporated in future trials examining PD-(L)1 with CTLA-4 blockade in NSCLC.	1,2,4,5-tetramethoxybenzene	0-3	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	67-73
30221055-2	2018	Here, we report that the mTORC1/2 dual kinase inhibitor vistusertib (AZD2014) potentiates anti-tumour immunity in combination with anti-CTLA-4 (alphaCTLA-4), alphaPD-1 or alphaPD-L1 immune checkpoint blockade.	vistusertib	56-67	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	136-142
29642147-1	2018	PURPOSE: Using bibliometrics, we analyzed the research status of immune checkpoint blockade (ICB, a popular tumor immunotherapy method represented by antibodies targeted CTLA-4 and PD-1/PD-L1) in tumor immunotherapy in China during the past 2 decades.	indole-2-carboxylic acid	93-96	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	170-176
30084412-2	2018	Cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) + 49 AA polymorphism is known to be associated with CaCx.	cacx	105-109	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	0-43
30084412-2	2018	Cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) + 49 AA polymorphism is known to be associated with CaCx.	cacx	105-109	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	45-51
30084412-7	2018	Objective: The aim of this study is to evaluate the levels of soluble CTLA-4 (sCTLA-4) in human papillomavirus (HPV)-infected women with or without CaCx and their association with the polymorphism at CTLA-4 + 49 A/G and CTLA-4 -318 C/T genotypes.	cacx	148-152	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	70-76
30084412-7	2018	Objective: The aim of this study is to evaluate the levels of soluble CTLA-4 (sCTLA-4) in human papillomavirus (HPV)-infected women with or without CaCx and their association with the polymorphism at CTLA-4 + 49 A/G and CTLA-4 -318 C/T genotypes.	cacx	148-152	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	79-85
30084412-7	2018	Objective: The aim of this study is to evaluate the levels of soluble CTLA-4 (sCTLA-4) in human papillomavirus (HPV)-infected women with or without CaCx and their association with the polymorphism at CTLA-4 + 49 A/G and CTLA-4 -318 C/T genotypes.	cacx	148-152	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	79-85
29682176-3	2018	In this study, we assessed the expression of CTLA-4 both at mRNA and protein levels in paraffin embedded-tissues from patients with thymomas.	Paraffin	87-95	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	45-51
29264740-0	2018	CTLA-4 polymorphisms are associated with treatment outcomes of patients with multiple myeloma receiving bortezomib-based regimens.	Bortezomib	104-114	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	0-6
29264740-2	2018	This study explored the association of CTLA-4SNPs with the development of myeloma and evaluated the outcome of patients receiving bortezomib-based regimens in relation to CTLA-4SNPs.	Bortezomib	130-140	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	171-177
29264740-9	2018	CTLA-4 rs733618 GG reduced the progression-free survival and the overall survival of patients with MM who received bortezomib-based therapy.	Bortezomib	115-125	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	0-6
29359792-4	2018	The aims of this study were to clarify the influence of PDCD1 and CTLA4 SNPs on the risk of developing cITP and its clinical features.	citp	103-107	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	66-71
29237802-0	2018	Phase I Dose-Escalation Study of Anti-CTLA-4 Antibody Ipilimumab and Lenalidomide in Patients with Advanced Cancers.	Lenalidomide	69-81	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	38-44
29619406-6	2018	A 51-year-old woman with metastatic melanoma was found to have a suppressed TSH and elevated free thyroxine concentration 14 days after starting treatment with nivolumab (PD-1 antagonist) plus ipilimumab (CTLA-4 antagonist) therapy.	Thyroxine	98-107	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	205-211
29511375-6	2018	Intriguingly, CTLA-4 -318 genotype was associated with circulatory triglycerides in T2DM subjects (P=0.019) although no significant association between CTLA-4 -318 (P=0.119) and +49 (P=0.2) genotypes with T2DM was identified.	Triglycerides	67-80	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	14-20
29520267-9	2018	In parallel, the donor-reactive CD4+CTLA4hi/CD4+CTLA4med/lo T cell ratio was reduced significantly in graft recipients without DCreg infusion, but increased in those given DCreg.	dcreg	127-132	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	36-41
29520267-9	2018	In parallel, the donor-reactive CD4+CTLA4hi/CD4+CTLA4med/lo T cell ratio was reduced significantly in graft recipients without DCreg infusion, but increased in those given DCreg.	dcreg	127-132	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	48-53
29511375-7	2018	In addition, CTLA-4 +49 genotype was significantly associated with the ratio between total cholesterol and high-density lipoprotein (P=0.004) in control subjects.	Cholesterol	91-102	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	13-19
29321374-3	2018	Here, we show that a potentially novel anti-CD28 domain antibody (dAb) that selectively blocks CD28 but preserves CTLA-4 coinhibition confers improved allograft survival in sensitized recipients as compared with CTLA-4 Ig.	3,3'-Diaminobenzidine	66-69	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	114-120
28751442-2	2018	At the time, ICBs had just entered clinical testing, an endeavor that culminated in 2011 with the approval of the first anti-CTLA-4 antibody for use in metastatic melanoma patients (ipilimumab).	icbs	13-17	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	125-131
29367462-3	2018	Based on high expression of CD5, we identified a subset of self-reactive Tregs expressing elevated levels of T-bet, GITR, CTLA-4, and ICOS, which imparted significant protection from autoimmune diabetes.	tregs	73-78	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	122-128
29321374-4	2018	However, both CTLA-4 Ig and anti-CD28 dAb similarly and significantly reduced the accumulation of donor-reactive CD8+ memory T cells, demonstrating that regulation of the expansion of CD8+ memory T cell populations is controlled in part by CD28 signals and is not significantly impacted by CTLA-4.	3,3'-Diaminobenzidine	38-41	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	290-296
28637095-7	2018	Interestingly, donor-reactive Tfh cells differentially upregulated CTLA4 expression, suggesting an important role for CTLA4 in mediating the superior inhibition observed with the anti-CD28 dAb.	3,3'-Diaminobenzidine	189-192	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	67-72
28637095-7	2018	Interestingly, donor-reactive Tfh cells differentially upregulated CTLA4 expression, suggesting an important role for CTLA4 in mediating the superior inhibition observed with the anti-CD28 dAb.	3,3'-Diaminobenzidine	189-192	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	118-123
29731463-3	2018	CTLA4-Ig, abatacept(ABT)was developed as a drug with multipotent inhibitor against activated T/B cells, monocytes, dendritic cells, macrophages and osteoclast progenitors expressing B7 molecules.	2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid	20-23	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	0-5
29061643-5	2018	Motolimod plus cetuximab also decreased induction of Treg and reduced markers of suppression, including CTLA-4, CD73, and membrane-bound TGFbeta.	VTX-2337	0-9	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	104-110
29066174-2	2017	We found that metformin (Met) reduced tumor-infiltrating Treg (Ti-Treg), particularly the terminally-differentiated CD103+KLRG1+ population, and also decreased effector molecules such as CTLA4 and IL-10.	Metformin	14-23	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	187-192
28856392-4	2017	We hypothesized that CTLA-4 blockade, despite a lack of clinical efficacy seen thus far in PDAC, might still alter T cell immunobiology, which would have therapeutic implications.	pdac	91-95	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	21-27
28807506-0	2017	Altered vulnerability to asthma at various levels of ambient Benzo[a]Pyrene by CTLA4, STAT4 and CYP2E1 polymorphisms.	Benzo(a)pyrene	61-75	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	79-84
28707078-5	2017	CTLA-4 expression in neither tumor epithelial cells (T-CTLA-4) nor stromal cells (S-CTLA-4) of primary tumors was significantly associated with disease-specific survival (DSS) in all patients.	dss	171-174	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	0-6
28707078-6	2017	However, high S-CTLA-4 expression independently predicted significantly improved DSS in the squamous cell carcinoma subgroup (HR 0.62, 95% CI 0.41-0.93, P = 0.021).	dss	81-84	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	16-22
28835386-9	2017	Interestingly, anti-CTLA4/anti-PD-1/PD-L1 combinations versus anti-PD-1/PD-L1 monotherapy was selected as a factor independent of TMB for predicting better RR (77% vs. 21%; P = 0.004) and PFS (P = 0.024).	1,2,4,5-tetramethoxybenzene	130-133	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	20-25
28963072-8	2017	PGE2 negatively modulated the expression of cytotoxic T lymphocyte antigen-4 (CTLA-4) and glucocorticoid-induced tumor necrosis factor receptor-related protein (GITR), as well as the production of interleukin (IL)-10 by Treg cells via EP2 receptors and cAMP/PKA signaling.	Dinoprostone	0-4	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	44-76
28963072-8	2017	PGE2 negatively modulated the expression of cytotoxic T lymphocyte antigen-4 (CTLA-4) and glucocorticoid-induced tumor necrosis factor receptor-related protein (GITR), as well as the production of interleukin (IL)-10 by Treg cells via EP2 receptors and cAMP/PKA signaling.	Dinoprostone	0-4	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	78-84
28648905-1	2017	BACKGROUND &amp; AIMS: Ligand binding to inhibitory receptors on immune cells, such as programmed cell death 1 (PD-1) and cytotoxic T-lymphocyte associated protein 4 (CTLA4), down-regulates the T-cell-mediated immune response (called immune checkpoints).	Adenosine Monophosphate	12-15	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	122-165
28878208-4	2017	We show that inhibition of HSP90 with ganetespib enhances T-cell-mediated killing of patient-derived human melanoma cells by their autologous T cells in vitro and potentiates responses to anti-CTLA4 and anti-PD1 therapy in vivo.	STA 9090	38-48	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	193-198
28715352-8	2017	Furthermore, a cell wall constituent of NPI, lipoteichoic acid, specifically recapitulates these effects and mediates increased expression of CTLA4-like ligands PDL1 and PDL2 on prostatic CD11b+ve antigen-presenting cells.	lipoteichoic acid	45-62	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	142-147
28687658-6	2017	Blockade of PD-L1/CTLA4 signaling dampened activation of SMX-NO-specific naive and memory T cells, whereas blockade of TIM-3 produced no effect.	4-nitrososulfamethoxazole	57-63	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	18-23
29147629-2	2017	Although considerable attention persists around the inhibition of cytotoxic T lymphocyte-associated protein 4 (CTLA4) and programmed cell death 1 (PDCD1, best known as PD-1) signaling, several other co-inhibitory T-cell receptors are being evaluated as potential targets for the development of novel ICBs.	icbs	300-304	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	111-116
28476779-6	2017	However, treatment with checkpoint inhibitors now in clinical use for peripheral solid tumors, such as those inhibiting cytotoxic T-lymphocyte-associated protein-4 (CTLA4) or programmed cell death-1 (PD1) receptors, results in further abnormalities of tryptophan metabolism.	Tryptophan	252-262	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	120-163
28186328-0	2017	Site-specific monitoring of N-Glycosylation profiles of a CTLA4-Fc-fusion protein from the secretory pathway to the extracellular environment.	Nitrogen	28-29	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	58-63
28186328-2	2017	In this study, we profiled the site-specific evolution of N-glycans on a CTLA4-Fc-fusion protein, from the intracellular secretory pathway to the conditioned medium (CM) in fed-batch cell culture.	n-glycans	58-67	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	73-78
28560327-4	2017	We report the impact of a cancer-derived immune modulator, the human-soluble natural killer group 2D (NKG2D) ligand sMIC (soluble major histocompatibility complex I chain-related molecule), on the therapeutic outcome of anti-CTLA4 antibody using an MIC transgenic spontaneous TRAMP (transgenic adenocarcinoma of the mouse prostate)/MIC tumor model.	SMIC	116-120	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	225-230
28588051-0	2017	WITHDRAWN: Correlations of CTLA-4 exon-1 rs231775A&gt;G and promoter region rs5742909C&gt;T polymorphisms with the therapeutic efficacy of 131I radionuclide in Graves" disease.	131i radionuclide	139-156	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	27-33
28476779-6	2017	However, treatment with checkpoint inhibitors now in clinical use for peripheral solid tumors, such as those inhibiting cytotoxic T-lymphocyte-associated protein-4 (CTLA4) or programmed cell death-1 (PD1) receptors, results in further abnormalities of tryptophan metabolism.	Tryptophan	252-262	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	165-170
28476779-7	2017	This implies that to obtain optimal results in the treatment of GBM, one may need to add an inhibitor of the kynurenine pathway to therapy with a CTLA4 or PD1 inhibitor, or use agents which can suppress multiple checkpoint molecules.	Kynurenine	109-119	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	146-151
28428880-3	2017	Two large studies with ipilimumab, an anti-CTLA-4 (cytotoxic T-lymphocyte antigen 4) antibody reported improved progression-free survival, but not statistically improved overall survival at the primary analysis (CA184 043 and CA184 095).	ca184	226-231	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	43-49
28326838-0	2017	CTLA-4 gene polymorphisms associate with efficacy of postoperative radioiodine-131 for differentiated thyroid carcinoma.	radioiodine-131	67-82	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	0-6
28326838-1	2017	AIM: To investigate the association of CTLA-4 polymorphisms with efficacy of postoperative radioiodine-131 (I-131) treatment for differentiated thyroid carcinoma (DTC).	radioiodine-131	91-106	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	39-45
28326838-1	2017	AIM: To investigate the association of CTLA-4 polymorphisms with efficacy of postoperative radioiodine-131 (I-131) treatment for differentiated thyroid carcinoma (DTC).	Iodine-131	108-113	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	39-45
28326838-1	2017	AIM: To investigate the association of CTLA-4 polymorphisms with efficacy of postoperative radioiodine-131 (I-131) treatment for differentiated thyroid carcinoma (DTC).	dtc	163-166	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	39-45
28359618-0	2017	Adjuvanticity of a CTLA-4 3" UTR complementary oligonucleotide for emulsion formulated recombinant subunit and inactivated vaccines.	Oligonucleotides	47-62	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	19-25
27816492-1	2017	BACKGROUND &amp; AIMS: Tremelimumab is a fully human monoclonal antibody that binds to cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) on the surface of activated T lymphocytes.	Adenosine Monophosphate	12-15	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	87-130
28112181-0	2017	IL-3 and CTLA4 gene polymorphisms may influence the tacrolimus dose requirement in Chinese kidney transplant recipients.	Tacrolimus	52-62	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	9-14
28064139-6	2017	Within the 59 clinical trials (totalling 9208 patients) analysed, the overall incidence of nAEs was 3.8% with anti-CTLA4 antibodies, 6.1% with anti-PD1 antibodies, and 12.0% with the combination of both.	naes	91-95	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	115-120
28333940-6	2017	At 20 WPV, the most significant transcriptional changes of Gag-specific CD8+ T cells were genes involved in TCR signaling, differentiation and maturation toward central memory cells, with increased expression of CCR7, TCRalpha, TCRbeta, CD28 and decreased expression of CTLA-4, IFN-gamma, RANTES, granzyme A and B.	Glycosaminoglycans	59-62	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	270-276
27816492-1	2017	BACKGROUND &amp; AIMS: Tremelimumab is a fully human monoclonal antibody that binds to cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) on the surface of activated T lymphocytes.	Adenosine Monophosphate	12-15	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	132-138
29491534-11	2017	Curcumin also suppressed the expression of costimulatory molecules CD40L and CTLA-4, as well as PBMC proliferation.	Curcumin	0-8	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	77-83
27775332-15	2017	The combination of the Pd-1-/- mouse and anti-CTLA-4 also unmasks the ability of other drugs such as isoniazid to cause delayed type liver injury.	Isoniazid	101-110	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	46-52
28203344-3	2017	To date, two main pathways, the cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and programmed death 1 (PD-1), have emerged as key targets of CBT demonstrating unprecedented activity particularly in heavily pretreated relapsed/refractory Hodgkin lymphoma and some forms of non-Hodgkin disease.	N,N-BIS(4-CHLOROBENZYL)-1H-1,2,3,4-TETRAAZOL-5-AMINE	147-150	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	32-75
28203344-3	2017	To date, two main pathways, the cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and programmed death 1 (PD-1), have emerged as key targets of CBT demonstrating unprecedented activity particularly in heavily pretreated relapsed/refractory Hodgkin lymphoma and some forms of non-Hodgkin disease.	N,N-BIS(4-CHLOROBENZYL)-1H-1,2,3,4-TETRAAZOL-5-AMINE	147-150	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	77-83
27877174-4	2016	5-Aza treatment enhanced the expression of Treg cell signature genes, such as CD25, FOXP3, CTLA-4, and GITR, in CD4+CD25h cells.	Azacitidine	0-5	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	91-97
27866850-5	2016	Inhibition of CSN5 by curcumin diminished cancer cell PD-L1 expression and sensitized cancer cells to anti-CTLA4 therapy.	Curcumin	22-30	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	107-112
27553906-13	2016	In the nivolumab with or without ipilimumab study, objective partial response at 12 weeks to PD-1 inhibitor with or without cytotoxic T-lymphocyte-associated protein 4 inhibitor was 25.5% to 33.3% and 5% in the MSI-H and MSS groups, respectively (100 patients in the MSI-H group, 20 patients in the MSS group).	MSS	221-224	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	124-167
27459735-12	2016	When T cells were co-cultured with TAMs, expression levels of Tim-3, PD-1 and CTLA-4 were significantly higher than controls, whereas levels of IFN-gamma and Granzyme B were significantly decreased, in a dose-dependent manner (p &lt; 0.05).	tams	35-39	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	78-84
27894401-8	2016	Interestingly, SLE patients with AA genotypes of CTLA-4 G-1661A have lower neopterin and MDA concentration compared with GA+GG genotypes.	Neopterin	75-84	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	49-55
27791067-5	2016	Although the frequency of regulatory T cells did not change after treatment, there was a significant decline in the expression of the inhibitory molecule cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) on CD4+ T cells of albendazole-treated individuals, -0.060 [-0.107 to -0.013] and -0.057 [-0.105 to -0.008] at 9 and 21 mo, respectively; Ptime = 0.017.	Albendazole	226-237	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	154-197
27791067-5	2016	Although the frequency of regulatory T cells did not change after treatment, there was a significant decline in the expression of the inhibitory molecule cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) on CD4+ T cells of albendazole-treated individuals, -0.060 [-0.107 to -0.013] and -0.057 [-0.105 to -0.008] at 9 and 21 mo, respectively; Ptime = 0.017.	Albendazole	226-237	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	199-205
27894401-8	2016	Interestingly, SLE patients with AA genotypes of CTLA-4 G-1661A have lower neopterin and MDA concentration compared with GA+GG genotypes.	Gallium	121-123	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	49-55
27894401-10	2016	In conclusion, our findings showed, that there is an association between systemic inflammatory markers, oxidative stress and the CTLA-4 G-1661A GG+AG genotypes, MDA and neopterin which are the most conventional risk factors for coronary heart disease, therefore these mutations may be consider as a risk factor for susceptibility to heart disease in SLE patients.	Neopterin	169-178	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	129-135
26990829-0	2016	Rapamycin Interferes With Postdepletion Regulatory T Cell Homeostasis and Enhances DSA Formation Corrected by CTLA4-Ig.	Sirolimus	0-9	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	110-115
27703455-1	2016	We have shown that cholera toxin (CT) and other cyclic AMP (cAMP)-elevating agents induce upregulation of the inhibitory molecule CTLA-4 in human resting CD4+ T lymphocytes, which following the treatment acquired suppressive functions.	Cyclic AMP	48-58	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	130-136
27703455-1	2016	We have shown that cholera toxin (CT) and other cyclic AMP (cAMP)-elevating agents induce upregulation of the inhibitory molecule CTLA-4 in human resting CD4+ T lymphocytes, which following the treatment acquired suppressive functions.	Cyclic AMP	60-64	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	130-136
27703455-3	2016	We found that cAMP-elevating agents induce upregulation of CTLA-4 in CD4+CD25- and further enhance its expression in CD4+CD25+ T cells.	Cyclic AMP	14-18	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	59-65
27703455-4	2016	We observed an increase of two isoforms of mRNA coding for the membrane and the soluble CTLA-4 molecules, suggesting that the regulation of CTLA-4 expression by cAMP is at the transcriptional level.	Cyclic AMP	161-165	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	88-94
27703455-4	2016	We observed an increase of two isoforms of mRNA coding for the membrane and the soluble CTLA-4 molecules, suggesting that the regulation of CTLA-4 expression by cAMP is at the transcriptional level.	Cyclic AMP	161-165	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	140-146
27328412-6	2016	Seven days after transplant, serum blood IFN-gamma levels were significantly lower in the CTLA-4 Ig with reparixin treatment group compared to controls.	reparixin	105-114	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	90-96
27328412-4	2016	CTLA-4 Ig treatment is known to significantly prolong kidney subcapsular islet allograft survival and enhance glucose tolerance.	Glucose	110-117	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	0-6
26990829-9	2016	This suggests that rapamycin after T cell depletion could affect Treg cells leading to an increase of Tfh cells and DSA production that can be reversed by CTLA4-Ig.	Sirolimus	19-28	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	155-160
26990829-9	2016	This suggests that rapamycin after T cell depletion could affect Treg cells leading to an increase of Tfh cells and DSA production that can be reversed by CTLA4-Ig.	dsa	116-119	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	155-160
26864661-0	2016	Tolerogenic responses of CD206+, CD83+, FOXP3+, and CTLA-4 to sericin/polyvinyl alcohol/glycerin scaffolds relevant to IL-33 and HSP60 activity.	Polyvinyl Alcohol	70-87	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	52-58
26864661-0	2016	Tolerogenic responses of CD206+, CD83+, FOXP3+, and CTLA-4 to sericin/polyvinyl alcohol/glycerin scaffolds relevant to IL-33 and HSP60 activity.	Glycerol	88-96	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	52-58
27122549-1	2016	Checkpoint inhibitors (CPI), namely anti-CTLA4 and anti-PD1/PD-L1 antibodies, demonstrated efficacy across multiple types of cancer.	methyl 2-isocyano-2-methylpropanoate	23-26	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	41-46
27347411-1	2016	The cytotoxic T-lymphocyte antigen 4 (CTLA-4) polymorphic loci -318 cytosine/thymine (-318C/T) has been previously implicated in malignant tumor susceptibility.	Cytosine	68-76	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	4-36
27347411-1	2016	The cytotoxic T-lymphocyte antigen 4 (CTLA-4) polymorphic loci -318 cytosine/thymine (-318C/T) has been previously implicated in malignant tumor susceptibility.	Cytosine	68-76	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	38-44
27347411-1	2016	The cytotoxic T-lymphocyte antigen 4 (CTLA-4) polymorphic loci -318 cytosine/thymine (-318C/T) has been previously implicated in malignant tumor susceptibility.	Thymine	77-84	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	4-36
27347411-1	2016	The cytotoxic T-lymphocyte antigen 4 (CTLA-4) polymorphic loci -318 cytosine/thymine (-318C/T) has been previously implicated in malignant tumor susceptibility.	Thymine	77-84	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	38-44
27347411-9	2016	The overall estimation demonstrated a significant association between CTLA-4 -318C/T polymorphism and malignant tumor risk in the Asian populations (TT+TC vs. CC: OR, 1.28; 95% CI, 1.07-1.53.	tt+tc	149-154	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	70-76
27478768-3	2016	The present study aimed to investigate the +49 A/G CTLA4 genetic polymorphism and predisposition to RSA.	rabbit sperm membrane autoantigen	100-103	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	51-56
26940199-6	2016	After 3 hrs, macrophages treated with DEX alone or with CTLA4-Ig-DEX or CTLA4-Ig-DEX-MTX showed a significant reduction (p&lt;0.05) for all cytokines gene expression, that was still significant for IL-1beta after 24 hrs (p&lt;0.05).	Dexamethasone	38-41	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	56-61
27050369-1	2016	To examine the relationship between cytotoxic T lymphocyte antigen-4 (CTLA-4) expression and esophageal carcinoma prognosis, CTLA-4 expression was immunohistochemically detected in paraffin-embedded primary tumor specimens from 158 patients with esophageal cancer.	Paraffin	181-189	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	125-131
26940199-6	2016	After 3 hrs, macrophages treated with DEX alone or with CTLA4-Ig-DEX or CTLA4-Ig-DEX-MTX showed a significant reduction (p&lt;0.05) for all cytokines gene expression, that was still significant for IL-1beta after 24 hrs (p&lt;0.05).	dex-mtx	81-88	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	72-77
27306793-10	2016	CONCLUSIONS: NACT may enhance host immune response but this effect is tempered by high/increased levels of PD-1, CTLA4, and PD-L1.	nact	13-17	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	113-118
27296673-9	2016	RESULTS: Cholecalciferol supplementation was associated with higher absolute numbers of Helios(+), CTLA-4(+), and total Tregs than calcitriol (p &lt; 0.001, p = 0.004, p = 0.001 respectively).	Cholecalciferol	9-24	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	99-105
27007547-5	2016	Cytotoxic T-lymphocyte-associated protein 4 CTLA-4 expression in the naive Treg was decreased in both preterm groups compared with those from term newborns and adults, and in the memory Treg from Group 1 compared with the other groups.	treg	75-79	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	0-43
27007547-5	2016	Cytotoxic T-lymphocyte-associated protein 4 CTLA-4 expression in the naive Treg was decreased in both preterm groups compared with those from term newborns and adults, and in the memory Treg from Group 1 compared with the other groups.	treg	75-79	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	44-50
27007547-5	2016	Cytotoxic T-lymphocyte-associated protein 4 CTLA-4 expression in the naive Treg was decreased in both preterm groups compared with those from term newborns and adults, and in the memory Treg from Group 1 compared with the other groups.	treg	186-190	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	0-43
27007547-5	2016	Cytotoxic T-lymphocyte-associated protein 4 CTLA-4 expression in the naive Treg was decreased in both preterm groups compared with those from term newborns and adults, and in the memory Treg from Group 1 compared with the other groups.	treg	186-190	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	44-50
27041081-7	2016	Furthermore, both vitamin D forms induced an expansion of CD25hi cells and upregulated their expression of CTLA-4 and Foxp3 regulatory markers.	Vitamin D	18-27	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	107-113
26940199-8	2016	After 24 hrs CTLA4-Ig-DEX induced a significant decrease of gene expression (p&lt;0.05) for TNF-alpha and IL-6, whereas CTLA4-Ig-DEX-MTX induced a decrease (p&lt;0.05) limited to IL-6, versus CNT.	dex-mtx	129-136	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	120-125
26940199-9	2016	Finally, ICC showed, after 24 hrs of CTLA4-Ig-DEX or CTLA4-Ig-DEX-MTX treatment a reduction (p&lt;0.05) of IL-1beta and IL-6 expression, versus CNT; DEX alone reduced only IL-1beta (p&lt;0.05).	Dexamethasone	46-49	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	37-42
26940199-9	2016	Finally, ICC showed, after 24 hrs of CTLA4-Ig-DEX or CTLA4-Ig-DEX-MTX treatment a reduction (p&lt;0.05) of IL-1beta and IL-6 expression, versus CNT; DEX alone reduced only IL-1beta (p&lt;0.05).	dex-mtx	62-69	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	53-58
26940199-9	2016	Finally, ICC showed, after 24 hrs of CTLA4-Ig-DEX or CTLA4-Ig-DEX-MTX treatment a reduction (p&lt;0.05) of IL-1beta and IL-6 expression, versus CNT; DEX alone reduced only IL-1beta (p&lt;0.05).	Dexamethasone	62-65	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	53-58
26940199-11	2016	CONCLUSIONS: CTLA4-Ig-DEX and CTLA4-Ig-DEX-MTX combined treatments, decreased at any level the inflammatory cytokine expression more efficiently then monotreatments on activated cultured human macrophages.	dex-mtx	39-46	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	30-35
26819277-2	2016	Anti-CTLA-4 monoclonal antibody, ipilimumab, is the first-approved immune checkpoint inhibitor and has shown durable objective responses for advanced melanoma beyond the effect of dacarbazine.	Dacarbazine	180-191	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	5-11
26801967-4	2016	In SDS-PAGE/inmunoblot analyses, CTLA4Fcepsilon appeared as a 70,000 MW polypeptide that forms homodimers.	Sodium Dodecyl Sulfate	3-6	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	33-38
26782543-5	2015	Polymorphisms in the TNF-alpha(rs1800629), CTLA-4 (rs231775), and PTPN22 (rs2476601) genes have been previous associated with T1D; however, there is no consensus regarding their role in T1D and scarce literature focusing on AIDT and/or CD.	aidt	224-228	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	43-49
26731721-10	2016	SplM spleens contained a high proportion of eTregs with CXCR3, CCR5 and CTLA4 upregulation and CCR7 downregulation.	etregs	44-50	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	72-77
26211942-0	2016	The effect of single course high dose dexamethasone on CD28/CTLA-4 balance in the treatment of patients with newly diagnosed primary immune thrombocytopenia.	Dexamethasone	38-51	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	60-66
26211942-1	2016	To evaluate the effect of a single course of high dose dexamethasone (HD-DXM) on CD28 and CTLA-4 expression in patients with newly-diagnosed primary immune thrombocytopenia (ITP).	Dexamethasone	55-68	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	90-96
26680373-10	2016	After transplantation with CB and rapamycin, donor-reactive Eomes(lo)CTLA4(hi) CD8+ T cells were reduced.	Sirolimus	34-43	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	69-74
26680373-12	2016	CONCLUSIONS: Low Eomes and high CTLA4 expression by donor-reactive CD8+ Tmem is associated with prolonged renal allograft survival induced by DCreg infusion in CTLA4Ig-treated monkeys.	tmem	72-76	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	32-37
26680373-12	2016	CONCLUSIONS: Low Eomes and high CTLA4 expression by donor-reactive CD8+ Tmem is associated with prolonged renal allograft survival induced by DCreg infusion in CTLA4Ig-treated monkeys.	tmem	72-76	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	160-165
26680373-12	2016	CONCLUSIONS: Low Eomes and high CTLA4 expression by donor-reactive CD8+ Tmem is associated with prolonged renal allograft survival induced by DCreg infusion in CTLA4Ig-treated monkeys.	dcreg	142-147	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	32-37
26680373-12	2016	CONCLUSIONS: Low Eomes and high CTLA4 expression by donor-reactive CD8+ Tmem is associated with prolonged renal allograft survival induced by DCreg infusion in CTLA4Ig-treated monkeys.	dcreg	142-147	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	160-165
27800130-9	2016	Significant associations were found between TT and TC genotypes of CTLA4 -1722T/C and T allele with acute rejection in CMV infected kidney transplant patients.	Technetium	51-53	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	67-72
26783747-6	2016	Our results suggest that decreased IL-10 production by Foxp3+ CD4+ T cells in the presence of IC87114 negates individual anti-inflammatory effects of IC8114 and CTLA4-Ig.	IC 87114	94-101	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	161-166
27076165-8	2016	In particular, targeted ablation of these barricades with novel agents, such as the immune checkpoint drug ipilimumab (anti-CTLA-4) approved recently for clinical use, may offer significant leverage to vaccinologists seeking to control and prevent malignancy.	cypermethrin	42-52	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	124-130
26606967-0	2015	Trastuzumab emtansine (T-DM1) renders HER2+ breast cancer highly susceptible to CTLA-4/PD-1 blockade.	t-dm1	0-21	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	80-86
26272303-7	2015	RESULTS: After high-dose dexamethasone therapy, CTLA-4 levels were significantly elevated not only in acute ITP patients (P&lt;0.001; P&lt;0.0001) but also in acute ITP responders (P&lt;0.0001; P&lt;0.0001).	Dexamethasone	25-38	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	48-54
25989700-0	2015	Rapamycin ameliorates the CTLA4-Ig-mediated defect in CD8(+) T cell immunity during gammaherpesvirus infection.	Sirolimus	0-9	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	26-31
25989700-4	2015	However, the addition of rapamycin to the CTLA4-Ig regimen was able to quantitatively and qualitatively restore the antigen-specific CD8(+) T cell response to the virus.	Sirolimus	25-34	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	42-47
25989700-5	2015	This improvement was physiologically relevant, in that CTLA4-Ig treated animals exhibited a greater viral burden following infection that was reduced to levels observed in untreated immunocompetent animals by the addition of rapamycin.	Sirolimus	225-234	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	55-60
26134669-0	2015	Vitamin D Antagonises the Suppressive Effect of Inflammatory Cytokines on CTLA-4 Expression and Regulatory Function.	Vitamin D	0-9	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	74-80
26317466-6	2015	In melanoma patients treated with an immune checkpoint therapy, high viral defense signature expression in tumors significantly associates with durable clinical response and DNMTi treatment sensitizes to anti-CTLA4 therapy in a pre-clinical melanoma model.	dnmti	174-179	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	209-214
26206937-7	2015	In LRBA-deficient cells, inhibition of lysosome degradation with chloroquine prevented CTLA4 loss.	Chloroquine	65-76	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	87-92
26134669-8	2015	Here we show that induction of CTLA-4 by 1,25(OH)2D3 can actually be enhanced in the presence of Th17 polarising cytokines.	Calcitriol	41-52	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	31-37
26134669-9	2015	Furthermore, its transendocytic function was maintained such that T cells generated in the presence of Th17 conditions and 1,25(OH)2D3 were highly effective at capturing CTLA-4 ligands from antigen presenting cells and suppressing T cell division.	Calcitriol	123-134	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	170-176
26134669-7	2015	We have previously shown a striking ability of 1,25 dihydroxyvitamin D3 (1,25(OH)2D3) to enhance CTLA-4, however, its effects upon B7 transendocytosis and its activity in the context of inflammation remained unknown.	Calcitriol	47-71	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	97-103
26134669-10	2015	Taken together, these data reveal an inhibitory effect of Th17 polarising conditions upon CTLA-4-mediated regulation and show that 1,25(OH)2D3 counteracts this effect.	Calcitriol	131-142	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	90-96
26134669-7	2015	We have previously shown a striking ability of 1,25 dihydroxyvitamin D3 (1,25(OH)2D3) to enhance CTLA-4, however, its effects upon B7 transendocytosis and its activity in the context of inflammation remained unknown.	Calcitriol	73-84	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	97-103
25893809-1	2015	To examine the relationship between cytotoxic T lymphocyte antigen 4 (CTLA-4) expression and breast cancer prognosis, CTLA-4 expression was immunohistochemically detected in paraffin-embedded specimens of primary tumors from 130 patients with breast cancer who had a mean follow-up period of 112 months.	Paraffin	174-182	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	118-124
25604080-12	2015	CONCLUSION: This study identifies a novel mechanism of action of MTX, in which treatment of RA patients with MTX restores defective Treg cell function through demethylation of the FOXP3 locus, leading to a subsequent increase in FoxP3 and CTLA-4 expression.	Methotrexate	65-68	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	239-245
27668268-4	2015	Lenalidomide upregulated critical T cell activation markers and costimulatory molecules (CD28, CD38, CD40L, CD69, ICOS), especially within the central memory CTL subset of XBP1-CTL, while decreasing TCRalphabeta and T cell checkpoint blockade (CTLA-4, PD-1).	Lenalidomide	0-12	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	244-250
27668268-5	2015	Lenalidomide increased the anti-tumor activities of XBP1-CTL memory subsets, which were associated with expression of Th1 transcriptional regulators (T-bet, Eomes) and Akt activation, thereby resulting in enhanced IFN-gamma production, granzyme B upregulation and specific CD28/CD38-positive and CTLA-4/PD-1-negative cell proliferation.	Lenalidomide	0-12	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	296-302
25604080-12	2015	CONCLUSION: This study identifies a novel mechanism of action of MTX, in which treatment of RA patients with MTX restores defective Treg cell function through demethylation of the FOXP3 locus, leading to a subsequent increase in FoxP3 and CTLA-4 expression.	Methotrexate	109-112	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	239-245
25689638-4	2015	We found evidence of the association between CTLA-4 A49G polymorphism and colorectal cancer risk (GG vs. AA: OR = 2.01, 95% CI = 1.29-3.07, P = 0.002; GA vs. AA: OR = 2.32, 95% CI = 1.53-3.57, P = 0.001; GA + GG vs. AA: OR = 2.16, 95% CI = 1.46-3.21, P = 0.001).	Gallium	151-153	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	45-51
25124890-10	2015	IPA revealed cytotoxic T-lymphocyte antigen 4 (CTLA4) signaling was the most significant pathway present in the peripheral whole blood of stroke patients 24-48 hr after onset.	ipa	0-3	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	13-45
25124890-10	2015	IPA revealed cytotoxic T-lymphocyte antigen 4 (CTLA4) signaling was the most significant pathway present in the peripheral whole blood of stroke patients 24-48 hr after onset.	ipa	0-3	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	47-52
25619164-4	2015	In recent years, the United States Food and Drug Administration (FDA) - approved several novel agents targeting the RAS/RAF/MEK/ERK pathway (vemurafenib, dabrafenib, and trametinib) - critical in cell division and proliferation of melanoma, and an immune checkpoint inhibitor (ipilimumab) directed against the cytotoxic T lymphocyte Antigen - (CTLA-4).	Vemurafenib	141-152	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	344-350
25619164-4	2015	In recent years, the United States Food and Drug Administration (FDA) - approved several novel agents targeting the RAS/RAF/MEK/ERK pathway (vemurafenib, dabrafenib, and trametinib) - critical in cell division and proliferation of melanoma, and an immune checkpoint inhibitor (ipilimumab) directed against the cytotoxic T lymphocyte Antigen - (CTLA-4).	dabrafenib	154-164	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	344-350
25619164-4	2015	In recent years, the United States Food and Drug Administration (FDA) - approved several novel agents targeting the RAS/RAF/MEK/ERK pathway (vemurafenib, dabrafenib, and trametinib) - critical in cell division and proliferation of melanoma, and an immune checkpoint inhibitor (ipilimumab) directed against the cytotoxic T lymphocyte Antigen - (CTLA-4).	trametinib	170-180	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	344-350
25627654-4	2015	Because of the vesicant activity of doxorubicin, microparticles made of biodegradable polymer poly(lactide-co-glycolide) or PLGA can safely deliver doxorubicin intratumorally and are effective vaccine adjuvants, (ii) enhancing T-cell activation using anti-OX40 and (iii) sustaining T-cell responses by checkpoint blockade using anti-CTLA-4.	Doxorubicin	36-47	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	333-339
25627654-4	2015	Because of the vesicant activity of doxorubicin, microparticles made of biodegradable polymer poly(lactide-co-glycolide) or PLGA can safely deliver doxorubicin intratumorally and are effective vaccine adjuvants, (ii) enhancing T-cell activation using anti-OX40 and (iii) sustaining T-cell responses by checkpoint blockade using anti-CTLA-4.	Polymers	86-93	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	333-339
25627654-4	2015	Because of the vesicant activity of doxorubicin, microparticles made of biodegradable polymer poly(lactide-co-glycolide) or PLGA can safely deliver doxorubicin intratumorally and are effective vaccine adjuvants, (ii) enhancing T-cell activation using anti-OX40 and (iii) sustaining T-cell responses by checkpoint blockade using anti-CTLA-4.	poly	86-90	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	333-339
25627654-4	2015	Because of the vesicant activity of doxorubicin, microparticles made of biodegradable polymer poly(lactide-co-glycolide) or PLGA can safely deliver doxorubicin intratumorally and are effective vaccine adjuvants, (ii) enhancing T-cell activation using anti-OX40 and (iii) sustaining T-cell responses by checkpoint blockade using anti-CTLA-4.	lactide-co-glycolide	99-119	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	333-339
25627654-4	2015	Because of the vesicant activity of doxorubicin, microparticles made of biodegradable polymer poly(lactide-co-glycolide) or PLGA can safely deliver doxorubicin intratumorally and are effective vaccine adjuvants, (ii) enhancing T-cell activation using anti-OX40 and (iii) sustaining T-cell responses by checkpoint blockade using anti-CTLA-4.	Doxorubicin	148-159	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	333-339
25185645-9	2015	Compared with controls, patients having a high titer of GADA (GADA &gt;= 180 IU/ml) had higher frequencies of the GG risk genotype of CTLA-4 + 49 A/G (49.4% vs. 35.1% OR = 1.807, 95% CI 1.125-2.903, P = 0.014), but there was no difference between patients having a low titer of GADA and controls.	gada	56-60	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	134-140
25185645-9	2015	Compared with controls, patients having a high titer of GADA (GADA &gt;= 180 IU/ml) had higher frequencies of the GG risk genotype of CTLA-4 + 49 A/G (49.4% vs. 35.1% OR = 1.807, 95% CI 1.125-2.903, P = 0.014), but there was no difference between patients having a low titer of GADA and controls.	gada	62-66	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	134-140
25185645-9	2015	Compared with controls, patients having a high titer of GADA (GADA &gt;= 180 IU/ml) had higher frequencies of the GG risk genotype of CTLA-4 + 49 A/G (49.4% vs. 35.1% OR = 1.807, 95% CI 1.125-2.903, P = 0.014), but there was no difference between patients having a low titer of GADA and controls.	gada	62-66	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	134-140
25185645-11	2015	The CTLA-4 + 49 A/G genotype distribution in LADA is associated with the GADA level.	gada	73-77	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	4-10
25267951-3	2014	METHODS: The methylation of CTLA4 gene promoter was evaluated by methylation-specific polymerase chain reaction (MSP) technique using 85 paraffin-embedded gastric cancer tissue samples and normal tissue on the tumor margins as control tissue samples.	Paraffin	137-145	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	28-33
25415283-9	2015	Immunosuppressive pathways, including regulatory T cells and CTLA-4 expression on T cells were overcome by the addition of vaccine and low-dose cyclophosphamide to PD-1 blockade.	Cyclophosphamide	144-160	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	61-67
25227919-0	2014	Highly efficient, in-vivo Fas-mediated apoptosis of B-cell lymphoma by hexameric CTLA4-FasL.	ammonium ferrous sulfate	26-29	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	81-86
24891289-5	2014	Methylation of the CTLA-4 gene promoter was analyzed by bisulfite-specific PCR, followed by sequencing.	hydrogen sulfite	56-65	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	19-25
25356901-2	2015	In the present study, we have made an attempt to investigate the impact of CTLA4 single nucleotide polymorphisms (SNPs) (rs231775, rs5742909, rs11571317, rs16840252, rs4553808, rs3087243) and dinucleotide (AT)n repeat polymorphism on the incidence of symptomatic HCMV infection (disease) among 270 renal allograft recipients.	Dinucleoside Phosphates	192-204	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	75-80
25252955-7	2014	Finally, 3M-052 therapy potentiated checkpoint blockade therapy with anti-CTLA-4 and anti-programmed death ligand 1 Abs, even when checkpoint blockade alone was ineffective.	MEDI9197	9-15	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	74-80
25279717-3	2014	Towards clinical application of vitamin D-induced Tregs in autologous adoptive immunotherapy for type 1 diabetes, we show here that 1,25-dihydroxyvitamin D3 [1,25(OH)2D3] and TX527 similarly imprint T cells from type 1 diabetes patients with a CD4+ CD25high CD127low regulatory profile, modulate surface expression of skin- and inflammation-homing receptors, and increase expression of CTLA-4 and OX-40.	Vitamin D	32-41	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	386-392
24906866-8	2014	Finally, we demonstrate that ansamitocin P3, due to its immunomodulatory properties, acts in synergy with antibody-mediated blockade of the T cell inhibitory receptors PD-1 and CTLA-4.	ansamitocins	29-43	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	177-183
23865833-5	2014	We observed increased Treg function, both in vivo and in vitro, due at least partially to an increase in CTLA-4 expression by concurrent treatment with dexamethasone and immune modulatory compounds (iMiDs).	Dexamethasone	152-165	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	105-111
25003519-9	2014	CONCLUSION: A predisposing effect of rs1863800*C, rs733618*C, and rs231775*G of CTLA4 gene to general risk of MG in Chinese was demonstrated for the first time, which was likely derived from EOMG, SPMG, MG without thymoma and the female patients.	eomg	191-195	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	80-85
25016259-10	2014	As a result of the increased frequency of TC, TT genotype and T allele at SNP-318, ALL children synthesized more CTLA-4 to deliver the inhibitive signal, and this lead to restraint of T cell activation.	Technetium	42-44	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	113-119
24373506-3	2014	This is why we checked LOMG patients for two further peculiar features of TAMG - its associations with the CTLA4(high/gain-of-function) +49A/A genotype and with increased thymic export of naive T cells into the blood, possibly after defective negative selection in AIRE-deficient thymomas.	tamg	74-78	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	107-112
24807557-7	2014	Mechanistically, engagement of CD80/86 by CTLA-4 induced activation of the enzyme indoleamine 2,3-dioxygenase (IDO) in osteoclast precursors, which degraded tryptophan and promoted apoptosis.	Tryptophan	157-167	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	42-48
24107844-6	2014	The number of circulating CD4(+)/CD25(high)/Foxp3(+)/CTLA4(+) Tregs, CD8(+)CD28(-) T cells, and HLA-G serum levels were higher in the rapamycin-treated group.	Sirolimus	134-143	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	53-58
24732038-6	2014	Activation-induced TRAIL and expression of cytotoxic T-lymphocyte antigen 4 (CTLA-4) in isolated CD4+ T cells were also reduced by minocycline.	Minocycline	131-142	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	43-75
24732038-6	2014	Activation-induced TRAIL and expression of cytotoxic T-lymphocyte antigen 4 (CTLA-4) in isolated CD4+ T cells were also reduced by minocycline.	Minocycline	131-142	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	77-83
24415757-4	2014	However, ligation of CD80/CD86 by CTLA4 also induces DC production of the immunosuppressive enzyme indoleamine 2,3-dioxygenase (IDO), which depletes local pools of the essential amino acid tryptophan, resulting in blockade of T cell activation.	essential amino acid tryptophan	168-199	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	34-39
24515439-3	2014	In this study, we demonstrate that CTLA-4 forms a multimeric complex comprised of TRIM and related LAX that in turn binds to GTP bound Rab8 for post-Golgi transport to the cell surface.	Guanosine Triphosphate	125-128	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	35-41
24396067-6	2014	We also showed that CTLA-4 receptor signaling mediates tyrosine phosphorylation in the C3G protein, and that this is required for augmented activation of Rap1 and increased adhesion mediated by leukocyte function-associated antigen type 1 (LFA-1).	Tyrosine	55-63	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	20-26
24586378-5	2014	Like TCDD,10-Cl-BBQ altered donor CD4(+) T cell differentiation during the early stages of a graft versus host (GVH) response resulting in expression of high levels of CD25, CTLA-4 and ICOS, as well as several genes associated with Treg function.	10-chloro-7H-benzimidazo(2,1-a)benzo(de)Isoquinolin-7-one	10-19	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	174-180
23851684-0	2013	Impaired function of CTLA-4 in the lungs of patients with chronic beryllium disease contributes to persistent inflammation.	Beryllium	66-75	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	21-27
24466173-6	2014	RESULTS: Cyclophosphamide treatment down-regulated expression of several genes mapped to immune/autoimmune activation and graft rejection including CD3, CD28, CTLA4, MHC II, PRF1, GZMB and IL-2R, and up-regulated immune-related receptor genes, e.g. IL1R2, IL18R1, and FLT3.	Cyclophosphamide	9-25	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	159-164
25484062-1	2014	CTLA4-Ig is a highly glycosylated therapeutic fusion protein that contains multiple N- and O-glycosylation sites.	Nitrogen	84-85	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	0-5
24376736-9	2013	The pooled results suggested the CTLA-4 60G/A polymorphism was significantly associated with an increased skin cancer risk (AA vs. GG: OR = 1.32, 95%CI = 1.09-1.59; AA vs. GA+GG: OR = 1.26, 95%CI = 1.07-1.48).	Gallium	172-174	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	33-39
23924790-2	2013	In particular, cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) antibodies have been successfully combined with GM-CSF cell-based vaccines (GVAX).	gvax	144-148	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	15-58
24581497-7	2014	Importantly, LXRbeta activation displayed melanoma-suppressive cooperativity with the frontline regimens dacarbazine, B-Raf inhibition, and the anti-CTLA-4 antibody and robustly inhibited melanomas that had acquired resistance to B-Raf inhibition or dacarbazine.	Dacarbazine	250-261	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	149-155
23851684-6	2013	Furthermore, CTLA-4 expression was greatest in the beryllium-responsive subset of CD4(+) T cells that retained the ability to proliferate and express IL-2.	Beryllium	51-60	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	13-19
23851684-7	2013	Functional assays show that the induction of CTLA-4 signaling in blood cells inhibited beryllium-induced T cell proliferation while having no effect on the proliferative capacity of beryllium-responsive CD4(+) T cells in the lung.	Beryllium	87-96	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	45-51
23607447-3	2013	We hypothesized that down-regulation of CD28 and up-regulation of alternate co-stimulatory molecules (CD134, CD137, CD152 and CD154) on T cells may be associated with BOS.	N-[4-(Aminosulfonyl)phenyl]-2-Mercaptobenzamide	167-170	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	116-121
23551963-1	2013	BACKGROUND &amp; AIMS: Single nucleotide polymorphisms (SNP) in the Cytotoxic T lymphocyte antigen-4 gene (CTLA-4) have been associated with several autoimmune diseases including autoimmune Hepatitis (AIH).	Adenosine Monophosphate	12-15	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	107-113
23811319-7	2013	Triple combination of a blocking CTLA4 antibody with GVAX and anti-FR4 further enhanced overall survival and reduced growth of well-established melanomas.	gvax	53-57	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	33-38
23340277-3	2013	Cytotoxic T lymphocyte-associated antigen 4 immunoglobulin fusion protein (CTLA-4-Ig, abatacept) is a unique biologic agent targeting the co-stimulatory molecules CD80/CD86, and is indicated for the treatment of moderate-to-severe RA in patients who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs, including methotrexate or anti-tumor necrosis factor agents.	Methotrexate	347-359	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	75-81
23602875-2	2013	Is this single amino acid difference of methionine (M) versus leucine (L) critical for the CTLA-4 binding?	Methionine	40-50	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	91-97
23602875-2	2013	Is this single amino acid difference of methionine (M) versus leucine (L) critical for the CTLA-4 binding?	Leucine	62-69	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	91-97
23594311-2	2013	Golgi N-glycan branching enzymes produce N-glycans, using UDP-GlcNAc as a substrate, which attach to the T cell receptor (TCR) and cytotoxic T-lymphocyte antigen-4 (CTLA-4).	n-glycan	6-14	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	131-163
23594311-2	2013	Golgi N-glycan branching enzymes produce N-glycans, using UDP-GlcNAc as a substrate, which attach to the T cell receptor (TCR) and cytotoxic T-lymphocyte antigen-4 (CTLA-4).	n-glycan	6-14	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	165-171
23594311-2	2013	Golgi N-glycan branching enzymes produce N-glycans, using UDP-GlcNAc as a substrate, which attach to the T cell receptor (TCR) and cytotoxic T-lymphocyte antigen-4 (CTLA-4).	n-glycans	41-50	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	131-163
23594311-2	2013	Golgi N-glycan branching enzymes produce N-glycans, using UDP-GlcNAc as a substrate, which attach to the T cell receptor (TCR) and cytotoxic T-lymphocyte antigen-4 (CTLA-4).	n-glycans	41-50	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	165-171
23594311-2	2013	Golgi N-glycan branching enzymes produce N-glycans, using UDP-GlcNAc as a substrate, which attach to the T cell receptor (TCR) and cytotoxic T-lymphocyte antigen-4 (CTLA-4).	Uridine Diphosphate N-Acetylglucosamine	58-68	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	131-163
23594311-2	2013	Golgi N-glycan branching enzymes produce N-glycans, using UDP-GlcNAc as a substrate, which attach to the T cell receptor (TCR) and cytotoxic T-lymphocyte antigen-4 (CTLA-4).	Uridine Diphosphate N-Acetylglucosamine	58-68	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	165-171
23594311-7	2013	Glucosamine treatment increased the number of T cells expressing beta1,6GlcNAc-branched N-glycans, with reduced ZAP-70 phosphorylation and enhanced CTLA-4 expression.	Glucosamine	0-11	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	148-154
23898270-3	2013	CASE PRESENTATION: We present here the case of a 65-year-old Caucasian male diagnosed with advanced melanoma in April 2011 and treated with ipilimumab (Yervoy( )), a monoclonal antibody targeting cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4), as second-line treatment after progression with dacarbazine, for (wild-type BRAF) metastatic melanoma.	Dacarbazine	298-309	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	196-239
23460536-5	2013	We have recently developed a new class of inhibitory (CTLA-4) and agonistic (4-1BB and OX-40) ligands composed of short oligonucleotide (ODN) aptamers that exhibited bioactivities comparable or superior to that of antibodies.	Oligonucleotides	120-135	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	54-60
23460536-5	2013	We have recently developed a new class of inhibitory (CTLA-4) and agonistic (4-1BB and OX-40) ligands composed of short oligonucleotide (ODN) aptamers that exhibited bioactivities comparable or superior to that of antibodies.	odn	137-140	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	54-60
22878899-0	2013	T cell profiling reveals high CD4+CTLA-4 + T cell frequency as dominant predictor for survival after prostate GVAX/ipilimumab treatment.	gvax	110-114	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	34-40
23017670-4	2013	Sixteen hours PMA/Ionomycin stimulation induced iTreg subsets with the phenotype CD4(+)CD25(+)Foxp3(+), CD4(+)IFNgamma(+)Foxp3(+) and CD4(+)CD25(+)IFNgamma(+) co-expressing CD95, CD152, CD178, CD279, Granzyme A, Granzyme B, Perforin, IL-10, and TGFbeta(1).	Ionomycin	18-27	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	179-184
22878899-7	2013	Unsupervised clustering of these immune biomarkers revealed cancer-related expression of CTLA-4(+) in CD4(+) T cells to be a dominant predictor for survival after Prostate GVAX/ipilimumab therapy and to thus provide a putative and much-needed biomarker for patient selection prior to therapeutic CTLA4 blockade.	gvax	172-176	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	89-95
22878899-7	2013	Unsupervised clustering of these immune biomarkers revealed cancer-related expression of CTLA-4(+) in CD4(+) T cells to be a dominant predictor for survival after Prostate GVAX/ipilimumab therapy and to thus provide a putative and much-needed biomarker for patient selection prior to therapeutic CTLA4 blockade.	gvax	172-176	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	296-301
23782302-6	2013	However, an association between SSc and the CTLA-4 -318 TT + TC genotype (OR = 1.642, 95% CI = 1.034-2.609, p = 0.036).	Technetium	61-63	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	44-50
23703660-12	2013	However, further studies are required to evaluate the role of sCTLA-4 in RA, as well as the molecular and functional basis of the association between both CTLA-4 gene SNPs and soluble levels of CTLA-4 in CS.	Cesium	204-206	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	155-161
23565286-2	2013	At steady state, most CTLA-4 resides in intracellular compartments due to constitutive internalisation mediated via a tyrosine based endocytic motif (YVKM) within the cytoplasmic domain.	Tyrosine	118-126	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	22-28
22951729-9	2013	GATA3 directly transactivated the CTLA-4 promoter, and knockdown of GATA3 messenger RNA and protein inhibited CTLA-4 induction mediated by bortezomib.	Bortezomib	139-149	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	34-40
22951729-9	2013	GATA3 directly transactivated the CTLA-4 promoter, and knockdown of GATA3 messenger RNA and protein inhibited CTLA-4 induction mediated by bortezomib.	Bortezomib	139-149	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	110-116
22759318-9	2012	In conclusion, we demonstrated that FR104 is devoid of agonist activity on human T cells and thus compatible with a clinical development that might lead to higher therapeutic indexes, by sparing CTLA-4, as compared to CD80/CD86 antagonists.	fr104	36-41	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	195-201
23152566-6	2012	These PAP-specific CD8(+)CTLA-4(+) suppressor T cells expressed IL-35, which was decreased after blockade of CTLA-4, and inhibition of either CTLA-4 or IL-35 reversed PAP-specific suppression of tvDTH response.	tvdth	195-200	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	25-31
22902304-0	2012	Genetic variants of TNFalpha, IL10, IL1beta, CTLA4 and TGFbeta1 modulate the indices of alcohol-induced liver injury in East Indian population.	Alcohols	88-95	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	45-50
23354631-3	2012	AIM: To correlate CTLA4 polymorphisms with caspase 3 expression in peripheral blood mononuclear cells (PBMC) simulating in vitro the glucose effect.	Glucose	133-140	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	18-23
22918925-9	2012	For example, in patients with NSCLC treated with paclitaxel and carboplatin, the phased administration of ipilimumab (an antibody against CTLA-4) resulted in substantial improvements in immune-related progression-free survival compared with chemotherapy alone (5.7 versus 4.6 months; P = 0.05).	Carboplatin	64-75	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	138-144
22495392-10	2012	Collectively, these data emphasize the potential of combining cancer treatment using anti-CTLA-4 monoclonal antibodies with T-cell activation and directed killing by TTS therapy.	Disulfiram	166-169	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	90-96
22678893-5	2012	In addition to its suppressive effects mediated via ICER, cAMP can also modulate the levels of surface-expressed cytotoxic T lymphocyte antigen-4 (CTLA-4) and its cognate B7 ligands on conventional CD4(+)  T cells and/or APCs, fine-tuning suppression.	Cyclic AMP	58-62	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	113-145
22678893-5	2012	In addition to its suppressive effects mediated via ICER, cAMP can also modulate the levels of surface-expressed cytotoxic T lymphocyte antigen-4 (CTLA-4) and its cognate B7 ligands on conventional CD4(+)  T cells and/or APCs, fine-tuning suppression.	Cyclic AMP	58-62	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	147-153
22503629-8	2012	First, an anti-tumor mAb conjugated with streptavidin (StAv) should be administered to be followed by the delivery of biotin-labeled anti-CTLA-4 mAb.	Biotin	118-124	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	138-144
22295566-2	2011	The results show evidence for the contribution of polymorphic variants in CCRS, DRB1, IFNG, TGFB1, IFNAR1, IL7RA and, probably, TNF and CTLA4 genes to copaxone treatment response.	Glatiramer Acetate	151-159	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	136-141
23144765-5	2012	In healthy T cells, calcitriol profoundly affects the phenotype of CD46-costimulated CD4+ T cells, by increasing the expression of CD28, CD25, CTLA-4 and Foxp3 while it concomitantly decreased CD46 expression.	Calcitriol	20-30	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	143-149
22236398-0	2012	Blocking of CTLA-4 on lymphocytes improves the sensitivity of lymphocyte transformation tests in a patient with nickel allergy.	Nickel	112-118	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	12-18
23118856-11	2012	Gene Set Enrichment Analysis (GSEA) of the microarray data showed significant enrichment of FOXP3 target genes, CTLA-4 and TGF-ss associated pathways in the patient cohort.	gsea	30-34	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	112-118
21900394-6	2011	However, this TAM-mediated induction of FOXP3 and CTLA-4 in T cells was independent of lipoxygenase and could not be reversed by inhibiting lipoxygenase activity.	tam	14-17	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	50-56
21753179-8	2011	We found additional interactions between high anti-EBNA IgG titer and SNPs in HLA-A (adjusted odds ratios [AOR] = 19.84 [95% confidence interval (CI) 5.95 to 66.21] for both factors compared to neither) and CTLA-4 genes (AOR = 0.31 [95% CI 0.13 to 0.76] for neither factor compared to both).	N-tert-Butyl-N-ethylnitrosamine	51-55	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	207-213
22357516-1	2011	OBJECTIVE: To study mRNA expression of immune-related genes (Foxp3, GATA3, CTLA4 and T-bet) in peripheral blood of the patients with allergic dermatitis induced by trichloroethylene (TCE).	Trichloroethylene	164-181	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	75-80
22357516-1	2011	OBJECTIVE: To study mRNA expression of immune-related genes (Foxp3, GATA3, CTLA4 and T-bet) in peripheral blood of the patients with allergic dermatitis induced by trichloroethylene (TCE).	Trichloroethylene	183-186	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	75-80
22027422-1	2011	The anti-CTLA-4 Mab ipilimumab is an efficient treatment of metastatic melanoma as a single agent and combined with dacarbazine chemotherapy.	Dacarbazine	116-127	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	9-15
21763239-1	2011	BACKGROUND &amp; AIMS: Inhibitory receptors such as programmed death 1 (PD-1) and cytotoxic T lymphocyte-associated antigen (CTLA)-4 mediate CD8+ T-cell exhaustion during chronic viral infection, but little is known about roles in dysfunction of CD4+ T cells.	Adenosine Monophosphate	12-15	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	92-132
21655351-5	2011	Moreover, there was an increase in the frequency of the population of Foxp3+ CD25(High)CD4+ cells that was also IL-10+ in the IND group, whereas in the cardiac (CARD) group, there was an increase in the percentage of Foxp3+ CD25(High) CD4+ cells that expressed CTLA-4.	indole	126-129	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	261-267
21082224-7	2011	The CTLA-4 (+49) A allele (AA+AG genotype), however, was significantly associated with CAL formation, especially in female patients.	cal	87-90	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	4-10
20606488-8	2011	CD28 and CD80 mRNA were decreased in short-term incubation with DEX whereas the effect of inhibition by DEX on CTLA-4 mRNA was detected only in long-term cultures.	Dexamethasone	104-107	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	111-117
21360567-8	2011	CONCLUSION: CTLA-4 is expressed by HBV-specific CD8 T cells with high levels of Bim and helps to drive this proapoptotic phenotype.	bim	80-83	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	12-18
20491567-5	2010	We found lower expression of the CTLA4 gene in blood lymphocytes from IBD patients compared to control subjects (p&amp;#x2009;&amp;lt;&amp;#x2009;0.001) and higher CTLA4 expression in biopsies taken from inflamed part of the colon compared to noninflamed part of the colon (p&amp;#x2009;=&amp;#x2009;0.021).	Adenosine Monophosphate	127-130	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	33-38
21789152-3	2011	An array of preclinical studies in multiple solid tumor types show that ixabepilone demonstrates therapeutic synergy with targeted therapies including trastuzumab, bevacizumab, brivanib, and cetuximab; with immune-modulating agents such as anti-CTLA-4 antibody; and with other chemotherapy drugs such as irinotecan and epirubicin.	ixabepilone	72-83	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	245-251
20491567-5	2010	We found lower expression of the CTLA4 gene in blood lymphocytes from IBD patients compared to control subjects (p&amp;#x2009;&amp;lt;&amp;#x2009;0.001) and higher CTLA4 expression in biopsies taken from inflamed part of the colon compared to noninflamed part of the colon (p&amp;#x2009;=&amp;#x2009;0.021).	Adenosine Monophosphate	115-118	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	33-38
20491567-5	2010	We found lower expression of the CTLA4 gene in blood lymphocytes from IBD patients compared to control subjects (p&amp;#x2009;&amp;lt;&amp;#x2009;0.001) and higher CTLA4 expression in biopsies taken from inflamed part of the colon compared to noninflamed part of the colon (p&amp;#x2009;=&amp;#x2009;0.021).	Adenosine Monophosphate	127-130	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	33-38
20491567-5	2010	We found lower expression of the CTLA4 gene in blood lymphocytes from IBD patients compared to control subjects (p&amp;#x2009;&amp;lt;&amp;#x2009;0.001) and higher CTLA4 expression in biopsies taken from inflamed part of the colon compared to noninflamed part of the colon (p&amp;#x2009;=&amp;#x2009;0.021).	Adenosine Monophosphate	127-130	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	33-38
20491567-5	2010	We found lower expression of the CTLA4 gene in blood lymphocytes from IBD patients compared to control subjects (p&amp;#x2009;&amp;lt;&amp;#x2009;0.001) and higher CTLA4 expression in biopsies taken from inflamed part of the colon compared to noninflamed part of the colon (p&amp;#x2009;=&amp;#x2009;0.021).	Adenosine Monophosphate	127-130	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	33-38
20491567-6	2010	We found lower expression of soluble CTLA4 isoform than membrane-bound full-length isoform in peripheral blood lymphocytes from IBD patients compared to control subjects (p&amp;#x2009;=&amp;#x2009;0.010) and in lymphocytes from IBD patients with CTLA4 CT60 GG genotype compared to IBD patients with AA genotype (p&amp;#x2009;=&amp;#x2009;0.034).	Adenosine Monophosphate	173-176	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	37-42
20491567-6	2010	We found lower expression of soluble CTLA4 isoform than membrane-bound full-length isoform in peripheral blood lymphocytes from IBD patients compared to control subjects (p&amp;#x2009;=&amp;#x2009;0.010) and in lymphocytes from IBD patients with CTLA4 CT60 GG genotype compared to IBD patients with AA genotype (p&amp;#x2009;=&amp;#x2009;0.034).	Adenosine Monophosphate	186-189	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	37-42
20090932-8	2010	In vitro studies revealed that catecholamines inhibit CTLA-4 upregulation in activated T cells.	Catecholamines	31-45	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	54-60
20661468-6	2010	Upon co-incubation with TMV, Treg showed an increased FasL, IL-10, TGF-beta1, CTLA-4, granzyme B and perforin expression (p&lt;0.05) and mediated stronger suppression of responder cell (RC) proliferation (p&lt;0.01).	tmv	24-27	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	78-84
20300120-6	2010	A significant association with CTLA4 was found for the TBII-positive GD (G carriers in patients vs controls, 97.1 vs 91.8%; odds ratio (OR)=2.97, 95% confidence interval=1.29-6.87, P=0.008), but the association was weak and not significant for the TBII-negative GD (94.4 vs 91.8%; OR=1.50, 95% confidence interval=0.57-3.98, P=0.41).	tbii	55-59	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	31-36
20300120-6	2010	A significant association with CTLA4 was found for the TBII-positive GD (G carriers in patients vs controls, 97.1 vs 91.8%; odds ratio (OR)=2.97, 95% confidence interval=1.29-6.87, P=0.008), but the association was weak and not significant for the TBII-negative GD (94.4 vs 91.8%; OR=1.50, 95% confidence interval=0.57-3.98, P=0.41).	tbii	248-252	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	31-36
20300120-7	2010	Stratification analyses suggested a possible synergistic interaction of CTLA4 with HLA-A 02 and -DPB1 0501 in the susceptibility to TBII-positive GD.	tbii	132-136	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	72-77
20358027-11	2010	CONCLUSIONS: The CTLA4 +49A/G polymorphism may contribute to the production of IgE in Korean children with asthma, especially in Dp/Df-specific IgE levels, but not in the direct development of asthma.	dp	129-131	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	17-22
20392239-4	2010	We also show that the bone loss and the stimulation of bone resorption induced by cPTH treatment are prevented by CTLA4-Ig, an inhibitor of T cell costimulation approved for the treatment of rheumatoid arthritis.	cpth	82-86	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	114-119
20140740-6	2010	In addition, the ratios of PBT expression of CD28 family to B7 family such as CTLA-4 to B7-H2 and PD-1 to B7-H2 were significantly higher in colon cancer patients with microscopic LVI than in those without LVI (P = 0.001 and P = 0.016, respectively).	(E)-2-(pent-3-en-1-yn-1-yl)thiophene	27-30	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	78-84
20470888-7	2010	In the individuals bearing the combination of the homozygous variant of low AT repeat number (82 bp) and the homozygous variant A (adenine) in CTLA-4 +49 A&gt;G, higher eGFR was observed at one year after KTx, which was also maintained at 10 years.	Adenine	131-138	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	143-149
20470888-7	2010	In the individuals bearing the combination of the homozygous variant of low AT repeat number (82 bp) and the homozygous variant A (adenine) in CTLA-4 +49 A&gt;G, higher eGFR was observed at one year after KTx, which was also maintained at 10 years.	ktx	205-208	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	143-149
20394753-1	2010	We present the crystal structure of an immunoglobulin light-chain-like domain, CTLA-4, as a strand-swapped dimer displaying cis-trans proline isomerisation and native-like hydrogen bonding.	Proline	134-141	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	79-85
20394753-1	2010	We present the crystal structure of an immunoglobulin light-chain-like domain, CTLA-4, as a strand-swapped dimer displaying cis-trans proline isomerisation and native-like hydrogen bonding.	Hydrogen	172-180	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	79-85
20090932-11	2010	The data demonstrate that surviving T cells in stroke patients remain fully functional and are primed towards a TH1 response, in addition we provide evidence that catecholamine mediated inhibition of CTLA-4 expression and serum HMGB1 release are possible mediators in stroke induced activation of T cells.	Catecholamines	163-176	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	200-206
20113596-3	2009	The objective of the study is to investigate the CTLA-4 expression and apoptosis in lymphocytes of children with MsPGN and the effects of dexamethasone (Dex) on the CTLA-4 expression and apoptosis.	Dexamethasone	138-151	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	165-171
19561360-7	2009	Contradictorily, DHA upregulated the mRNA expression of Foxp3, CTLA-4, TGF-beta, and IL-10; nonetheless, this fatty acid increased the expression of p27(KIP1) mRNA, known to be involved in Treg cell unresponsiveness.	Docosahexaenoic Acids	17-20	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	63-69
20113596-0	2009	[Effects of dexamethasone on CTLA-4 expression and apoptosis in lymphocytes obtained from children with mesangial proliferative nephritis].	Dexamethasone	12-25	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	29-35
19706602-1	2009	T cell receptor (TCR) signaling enhances beta1,6GlcNAc-branching in N-glycans, a phenotype that promotes growth arrest and inhibits autoimmunity by increasing surface retention of cytotoxic T lymphocyte antigen-4 (CTLA-4) via interactions with galectins.	beta1,6glcnac	41-54	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	180-212
19706602-1	2009	T cell receptor (TCR) signaling enhances beta1,6GlcNAc-branching in N-glycans, a phenotype that promotes growth arrest and inhibits autoimmunity by increasing surface retention of cytotoxic T lymphocyte antigen-4 (CTLA-4) via interactions with galectins.	beta1,6glcnac	41-54	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	214-220
19706602-1	2009	T cell receptor (TCR) signaling enhances beta1,6GlcNAc-branching in N-glycans, a phenotype that promotes growth arrest and inhibits autoimmunity by increasing surface retention of cytotoxic T lymphocyte antigen-4 (CTLA-4) via interactions with galectins.	n-glycans	68-77	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	180-212
19706602-1	2009	T cell receptor (TCR) signaling enhances beta1,6GlcNAc-branching in N-glycans, a phenotype that promotes growth arrest and inhibits autoimmunity by increasing surface retention of cytotoxic T lymphocyte antigen-4 (CTLA-4) via interactions with galectins.	n-glycans	68-77	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	214-220
19706602-6	2009	Together, these data suggest that TCR signaling differentially regulates multiple N-glycan-processing enzymes at the mRNA level to cooperatively promote beta1,6GlcNAc branching, and by extension, CTLA-4 surface expression, T cell growth arrest, and self-tolerance.	n-glycan	82-90	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	196-202
20113596-3	2009	The objective of the study is to investigate the CTLA-4 expression and apoptosis in lymphocytes of children with MsPGN and the effects of dexamethasone (Dex) on the CTLA-4 expression and apoptosis.	Dexamethasone	153-156	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	165-171
20113596-5	2009	CTLA-4 expression in in vitro cultured lymphocytes with or without Dex treatment was measured by flow cytometry following direct immune fluorescene.	Dexamethasone	67-70	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	0-6
20113596-5	2009	CTLA-4 expression in in vitro cultured lymphocytes with or without Dex treatment was measured by flow cytometry following direct immune fluorescene.	fluorescene	136-147	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	0-6
19530270-2	2009	The cytotoxic T-lymphocyte antigen 4 (CTLA-4) gene was recently associated with AITD and PGA, and the CTLA-4 protein is a strong inhibitor of T-cells.The tumor necrosis factor alpha (TNF-alpha) is a proinflammatory cytokine.	Folic Acid	89-92	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	4-36
19843932-0	2009	1,25-Dihydroxyvitamin D3 and IL-2 combine to inhibit T cell production of inflammatory cytokines and promote development of regulatory T cells expressing CTLA-4 and FoxP3.	Calcitriol	0-24	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	154-160
19530270-2	2009	The cytotoxic T-lymphocyte antigen 4 (CTLA-4) gene was recently associated with AITD and PGA, and the CTLA-4 protein is a strong inhibitor of T-cells.The tumor necrosis factor alpha (TNF-alpha) is a proinflammatory cytokine.	Folic Acid	89-92	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	38-44
19530270-3	2009	This study aimed to analyze the association of the CTLA-4 CT60 and TNF-alpha-863 polymorphisms with PGA.	Folic Acid	100-103	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	51-57
19530270-9	2009	In conclusion the CTLA-4 CT60 polymorphism is associated with PGA.	Folic Acid	62-65	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	18-24
19224637-3	2009	We demonstrate that signals induced by CD152 reduce the frequency of IFN-gamma and granzyme B expressing CD8(+) T cells independently of the transcription factors T-bet or cKrox by selectively inhibiting accumulation of Eomesodermin mRNA and protein.	ckrox	172-177	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	39-44
19405949-6	2009	We show that PP2A interacts with the cytoplasmic tail of CTLA-4 in two different sites, one on the lysine rich motif, and the other on the tyrosine residue located at position 182 (but not the tyrosine 165 of the YVKM motif).	Lysine	99-105	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	57-63
19405949-6	2009	We show that PP2A interacts with the cytoplasmic tail of CTLA-4 in two different sites, one on the lysine rich motif, and the other on the tyrosine residue located at position 182 (but not the tyrosine 165 of the YVKM motif).	Tyrosine	139-147	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	57-63
19380781-6	2009	Apoptosis protection conferred by CD152 is mediated by phosphatidylinositol 3"-kinase-dependent activation of the kinase Akt, resulting in enhanced phosphorylation and thereby inhibition of the proapoptotic molecule Bad.	Phosphatidylinositols	55-75	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	34-39
19405949-9	2009	CONCLUSION: Our studies demonstrate that PP2A interacts with the cytoplasmic tail of human CTLA-4 through two motifs, the lysine rich motif centered at lysine 155 and the tyrosine residue 182.	Lysine	122-128	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	91-97
19405949-9	2009	CONCLUSION: Our studies demonstrate that PP2A interacts with the cytoplasmic tail of human CTLA-4 through two motifs, the lysine rich motif centered at lysine 155 and the tyrosine residue 182.	Lysine	152-158	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	91-97
19405949-9	2009	CONCLUSION: Our studies demonstrate that PP2A interacts with the cytoplasmic tail of human CTLA-4 through two motifs, the lysine rich motif centered at lysine 155 and the tyrosine residue 182.	Tyrosine	171-179	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	91-97
18757416-6	2008	We found that the 49G>A polymorphism in the CTLA-4 leading sequence causing (17)Ala to (17)Thr amino acid substitution is associated with increased susceptibility to multiple cancers, including lung, breast, esophagus, and gastric cardia cancers.	Alanine	80-83	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	44-50
18976293-7	2009	CD154 expression correlated with proliferative alloresponses (r = 0.835, p = 7.1e-07), and inversely with CTLA4 expression of allospecific CD154 + Tc-memory cells (r =-0.706, p = 3.0e-05).	Technetium	147-149	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	106-111
18699801-0	2008	Effects of inhaled fluticasone propionate on CTLA-4-positive CD4+CD25+ cells in induced sputum in mild asthmatics.	Fluticasone	19-41	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	45-51
18699801-2	2008	The aim of this study was to evaluate the effects of fluticasone propionate (FP) on CD4+CD25+ T cell co-expression of CTLA-4 in the sputum of mild asthmatic subjects.	Fluticasone	53-75	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	118-124
18845086-9	2008	FK506 can not only inhibit the expression of positive co-stimulatory molecules CD28 and ICOS but also promote the expression of negative co-stimulatory molecule CD152, while CsA can exert its immunosuppressive effect mainly through promoting the expression of CD152.	Tacrolimus	0-5	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	161-166
18845086-9	2008	FK506 can not only inhibit the expression of positive co-stimulatory molecules CD28 and ICOS but also promote the expression of negative co-stimulatory molecule CD152, while CsA can exert its immunosuppressive effect mainly through promoting the expression of CD152.	Tacrolimus	0-5	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	260-265
18845086-9	2008	FK506 can not only inhibit the expression of positive co-stimulatory molecules CD28 and ICOS but also promote the expression of negative co-stimulatory molecule CD152, while CsA can exert its immunosuppressive effect mainly through promoting the expression of CD152.	Cyclosporine	174-177	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	260-265
19233349-9	2009	Statistically significant correlation between proliferation assessed as (3)H-thymidine incorporation and expression of activation markers was found in the case of CD25, CD27, CD38, CD152, CD71, still only in samples with higher proliferation activity (SI&gt;25).	Thymidine	77-86	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	181-186
19173804-13	2008	There exist correlations between Fas expression and axillary lymph node matastasis, CTLA-4 expression and disease stage, and RhoBTB2 expression and pathological type of breast cancer.	ammonium ferrous sulfate	33-36	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	84-90
18757416-6	2008	We found that the 49G>A polymorphism in the CTLA-4 leading sequence causing (17)Ala to (17)Thr amino acid substitution is associated with increased susceptibility to multiple cancers, including lung, breast, esophagus, and gastric cardia cancers.	Threonine	91-94	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	44-50
18757416-8	2008	Biochemical analyses showed that CTLA-4-(17)Thr had higher capability to bind B7.1 and stronger inhibitory effect on T-cell activation compared with CTLA-4-(17)Ala.	Threonine	44-47	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	33-39